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Background & Purpose: 
Stroke is the third leading cause of death in industrialized countries. Incidence in the UK is 
estimated at 2 per 1000, rising dramatically with age. Ischaemic stroke accounts for the majority of these 
events, and may arise due to embolism, thrombosis or haemodynamic mechanisms. At present, there is no 
proven accepted treatment for the acute ictus, and management - both medical and surgical - places the 
emphasis on secondary prevention. 
The presence of carotid artery stenosis is one factor known to be associated with increased stroke 
risk, whether symptomatic or asymptomatic. This may arise indirectly, due to its association with other 
vascular risk factors, such as hypertension and diabetes, or directly to cause both embolic and 
haemodynamic stroke. Two large trials have shown significant reduction in stroke risk following carotid 
endarterectomy in patients who have had recent symptoms. In patients with asymptomatic carotid artery 
stenosis, surgery is not routinely recommended, on the basis of risk- benefit analysis. 
It is possible to monitor for asymptomatic embolic signal using transcranial Doppler ultrasound 
(TCD) to record from the intra- cerebral vessels. These have been shown to occur in patients with carotid 
artery stenosis, and correlate with a number of individual markers of clinical risk. However, several areas 
in the application of TCD to asymptomatic embolus detection are unclear, and will be addressed as below. 
Contents: 
i) Assessment of Multi -Gated Doppler - use of transcranial Doppler ultrasound is hindered by lack 
of an automated system for analysis of patient recordings. Issues surrounding this will be discussed, and a 
new method to aid in differentiation of embolic signals from artifact is assessed both in a model and in 
patients. 
ll) Clinical Significance and Variability of Embolic Signals - presence of embolic signals as an 
independent risk factor for stroke is not proven, and studies have assessed their correlation with individual 
risk markers in small numbers. In a larger patient group clinical assessment of a number of factors is made 
in combination with transcranial Doppler studies. In a smaller sub -group, the temporal variability of 
embolic signals is assessed. 
iii) Reduction of Embolisation Using S- Nitrosoglutathione - though evidence from validation 
studies in vitro and in animal models supports the particulate nature of emboli detected by transcranial 
Doppler, no definite conclusions can be drawn regarding the nature of the embolic material. By studying 
anti- platelet and anti -thrombotic agents in patients with frequent embolic signals it may be possible to 
reduce these signals - combining intervention studies with a knowledge of the molecular action of such 
agents may allow a better understanding of the mode of embolisation in such a setting. A study of the use 
of' an anti -platelet agent, S- Nitrosoglutathione. GSNO, to reduce embolisation rates in the setting of 
carotid endarterectomy is described. 
PGS/ABST/94 Use this side only 
Chapter 1 
Stroke - Introduction 
1.1 Stroke - Definitions 
Stroke is the third leading cause of death in the Western world. It places a 
major burden on the resources of the National Health Service (NHS) both in terms of 
acute hospital admissions and long -term support for those left disabled by the initial 
ictus. The World Health Organisation (WHO) definition of stroke is 'rapidly 
developing clinical signs of focal (or global) disturbance of cerebral function, with 
symptoms lasting 24 hours or longer or leading to death with no apparent cause other 
than of vascular origin ". The definition includes subarachnoid haemorrhage but 
excludes transient ischaemic attacks (TIA), subdural haematoma, and haemorrhage or 
infarction caused by infection or underlying tumour. Clinically, the distinction is 
drawn between TIA and stroke by defining TIA as causing loss of neurological 
function lasting <24 hours. 
Strokes may therefore be one of two types - ischaemic (infarction) or 
haemorrhagic. Ischaemia causes the majority of strokes - approximately 80% - and 
arises either from temporary or permanent occlusion of the arterial supply to an area 
of brain. Haemorrhage causes approximately 15% of all strokes (10% primary 
intracerebral haemorrhage, 5% subarachnoid haemorrhage), with the mechanism of 
the other 5% of strokes being `uncertain'. Stroke related to cerebral haemorrhage will 
not be considered further in this thesis - the term 'stroke' will be taken to mean 
' ischaemic stroke' from this stage on. 
1.2 Stroke - Sub -types and Classification 
Ischaemic stroke may be classified according to clinical presentation 
mechanism or arterial site. 
Clinical categorisation was the method used to subdivide patients in the 
Oxford Community Stroke Project2 - with subdivisions into Total Anterior Circulation 
Syndrome (TACS), Partial Anterior Circulation Syndrome (PACS), Posterior 
Circulation Syndromes (POCS) and Lacunar Syndromes (LACS). These syndromes 
predict volume of cerebral infarction, and therefore correlate with outcome - as such 
they are clinically useful. 
Stroke may alternatively be categorised according to the pathophysiologic 
mechanism - such as used in the Stroke Data Bank study'. Pathophysiological 
classifications used were: large artery atherosclerosis, lacunar, cardiac embolism, 
tandem arterial pathology, infarct of unknown origin and other. Classification was 
largely done on the basis of neuroimaging, and in fact it was not possible to categorise 
40% of patients assessedd'. 
The National Institute of Neurological Diseases and Stroke (NINDS) 
classification subdivides according to a combination of pathological mechanism, 
clinical category and arterial distribution'. Again difficulties may be encountered - 
similar clinical deficits may result from arterial occlusions at different sites, or 
conversely arterial occlusion may occur without necessarily causing any symptoms. 
3 
NINDS Classification 
Mechanism: thrombotic; embolic; haemodynamic 
Clinical. atherothrombotic; cardioembolic; lacunar 
Arterial site: internal carotid; middle cerebral; anterior cerebral; vertebral; basilar; 
posterior cerebral 
More recently, the Trial of ORG10172 in Acute Stroke Therapy (TOAST) 
study categorised stroke as atherothromboembolic, cardioembolic, small vessel 
thrombotic, other and unknown. Here there was failure to clearly categorise in 15% 
of patients, and on many occasions the imaging diagnosis was at odds with that 
obtained clinically. 
1.3 Stroke Incidence 
Incidence of stroke is 1.5 /1000 /year, rising with age to 10 /1000 /year by the 
age of 75. In addition to the burden of mortality, it also accounts for significant 
morbidity and disability placing both social and financial burdens on carers and caring 
services. Stroke currently accounts for approximately 5% of UK NHS resources. 
There is some evidence to suggest that stroke mortality may be decreasing 
over times. Potential reasons for this may include decreased reporting rates (death 
certification), previous diagnostic inaccuracies (improvement with imaging 
techniques), changing incidence of the different sub -types and improved survival time 
- hence decreased mortality may be unrelated to stroke incidence. 
Reduction of this burden - both on a personal level and on society - will 
depend on primary preventive measures, secondary preventive measures, and 
provision of treatment of the acute event - though presently there is no proven 
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effective treatment in acute stroke. Strategies for stroke prevention will be discussed 
further below. 
1.4 Stroke - Primary Prevention 
This refers to prevention of stroke in individuals with no clinical evidence of 
the disease. As only approximately 20% of strokes occur with any preceding 
symptoms, then to produce any reduction in the overall incidence of events, effective 
primary prevention is needed. Preventive measures can be divided into general risk 
factor reduction and specific pharmacological and surgical therapies. Surgical 
management, both as a primary and secondary measure, will be considered under the 
general heading `Carotid Artery Stenosis'. 
1.4.1 Primary Prevention - Risk Factor Control 
Hypertension is the most powerful and treatable risk factor for stroke. Both 
systolic and diastolic blood pressure are independently related to stroke incidence. 
Reduction of elevated blood pressure significantly lowers stroke risk. Meta -analyses 
of blood pressure lowering trials found that an average reduction in diastolic blood 
pressure of 6mmHg produces a 42% reduction in stroke incidence9.10 Treatment of 
isolated systolic hypertension in people over the age of 60 years has been shown to 
reduce stroke incidence by 36 %, without excessive side effects such as depression or 
demential'. 
Cigarette smoking is a further significant risk factor in stroke, increasing the 
risk by a factor of 1.5 to 2.212-14. Risk of stroke correlates with numbers of cigarettes 
smoked, and risk decreases promptly with cessation of smoking'z'13'l' 
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In diabetic subjects, good glycaemic control is important in risk reduction16. 
The role of hypercholesterolaemia in stroke risk has not been clearly defined - a meta - 
analysis of lipid- lowering trials found no benefit in terms of stroke risk reductiont7. A 
more recent study of lipid lowering in coronary artery disease's showed a reduction in 
both fatal and non -fatal strokes in patients taking simvastatin - however this was done 
on post -hoc analysis rather than used as a primary endpoint. There are other lipid - 
lowering studies reporting a slowing of the progression of atherosclerosis as assessed 
ultrasonographically19'20. The shared risk factors for coronary and carotid 
atherosclerosis suggest that risk factor reduction strategies for both should be similar, 
though there has been a reluctance to generalise studies in one setting to the other. 
Excessive alcohol consumption is associated with increased stroke risk - 
moderate consumption has been shown to have no effect in some studies or to confer 
a degree of protection21'22. Those taking alcohol to excess should be advised to cut 
back their intake. Current recommended limits in the UK are <_14 units per week for 
females and 21 units per week for males'''. 
1.4.2 Primary Prevention - Pharmacological Measures 
i) anti -platelet agents 
There have been two clinical trials addressing the role of low -dose aspirin in 
primary prevention of stroke24'25 neither have found any significant difference in the 
incidence of stroke between the treatment and control groups. Indeed, the British 
tria125 found a higher incidence of disabling stroke in those taking aspirin. 
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ii) anticoagulants 
Patients with atrial fibrillation (AF) are known to be at increased risk of 
stroke. In cases where AF is secondary to rheumatic heart disease, or where the 
patient is about to undergo DC cardioversion this risk appears to be particularly high. 
Though there are no controlled trials in those specific areas, conventional treatment is 
to anticoagulate with warfarin. 
Non -rheumatic AF (NRAF) has a prevalence in the community of 0.4 %26, 
rising to 2% in those over the age of 60, and further to 10% in those over 70 years of 
age27. Both the Framingham and Whitehall studies found patients with NRAF to be at 
a fivefold risk of stroke compared to matched subjects in sinus rhythm, even after 
controlling for age, sex and associated hypertension28'29. There have been several 
studies addressing the use of warfarin in prevention of primary stroke events in 
NRAF patients30'31, showing overall benefit with warfarin treatment. The results of 
these trials are summarised in Table 1.1. 
Study N PT/INR Relative Risk Reduction 
BAA.TAF3o 420 1.2-1.5 (PT) 86% 
AFASAK32 1007 2.8-4.2 (INR) 64% 
SPINAF33 571 1.2-1.5 (PTR) 79% 
SPAF-I34 1330 2.0-4.5 (INR) 67% 
SPAF-II3l 1000 2.0-4.5 (INR) 40% 
Table 1.1. Summarising the major trials of warfarin versus aspirin or placebo in patients with 
NRAF in primary stroke prevention. BAATAF - Boston Area Anticoagulation Trial for Atrial 
Fibrillation; AFASAK - Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation Trial; SPINAF 
Stroke Prevention in Non -rheumatic Atrial Fibrillation Trial; SPAF -I - Stroke Prevention in 
Atrial Fibrillation Study; SPAF -II - Stroke Prevention in Atrial Fibrillation II Study. 
7 
NRAF has an attributable risk of stroke of 1.5% for those age 50 -59, rising to 
23.5% for those aged 80 -89 years27. In patients younger than 60 years with `lone' 
atrial fibrillation (no other heart disease or risk factors) the risk of stroke is low at 0.5- 
1.0% per annum. With increasing age and presence of a number of other risk factors 
(including hypertension, diabetes, previous venous thromboembolism, ischaemic heart 
disease, cardiac failure, atrial enlargement as demonstrated on echocardiography and 
evidence of an ischaemic lesion on CT scanning) the stroke risk is much higher and 
therefore benefit of anticoagulation greater31. In patients where warfarin is 
contraindicated, aspirin is superior to no treatment. 
1.5 Stroke - Secondary Prevention 
By definition, secondary prevention refers to a population with previous TIA 
or stroke. The same principles will apply as in primary prevention, but the risk -benefit 
ratios will alter - this will be discussed under each sub -heading. 
1.5.1 Secondary Prevention - Risk Factor Control 
As discussed above, only about 20% of strokes are preceded by any 
symptoms, but in these patients risk of future events is of the order of 12% in the 
following year, falling to approximately 7% per annum in subsequent years35. A 
similar approach to risk factor reduction as in primary prevention is therefore 
required. Exceptions to this include over -aggressive treatment of hypertension in the 
acute phase following stroke and in patients with severe carotid artery stenosis - in 
both these settings this may lead to hypoperfusion and worsening cerebral ischaemia. 
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1.5.2 Secondary Prevention - Pharmacological Measures 
i) anti- platelet agents 
Following observation of platelet thrombi in the retinal arterioles of patients 
with amaurosis fugax36'37, aspirin, a known anti -platelet agent, was given to patients 
with recurrent amaurosis and found to be of benefit38'39 Clinical trials of platelet 
inhibitors were subsequently launched, and there have since been many randomised 
controlled trials assessing aspirin in secondary prevention - a meta - analysis of these 
trials showed a reduction in stroke and other serious vascular events by 23% 
40 
Aspirin acts by inhibition of the cyclo- oxygenase pathway for the lifetime of the 
platelet to inhibit aggregation. 
A recent study has shown an additive effect if dipyridamole is prescribed in 
combination with the aspirin, though the dose of aspirin used in this study was small 
compared to that given in standard practice41 
Newer anti -platelet agents are emerging, including ticlopidine, clopidogrel and 
the anti- integrins, such as abciximab. 
Ticlopidine is a thienopyridine derivative, and does not affect the cyclo- 
oxygenase pathway. It inhibits the platelet aggregation induced by adenosine 
diphosphate and other agonists by altering the platelet membrane to interfere with the 
membrane -fibrinogen interaction and blocking the platelet glycoprotein IIb/lila 
receptor42. Ticlopidine has been shown in two studies to reduce stroke risk - the 
Canadian American Ticlopidine Study (CATS)43 compared ticlopidine to placebo with 
reduction in stroke and stroke death of 33.5 %. The Ticlopidine Aspirin Stroke Study 
(TASS) 44 compared aspirin and ticlopidine directly with a mean patient follow -up of 
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5.8 years, finding ticlopidine to be as, if not more, effective than aspirin. However, 
there is an associated risk of neutropaenia - reported in 2% of patients in the TASS - 
hence monitoring of the full blood count is required. It is presently available in the UK 
on a named patient basis only. 
A similar preparation to ticlopidine without the concomitant risk of 
neutropaenia is clopidogrel - a second thienopyridine derivative which inhibits platelet 
aggregation stimulated by adenosine diphosphate. Its role in secondary prevention has 
been evaluated against aspirin in a large trial``' involving 19185 patients with 
symptomatic cerebrovascular disease, ischaemic heart disease and peripheral vascular 
disease. A marginal benefit was shown (p= 0.043). 
The final step in platelet aggregation is binding of fibrinogen or von 
Willebrand factor with the integrin receptor glycoprotein (GP) IIb/IIIa. It is possible 
to inhibit platelet aggregation by preventing binding to this receptor, either with a 
blocking antibody (e.g. abciximab), or by synthetic compounds (e.g. integrilin, 
eptifibatide). Such agents have been used to inhibit platelet aggregation in normal 
volunteers46 and in the setting of unstable angina', acute myocardial infarction" and 
following coronary angioplasty49. There have been no studies of such agents in 
cerebrovascular disease in humans, though there has been a recent report of the use of 
TP -9201, a further GP IIb/IIIa antagonist, in prevention of carotid artery re- 
thrombosis in an animal model'''. 
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1.6 Stroke - Surgical Prevention - Carotid Artery Stenosis 
1.6.1 Carotid Artery Stenosis - Prevalence 
Atherosclerotic change is common at the bifurcation of the common carotid 
artery in the neck where it may progress to cause initially asymptomatic stenosis of 
the origins of the internal and external carotid arteries. Complications of internal 
carotid artery stenosis (CAS) include embolisation or thrombotic occlusion, which 
may lead to neurological symptoms such as TIA, stroke or retinal ischaemia. 
Following such an event the lesion would then be termed symptomatic carotid 
stenosis. It is possible for either embolism or occlusion to occur in the absence of 
clinical symptoms or signs. It has been estimated that carotid artery disease may be 
responsible for 20 -30% of all new strokes''. 
Asymptomatic CAS may be detected incidentally during investigations for 
vascular disease during surgical work -up, e.g. in preparation for coronary artery 
bypass grafting. It may be found during investigation for cause of a neurological event 
in another vascular territory, or through inappropriate investigation for the cause of 
some other non -vascular neurological symptom. Auscultation of the neck during 
clinical examination may reveal the presence of a carotid bruit, which may arise from 
turbulent flow in the underlying narrowed artery. Bruits are not a reliable indicator of 
either presence or severity of CAS - one series of 500 patients with asymptomatic 
neck bruits found degree of CAS of >75% in only 113 of the subjects - this following 
exclusion of 40 patients with `non -arterial' neck murmurs52. A second study, 
performed in the UK, examined a series of 331 patients referred to a cerebrovascular 
clinic, 110 of whom were noted to have a carotid bruit. Of these, 41(37 %) were 
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found to have moderate to severe (30 -99 %) stenosis of the underlying carotid artery. 
Investigation of the remaining 221 patients without a bruit found the same degree of 
disease in 38(17 %)53 
There have been three large population -based studies examining the 
prevalence of carotid artery stenosis (most cases studied being asymptomatic) - this 
rises from 0.5% in people in their 50's to approximately 10% in those over the age of 
8054-56. Risk factors for development of CAS are shared with those causative of other 
vascular disease, and include hypertension, cigarette smoking, elevated blood lipids 
and genetic factors. Management of these risk factors has been discussed in detail 
above, and applies equally in the setting of both asymptomatic and symptomatic CAS. 
Diagnosis of CAS can be made using several imaging modalities - non- 
invasive techniques include Duplex ultrasonography, spiral CT and magnetic 
resonance angiography. Intra- arterial angiography remains the `gold standard' yet 
invasive technique. As centres validate Duplex and MRA results against angiography, 
non - invasive techniques may replace intra -arterial angiography in the future. 
1.6.2 Carotid Artery Stenosis - Natural History 
There have been 5 prospective studies of asymptomatic CAS with sample 
sizes greater than 1005761. For the greater part, stenoses were left unoperated unless 
they became symptomatic. The rate of development of symptoms attributable to the 
CAS reported from all these studies would appear to range from 2 -5% per annum. 
Risk tends to increase with degree of stenosis, appearing greatest with reduction of 
the luminal diameter by 75- 90 %62. There is a close association between CAS and 
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coronary artery disease, and risk of death from cardiac events appears greater than 
from stroke in this group6o,63 
Once a stenosis has become symptomatic, then the risk of further ipsilateral 
symptoms increases greatly - this having been demonstrated in two large trials - the 
European Carotid Surgery Trial (ECST)64 and the North American Symptomatic 
Carotid Endarterectomy Trial (NASCET)65. Both these trials randomised patients 
with symptomatic CAS between medical treatment and surgical carotid 
endarterectomy. It is from the medically managed arm of each trial that much 
information can be learned concerning the natural history of the disease. Immediately 
following ischaemic stroke or TIA due to CAS, risk of further events is highest during 
the first few weeks to months. In the ECST, the risk of any stroke within 3 years was 
21.9% in those receiving medical therapy alone for those with severe (70 -99 %) CAS. 
In the NASCET the risk of development of an ipsilateral stroke within 2 years was 
26% for those receiving medical therapy alone. There is further evidence to suggest 
that the risk of further events may be higher following non -disabling stroke than 
hemispheric TIA which is in turn of higher risk than ipsilateral amaurosis fug 
1.6.3 Carotid Artery Stenosis - Therapeutic Implications 
A. Primary Prevention 
6 ax 6 . 
As described above, patients with asymptomatic carotid artery stenosis are at 
increased risk of stroke at the rate of approximately 2% per annum. There has been a 
trial of carotid endarterectomy in such patients, the Asymptomatic Carotid 
Atherosclerosis Study, or ACAS57 addressing the question of whether carotid 
endarterectomy reduces the overall 5 -year risk of carotid stroke. For the purpose of 
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this study, CAS was defined as >_60%. They reported a significant, though small, 
stroke reduction in the operative group - in order to prevent one stroke over a five 
year period 17 operations would be needed. This benefit would be lost if the surgical 
complication rate were higher - in this study the risk of surgical or angiographie death 
rate was only 2.3 %. The question of identification of a high risk group for whom to 
target surgery has become a key issue. It has been suggested that in addition to 
absolute degree of CAS 58,62, male sex and coexisting heart disease may confer 
additional risk52. 
The UK based Asymptomatic Carotid Surgery Trial, ACST67 continues to 
randomise patients. It is likely that again risk stratification will be of importance here - 
potential indicators of risk being evaluated include degree of stenosis, presence of a 
CT infarct, identification of an echolucent plaque on carotid ultrasound and impaired 
cerebral haemodynamics estimated by transcranial Doppler ultrasound. 
At present, carotid endarterectomy is not recommended routinely for patients 
with asymptomatic carotid artery stenosis in the UK. In the United States, a recent 
American Heart Association Statementó8 recommends surgery as of proven benefit for 
patients with a surgical risk of <3% and life expectancy of at least 5 years. 
B. Secondary Prevention 
As a result of the ECST and NASCET trials as described above, carotid 
endarterectomy is of proven benefit against best medical therapy alone in patients with 
`severe'(70 -99 %) symptomatic CAS. The surgical complication rates were 7.5% in 
ECST and 5.8% in NASCET. For ECST surgery conferred a 3 -year risk of 
perioperative death or ipsilateral stroke of 12.3 %, an absolute risk reduction of 9.6 +/- 
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3.3 %. For NASCET, the risk of an ipsilateral cerebral infarct within 2 years was 
reduced from 26% to 9 %, an absolute risk reduction of 17 +1 -3.5 %. 
For mild (0 -29 %) stenosis, neither study showed any benefit conferred by 
surgery. In patients with moderate (30 -69 %) stenosis, both studies have shown a 
marginal benefit of surgery versus best medical therapy within certain subgroups, and 
at present surgery is not recommended routinely for this group69'7o 
At present, accepted clinical practice in the treatment of symptomatic CAS is 
therefore carotid endarterectomy. There has also been interest in the possibility of 
percutaneous transluminal angioplasty (PTA) for treatment of the carotid lesion. This 
procedure precludes the need for a general anaesthetic or neck incision with the 
potential complications of both being avoided, and early studies of the procedure 
produced encouraging results''. The risks and benefits of PTA versus endarterectomy 
have been recently addressed in a randomised clinical trial, as part of the Carotid and 
Vertebral Artery Transluminal Angioplasty Study, or CAVATAS. Final results have 
not been published, but preliminary data suggest that at 2 years of follow -up the 
procedures are equivalent72(CAVATAS Collaborators Meeting, London, U.K., 
October 1998). 
1.7 Carotid Artery Stenosis - Embolisation and Clinical Implications 
The mechanism by which carotid artery stenosis causes stroke is by either 
distal embolisation or thrombotic occlusion. It is now possible to detect embolic 
material within the cerebral circulation by means of transcranial Doppler ultrasound'. 
The ability to detect circulating cerebral emboli in patients with carotid artery disease 
is of potential use in the following situations: 
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i) identifying individuals at highest risk of stroke. Presuming that asymptomatic 
embolic activity is an indicator of increased clinical risk, in much the same way as 
TIA's can indicate increased stroke risk, then treatment can be more efficiently 
targeted. This would be particularly helpful in aiding risk -benefit decisions in patients 
with asymptomatic carotid artery stenosis, where surgery is as yet only of proven 
benefit in centres with negligible complication rates57, though studies continue of 
potential risk stratification markers67. 
A further group in which management is unclear, and where the results of 
large studies have not been entirely conclusive, is in patients with moderate carotid 
stenosis, of the order of 30 -69 %. Results from the NASCET study for this group have 
been reported in abstract form69, suggesting that the risk- benefit ratio may only be 
favourable in certain subgroups, though by definition such sub -group analysis 
produces its own statistical difficulties. 
ii) in patients with more than one potential embolic source - for example carotid 
artery stenosis and atrial fibrillation - transcranial Doppler can be employed to localise 
the embolic source. This may be done both by use of bilateral middle cerebral artery 
(MCA) monitoring and by recording both above and below the level of the 
atherosclerotic lesion simultaneously to allow `tracking' of the embolic signal74. 
iii) where embolic signals are frequent, it may be used to monitor efficacy of 
therapeutic measures. As yet it is not possible to distinguish the nature of the embolic 
material on Doppler spectral characteristics alone - were this to become possible it 
would allow treatment to be targeted specifically - anti -platelet agents for platelet 
emboli, anti -coagulants for thrombus. 
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iv) monitoring of procedures. Emboli have been shown to be associated with 
adverse outcome in the setting of cardio -pulmonary bypass, carotid endarterectomy 
and carotid angioplasty. Monitoring in these situations is of use to develop strategies 
for avoidance of embolisation and to monitor their effectiveness. Further to this it may 
allow us to draw conclusions regarding the pathophysiology of embolisation in each 
situation. 
In the chapters that follow, the background and history of transcranial Doppler 
will be described (Chapter 2). I will go on to discuss validation and evaluation of the 
technique both in the clinical setting and in a flow model (Chapter 3, Chapter 4). 
Further work in the clinical setting assessing the incidence and natural history of 
embolisation rates in CAS will be presented in Chapters 5 & 6. In Chapter 7 the use 
of transcranial Doppler in monitoring of interventional procedures will be discussed 
and results of an interventional study using a new anti -platelet agent will be presented. 
All patient studies were approved by the King's Healthcare Ethical 
Committee, with informed consent obtained from each subject. 
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Chapter 2 
Transcranial Doppler Ultrasound and Embolus Detection - Background and 
History 
2.1 Ultrasound 
Sound waves are transmitted in longitudinal fashion by propagation of the 
vibration of air molecules from the sound source (transmitter) to the ear of the listener 
(receiver). The rate of vibration is measured in cycles per second (Hertz, Hz) and the 
pitch or frequency of the sound depends on this rate. At greater than 20kHz, the 
sound is no longer audible to the human ear and is then termed `ultrasound'. 
Ultrasound waves are transmitted as compression waves within a medium, 
also known as longitudinal waves. The source has a known frequency (f, cycles per 
second) and periodicity (T, period of time between similar points on consecutive 
cycles of the waveform). The relationship between these two factors may be described 
as: 
f= 1/T 
The wave is transmitted by causing similar motion of the particles of the insonated 
medium with the same frequency as the source. As the wave is propagated through 
the medium there will be compression of the medium as particles move in the same 
direction as their neighbours, causing a local increase in pressure. As particles then 
move back in the opposite direction, there will be a local reduction in pressure. This 
change in pressure is known as the excess pressure. The displacement, velocity and 
excess pressure of the particle at any point within the medium in front of the source 
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will vary over time in a sinusoidal fashion with the same frequency as the source. The 
maximum value of any of these quantities is known as its amplitude. As the wave 
moves with fixed velocity but varying amplitude, the wavelength (distance between 
similar points on consecutive cycles of the waveform) will vary. Wavelength and 
frequency are related to the speed of sound (c) by: 
hence: 
c = T 
=kf 
The speed of transmission of ultrasound depends on both the mass and spacing of the 
particles and the strength of the forces of attraction between particles. Speed of 
transmission will increase as the strength of the attractive forces between particles 
increases (so c is higher for stiffer materials) and decreases as the mass of the particles 
increases - i.e. the material is more dense. 
This relationship can be illustrated as: 
c = V K/p m/s 
where p = density (kg/m') 
and K = elastic modulus (stiffness) which is also equal to stress /strain. 
1/K equals x, or compressibility. 
The velocity of sound in various biological media is shown in Table 2.1 overleaf. 
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Medium Velocity (m/s) 
Air 330 





Soft tissue (mean) 1540 
Table 2.1. Velocity of sound in biological media. (Adapted from Fish, P., Diagnostic 
Medical Ultrasound, John Wiley & Sons, Chichester, England. 1990.) 
The velocity with which sound moves through a medium can be related to the 
excess pressure using the formula: 
Z = Excess pressure/Particle velocity 
normally calculated by Z = pc = A/p /x rayls or kg/m2/s 
where Z is the tissue, or acoustic impedance of the material. 
Values of the acoustic impedance for a selection of media are tabulated in 
Table 2.2. (Adapted from Evans, McDicken, Skidmore & Woodcock; Doppler 
Ultrasound. John Wiley & Sons, Chichester, England 1989.) 
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Medium Acoustic impedance 
(kg /m2 /s x 106) 
Air 0.0004 
Water (20 °C) 1.48 
Fat 1.38 
Blood 1.6 
Table 2.2. Acoustic impedance values for a variety of media. 
The ultrasound source emits the wave from all points on its surface, therefore 
producing ultrasound throughout a predictable volume in front of the source. The 
surface joining all similar points on a similar cycle is known as a wavefront. Direction 
of travel of the ultrasound beam and the wavefront are perpendicular to one another. 
If produced by a plane transducer, then those wavefronts close to the transducer will 
be plane, but as the wave travels the beam begins to diverge. As the distance from the 
transducer increases, wavefronts become part of a spherical surface. 
Ultrasound waves used medically are normally produced by an 
electromechanical transducer contained within a probe which is placed onto the skin 
surface - the transducer acting as a transmitter. Electrical energy (Joules) is used to 
drive the transducer to produce mechanical energy. Absorption of this mechanical 
energy by the insonated medium can generate heat. The rate of generation is also 
known as the power of the source, measured in Joules /second, or Watts. Power will 
vary at different points within the insonated medium depending on the width of the 
beam produced and any focusing effect. This is known as the intensity of the 
ultrasound beam - the power passing through unit area, perpendicular to the direction 
of propagation. It is not uniform across the beam, but tends to peak towards the 
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centre of the beam and reduce towards its outer aspect. The average intensity can be 
calculated, and is known as the spatial average. 
Ultrasound waves may be one of two types - continuous wave and pulsed 
wave. 
2.1.1 Continuous Wave (CW) Ultrasound 
CW ultrasound produces a continuous beam of ultrasound into the tissues. 
The beam thus transmitted is reflected from any acoustic interface encountered. As 
everything within the path of the beam is insonated it is impossible to estimate the 
position of the examined site. The only setting in which CW is used routinely is in 
evaluation of peripheral vascular disease, as CW Doppler using high frequency probes 
to insonate superficial vessels of known position. The technology involved is relatively 
simple and relatively inexpensive. 
2.1.2 Pulsed Wave Ultrasound 
Medical ultrasound mainly utilises pulses, allowing information to be gathered 
regarding depth of the insonated area and hence localisation. As applied using 
Doppler to examine flow in insonated vessels it gives information about location and 
directionality of flow in addition to waveform information. 
The intensity of pulsed ultrasound varies over time as well as space - therefore 
instead of a spatial average there is a temporal average of ultrasound intensity. With 
pulsed wave ultrasound, the transducer acts as both transmitter and receiver, emitting 
pulses of ultrasound at a known frequency. The duration of the ultrasound pressure 
pulse produced is known as the pulse length. Each emitted pulse contains a certain 
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energy - energy emitted per second, or average transmitted power is equal to the 
pulse energy multiplied by the pulse repetition frequency (PRF). 
As the ultrasound pulse is transmitted into the tissues, it will be altered by the 
structures insonated. At boundaries between different tissue types it may be reflected 
or refracted, it may undergo scattering by small tissue structures and also lose energy 
by absorption. These factors will be considered in further detail below. The time 
between transmission of the sound wave and detection of the reflected beam allows an 
indication of the depth of any interface to be calculated. 
2.1.3 Ultrasound Propagation 
i. Reflection 
Any sound beam incident at an interface will undergo modification - part of 
the beam will be transmitted through the interface, a proportion will be reflected and 
some energy will be lost by absorption. If the interface is perpendicular to the 
direction of propagation of the beam, then the amount of ultrasound reflected depends 
on the acoustic impedance of the two tissues involved. Where the difference in 
acoustic impedance is high - for example at soft tissue -air interfaces - then there will 
be a high degree of reflection. At boundaries between differing types of soft tissue, the 
amount of reflection will be less. Where the angle of insonation is greater than zero, 
this will influence both the reflected and transmitted intensities. Where ultrasound is 
incident on a rough surface, or on small objects, then the beam is scattered rather than 
reflected. The proportion of the beam scattered or reflected determines the intensity 
of the received signal. 
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ii) Refraction 
Deviation of the ultrasound beam also occurs at tissue interfaces, but is 
dependent on the difference of the speed of ultrasound transmission, not acoustic 
impedance. The sound will bend away from the perpendicular if the speed in the 
second medium is higher than in the first and vice versa. 
iii) Scatter 
If instead of a smooth interface larger than the wavelength of the insonating 
beam, the ultrasound is incident on a rough surface, or on small particles of a size 
smaller than or comparable with the beam wavelength, then the beam will be scattered 
in all directions rather than reflected. The amount of power lost increases with 
increased frequency. 
iv) Absorption 
Some power will be lost secondary to absorption of energy by the insonated 
tissue, with conversion to heat. Loss due to absorption increases with frequency. 
Combinations of the above factors effect a reduction in ultrasound intensity 
during its passage through any medium - this is termed attenuation of the beam. 
Attenuation produced by either scatter or absorption is tissue specific, therefore 
attenuation due solely to these factors can be quantified for any tissue - the fractional 
rate of change of intensity with distance that would occur if a non -diverging or 
converging beam were used in a uniform sample of tissue (i.e. with no boundaries 
allowing reflection or refraction. This is termed the attenuation coefficient (a), and 




where AI is the loss of intensity from incident intensity I during passage through a thin 
layer of thickness Ax and where AI /I «1. The overall attenuation coefficient is the 
sum of the absorption and scatter coefficients. 
As the fractional change in intensity is a ratio, it may be expressed in decibels - 
total decibel attenuation coefficient is defined as: 
4.3a dB/m 
which is roughly proportional to frequency. Hence for the frequency of the transducer 
used the attenuation may be calculated by: 
A=qcf 
where k is in dB /m/MIIz - or the value of ,u at 1MHz, and f is the frequency in MHz. 
Typical attenuation coefficients are shown in Table 2.3. (From Evan, McDicken, 
Skidmore & Woodcock; Doppler Ultrasound. John Wiley & Sons, Chichester, 
England 1989) 



















Table 2.3. Typical attenuation coefficients. 
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* Huetner, 1952 
2.2 The Doppler Principle 
Ultrasound as described above can be used to study and scan static structures, 
or structures where there is little movement to produce anatomical or structural 
information. Movement of any echo - generating tissues can be displayed as a function 
of time by means of the M -mode display, as used in echocardiography to measure 
heart valve dynamics. 
Movement of reflectors or scatterers within the insonated area will in addition 
change the frequency of the received signal - the change from the transmitted 
frequency being known as the Doppler effect, and the magnitude of the change 
(Doppler shift) being proportional to the reflector or scatterer velocity. By 
exploitation of this phenomenon, it is possible to monitor the cyclical variation in 
blood velocity within arteries, and to interpret disease -induced changes in velocity 
waveform or the increased range of Doppler shift frequencies resulting from disturbed 
flow. Combination of real -time scanners with Doppler effect instruments may be used 
to display both vessel anatomy and velocity waveform simultaneously. 
The Doppler effect is the change in the observed frequency of a wave due to 
motion - whether of the source or the observer. When motion is towards the source 
then there is a perceived increase in frequency as more wave cycles per second are 
passed. This increased frequency may be calculated according to the formula: 
f =f c +v 
c 
where f is the transmitted frequency and v is the velocity of the observer. 
Conversely, when motion is away from the sound source, the perceived 
frequency is lower, as fewer wave cycles per second are passed. 
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If the observer is at rest and the source moves with velocity y in the direction 
of wave travel, then the wavelengths are compressed and again the perceived 
frequency is higher. 
The Doppler principle was first formulated in 1842 by the Austrian physicist, 
Christian Doppler, at the Royal Bohemian Society of Sciences in Prague75'76. It was 
three years later that the theory was experimentally verified, in fact in an experiment 
designed to prove the theory wrong. The Dutch physicist, Buys Ballot, used a band of 
horn players on a railroad flatcar moving at 65km/hour to demonstrate that the shift in 
tone between approaching and receding was perceived to be two steps on the musical 
12 -tone scale (approximately +/- 6 %)77. 
2.3 Transcranial Doppler Ultrasound 
Application of ultrasound for cardiovascular assessment combines this 
Doppler principle with the radar principle outlined above. It was first suggested in 
1960 by two workers in Osaka, Japan78; indeed the second of these workers first 
suggested the possibility of applying the technique to insonate the intracranial 
vessels79. However, the large attenuation effect on the ultrasound beam by the skull 
was perceived as problematic, and this preconception delayed the development of 
Doppler ultrasound for transcranial use. It was not until 1981 that Rune Aaslid in 
Bern, Switzerland made the first transcranial Doppler (TCD) recordings8 °'81. To do 
this he used a low frequency (2MHz) transducer, and utilised the naturally- occurring 
`acoustical windows' - the transtemporal window, first described by Aaslid and 
colleagues in 198280, the transorbital window82 and the transforaminal window". The 
transtemporal approach can be used to examine the middle cerebral, anterior 
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communicating, distal internal carotid and posterior communicating arteries. Using 
the transorbital approach, the orbital and distal internal carotid arteries may be 
studied. From a submandibular approach, the distal carotid may be studied. and via 
the foramen magnum it is possible to study the vertebral arteries and their 
continuation into the basilar artery. 
Most studies to date utilise the transtemporal approach, and the studies 
described here are all made from the middlé cerebral artery using this approach. The 
relative thinness of the temporal bone means lower attenuation of the ultrasound 
beam, but still the acoustical intensity of the ultrasound conducted into the brain tissue 
is always less than 35% of the original beam84. Modifications to the maximum 
acoustical intensity of the transducer have improved on the possible performance of 
the technique; however there remains a sub -population in whom it is not possible to 
obtain an adequate signal - reported failed insonation rates vary between 10 to 
23%85,86. 
Since 1982, and the first description of the use of transcranial Doppler, there 
has been a rapid expansion of the application of the technique. It has been used to 
examine cerebral haemodynamics including demonstration of collaterals, to 
demonstrate the anatomy of the circle of Willis and also to demonstrate embolic 
material within the circulation. As the work here is concerned with detection of 
embolic material within the middle cerebral artery and its clinical relevance, the other 
applications will not be considered further in this work. 
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2.4 Detection of Embolic Material 
As described above, the intensity of the returned ultrasound signal provides 
information regarding the proportion of the transmitted beam which is scattered or 
reflected, which in turn is dependent on the material through which the beam is 
directed. The degree of reflection, scatter or transmission is determined by the 
acoustic impedance of the tissue examined. Where there is an interface between two 
materials of widely differing acoustic impedance the proportion of the ultrasound 
energy reflected will be high. 
Air has a high acoustic impedance compared with the other media (see Table 
2.2) - hence the ultrasound reflected at an interface between air and a second medium 
will be high. The proportion of the beam reflected may be determined by the reflection 
coefficient, defined by the equation: 
Reflection coefficient, k = [Z2- Z, /Z2 +Zi]2 
where Z, is the acoustic impedance of the first medium and Z2 is that of the second 
medium. Multiplying the reflection coefficient by 100 gives the percentage reflection 
at the interface. As the original equation squares the value obtained, the amount of 
reflection will be the same at the tissue interface irrespective of the direction of 
movement of the beam, whether from high to low, or from low to high, acoustic 
impedance. 
Of course, the amount of reflection from the interface does not only depend 
on the above coefficient, but also the size or area of the interface. Where the interface 
is greater than the wavelength of the insonating beam, reflection will be determined 
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entirely as above, but where the interface is approximately equal to or smaller than the 
wavelength of the beam, Rayleigh scattering increases in importance. Here there is 
scattering of the beam in all directions, and the signal detected will only be a 
proportion of that reflected towards the receiver. 
It can be seen from the above that any embolic material within the circulating 
blood may act to reflect a proportion of the ultrasound beam. The amount of signal 
reflected to the receiver will depend to some extent on the composition of the 
embolus, its size and the wavelength of the ultrasound used. The difference between 
scatter and reflectance of the beam by the embolus and that produced by the 
surrounding blood may allow its detection by Doppler ultrasound. Information 
regarding the intensity of the reflected signal may allow some inference to be drawn 
regarding the size and composition of the embolic material87. 
There have been previous studies describing the use of Doppler ultrasound in 
detection of emboli within the circulation. Detection of gaseous emboli was described 
as long ago as 196588. They have been detected in the venous circulation of divers in 
decompression chambers89, and were shown to be associated with `the bends'90. 
Such signals have also been described in the setting of cardiopulmonary 
bypass, again first in humans in 196991, both in the extracorporeal circuit and in 
vessels. TCD has since been used to detect air embolism occurring during the time of 
aortic cannulation, during initiation of the bypass and intermittently during the 
duration of the bypass92. Observation of such signals, and preliminary studies 
suggesting that such embolic events correlate with poorer outcome as assessed by 
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neuropsychological testing, have led to development of strategies to avoid such 
embolic activity93'94. 
Although abnormal signals thought to represent fat emboli in the venous 
circulation of patients undergoing hip replacement were detected as long ago as 
197595, this observation was not taken further. Then in 1990, Spencer and co- 
workers73 reported signals thought to represent solid emboli in the middle cerebral 
artery prior to arteriotomy in the setting of carotid endarterectomy. There had been 
previous reports of detection of embolic signals, particularly with relation to insertion 
of shunts and release of the cross -clamp, felt to be secondary to air emboli96, but ES 
had not previously been noted prior to opening of the artery. From this first 
observation, Spencer et al described typical features of an embolic signal from 
presumed solid material as transient (0.01 -0.1 seconds), hyperintense (up to 40 dB 
greater than background) and with an accompanying audible `chirp'73. A typical 
embolic signal is illustrated in Figure 2.1. 
Figure 2.1. Typical embolic signal (arrowed) within the Doppler waveform of a 
middle cerebral artery. It is of much higher intensity than the surrounding Doppler 
signal - this may be calculated from an accompanying intensity scale. 
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Following these observations, reports followed of detection of similar signals 
in individuals at increased risk of thromboembolic stroke including atrial fibrillation', 
carotid artery stenosis98 and cardiac valve prostheses'''. However, such initial reports 
were viewed with caution - artefact such as that produced by probe movement or by 
movement or speech from the patient also produces transient high intensity signals, 
and it is important to be certain that these signals do not merely represent artefact or 
turbulent or abnormal flow patterns. 
Validation studies were therefore necessitated, both in vitro and in animal 
models. Their findings are summarised below. 
2.4.1 Embolus Detection - In -Vitro Studies 
Markus and Brown 87 set up a flow model to both validate the technique for 
embolus detection and to investigate the possibility of discrimination between 
different embolic materials. Emboli of known size and composition (thrombus, 
platelet -rich aggregates, atheromatous material and fat) were introduced into the flow 
circuit and reliably produced transient high- intensity signals as previously described in 
patients. They found a highly significant correlation between embolus size and 
maximum amplitude of the reflected signal for all materials used. In addition they 
suggested that platelet -rich aggregates produce lower intensity ES than seen with 
atheroma. 
A second in vitro study10° examined reliability of the technique in detection of 
air emboli and related the intensity of the resulting signals to the volume of air 
injected. They showed that air volumes of 0a111 were detected 80% of the time, 
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increasing to 100% for bubbles of >_0.7541. Bubble volumes of the order of 30 -404l 
resulted in signal saturation. 
2.4.2 Embolus Detection - Animal Studies 
The first in -vivo validation study was performed by Russell et al in 1991101 in 
a rabbit model. Embolic material was introduced into the aorta via cannulation of the 
left renal artery, with insonation of the distal aorta 7cm caudal to the point of 
cannulation. This was chosen as the rabbit aorta in this portion is of comparable 
diameter to the human MCA. Though no definitive analysis of the resulting signal 
intensities was performed in this paper, they reported higher intensity signals resulting 
from air and fat emboli over emboli composed of clotted whole blood, platelets or 
atheromatous material. 
Further to this work, a second validation study102 examined embolus detection 
in a sheep model - allowing insonation of a cerebral vessel with a flow waveform 
similar to that seen in the human cerebral circulation with preserved diastolic flow. 
Again they reported a correlation between embolus size and maximum relative 
intensity of the embolic signal. It was not possible to introduce embolic material of 
___400p.m into the model - hence the lower limit of solid embolus detection could not 
be defined. Signals from platelet emboli were less intense than atheromatous and 
thrombus emboli, but only small numbers were studied. 
A third study10° looked further at detection and quantification of air 
embolisation in the middle cerebral artery of Macaque monkeys, recording via the 
transtemporal route. As for their in -vitro study described above they found early 
33 
saturation of the receiver at the same bubble volumes, with air bubbles reliably 
producing ES. 
In each model introduction of embolic material resulted in production of a 
short duration high- intensity (high -amplitude) transient signal. In both the rabbit and 
Macaque models signals were described as having an accompanying characteristic 
`chirp'. Combining the findings provides strong evidence that the signals detected in- 
vivo are consistent with those produced by embolic material in- vitro, and supports the 
argument that these signals in -vivo do represent embolic activity. 
2.5 Factors Influencing Embolus Detection 
Preliminary work utilising TCD to record for ES in the setting of carotid 
artery stenosis produced widely varying results - both regarding percentages of 
patients found to be ES positive and rates of ES per hour in subjects where ES were 
detected. In symptomatic CAS the numbers of patients defined as ES positive has 
ranged from 20- 90 %103.b07. The results from these studies are summarised in Table 
2.4 overleaf. 
This variability in results can arise from many possible sources - technical 
factors, patient characteristics, recording protocols used and analysis of any 






































































































































































































































































































































































































































































































































































2.5.1 Technical Factors Influencing Detection 
The most important technical parameters affecting the detectability of ES are: 
1) the relationship between the backscattered power from emboli and that from the 
blood (relative intensity increase); 2) the detection threshold; 3) the size of the sample 
volume; 4) the fast Fourier transform (FFT) frequency resolution; 5) the FFT 
temporal resolution; 6) the FFT temporal overlap; 7) the dynamic range of the 
instrumentation; 8) the transmitted ultrasound frequency; 9) filter settings and 10) 
recording time112. Both the use of an intensity threshold and recording time will be 
considered under `Recording Factors'. In addition, scale, sweep speed and gain 
settings will influence results. 
i) Relative Intensity Increase 
This represents the ratio of the acoustic power backscattered from the 
embolus to that of the surrounding moving blood113, and is normally measured in 
decibels (see Chapter 3). The relative intensity increase will be affected to some extent 
by the transmitted ultrasound frequency and gain settings, and is also dependent on 
embolus size and composition and the blood volume in the insonated sample. 
There are differing methods of determining the intensity increase associated 
with an ES - different methods being used in different devices. It is also possible to 
determine the increase manually. For instance, the intensity of the background signal 
may be expressed as a mean or median value over a certain time period or frequency 
range, both of which may be variable. Therefore, for any given ES, differing values of 
intensity increase may be derived, even with all other settings kept constant. 
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This could potentially have a major influence on ES detection if an intensity 
threshold is used. This effect is examined in Chapter 3. 
ii) Sample Volume 
The cross -sectional area of the sample volume at the insonation depth is 
referred to as the `beam -width'. For any given probe, the transmitted ultrasound is not 
uniform, and the beam width will vary with insonation depth - this source of 
variability is beyond the control of the investigator. It is possible, however, to adjust 
the axial length of the sample volume. The larger the sample volume, the greater the 
power output of the transducer. Alterations in axial sample volume will effect a strong 
influence on measurements of relative intensity increase, and this has been 
demonstrated in an experimental set- up114. As axial sample volume increases, the 
number of small ES detected will be reduced - ultrasound reflected from the 
surrounding blood will be greater and the ratio of signal reflected by the embolus to 
background signal will be reduced. This ratio may also be described as the 
embolus:blood ratio, or EBR113 
iii) Frequency Resolution and Temporal Resolution - Fast Fourier 
Transformation 
TCD systems use a method of analysis known as Fast Fourier Transformation 
(FFT) to convert the Doppler audio (time domain) signal into the standard time - 
frequency spectrum display (frequency domain). Intrinsic to FFT processing is that 
there is an inversely proportional relationship between time and frequency resolution, 
such that to simultaneously produce high levels of both is impossible, and some 
compromise has to be made115. As ES are of short duration (often only 10 
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milliseconds) it would be necessary to produce time resolution of just 1 millisecond to 
accurately measure their duration. It is not possible to do this, as it would require too 
great a reduction in frequency resolution - i.e. increasing the time resolution to cope 
with very short duration ES decreases the frequency resolution such that no useful 
information on ES velocity can be obtained. 
Each FFT is displayed as a column on the frequency display, and execution of 
each FFT requires a specific amount of time. To obtain a reasonable temporal 
resolution, the data segment analysed should not exceed 5 to 10 milliseconds "`. The 
greater the number of points used for the FFT, the poorer will be the temporal 
resolution - an FFT resolution of 64, 128 or 256 points is preferred at present'''. 
Depending on the speed of the processor, a variable amount of each FFT can 
be overlapped with the next FFT. If there is no overlap, then it is possible that an ES 
may be missed by virtue of an embolus passing through the sample volume but 
arriving between the sampling period of the two time windows and therefore not 
being displayed on screen. Inadequate FFT overlap may produce variability in the 
measurement of the intensity increase associated with an ES if it occurs at the 
temporal edge of the FFT time window` 16. The FFT settings should be kept constant 
for all recordings - an overlap of >_50% is essential, as smaller overlaps (e.g.10 %) will 
risk missing individual ES1'' 
iv) Dynamic Range 
Large solid emboli or those resulting from gaseous bubbles in the circulation 
may produce very high- intensity ES with receiver overload and aliasing - precluding 
assessment of both the intensity increase and ES velocity ''. Such signals may appear 
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similar to those produced by artefact. Determination of the intensity increase may 
therefore be hindered by a low dynamic range - especially with older machines. To 
minimise the effect of this restriction in clinical practice, it is best to record at low 
power and gain settings'''. 
v) Transmitted Ultrasound Frequency 
A 2MHz probe is almost universally applied for TCD recording purposes - use 
of a different transmitted ultrasound frequency will change both background signal 
and that reflected from an embolus. Higher frequencies produce lower sensitivity, 
while reports of use of a lower frequency (1MHz) probe in ES detection in both in- 
vitro 1 18 and in-vivo' 9 models have been promising - showing an increased 
signal:background ratio. 
vi) Scale 
The scale can be adjusted to alter the velocity range of the Doppler signal. The 
lowest scale setting will therefore allow the full velocity range of the Doppler signal to 
be accommodated. The higher the scale setting, the higher the pulse repetition 
frequency (PRF, number of pulses per second), and therefore higher ultrasound, or 
power, output. Scale should therefore be kept constant for all recordings. Decreasing 
the scale may increase the numbers of ES missed as there will be reduced temporal 
resolution with lower PRF and velocity range. Scale should be kept constant where 
possible - where the maximal velocity of the Doppler spectrum extends beyond the 
velocity range it should be possible to alter the position of the zero baseline rather 
than alter the scale. 
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vii) Sweep Speed 
Adjustments to sweep speed effectively adjust FFT overlap - the faster the 
sweep speed, the greater the degree of overlap between successive time frames, with 
effects on ES detection as described above. 
viii) Gain 
The gain setting may be adjusted to change the amplification of the received 
Doppler spectrum, such that a clearly defined spectrum is obtained. The intensity scale 
is colour -coded and adjustable in configurable steps. Recording acquisition should be 
done at constant low gain settings, such that the Doppler spectrum is just visible - this 
increases the effective dynamic range over which the intensity increase can be 
measured "4. 
2.5.2 Recording Factors Influencing Detection 
i) Documentation 
The most widely used documentation system presently in use is to record the 
pre -FFT signal (time domain signal) to digital audio tape'20. This allows analysis of 
recordings to be made off-line, blinded to clinical information; also peimitting re- 
examination of regions of interest and exchange of data between centres. 
ii) Duration 
Studies have shown that both incidence and frequency of ES may vary greatly 
over time107,121,122. It can be seen in Table 2.4 that recording times used have varied 
from 20 minutes to 1 hour. The influence of recording time on ES detection will be 
considered in greater depth in Chapter 6. 
40 
iii) Interpretation of Results 
In interpretation of recordings made for ES detection there is great potential 
for bias and intra- and inter- observer variation. These factors can be minimised by: 
i) analysing all recordings with no knowledge of patient data - i.e. off-line, and 
ii) standardised training of personnel who are to interpret the recordings. 
A study in 1996 examined reproducibility between two centres which had 
different reporting rates of ES positive subjects`''. Using a standard tape made of 
composite recordings from 8 subjects with ipsilateral CAS in whom ES had been 
detected in a previous study, they assessed both within- and between- centre 
agreement by examining reporting rates from a total of 4 experienced observers. They 
reported a high level of agreement, both between all observers (0.90), between three 
observers in one centre (0.89) and between observers in the two different centres 
(0.94). Probability of detection was independently related to the relative intensity of 
the embolic signal (P= <0.0001) and also to the position of the ES in the cardiac cycle, 
(P =0.02) - signals were more reliably detected in systole. The fact that the more 
intense ES were more likely to be detected led the group to examine the effect of 
setting a decibel threshold to further define an embolus - though this increased rates of 
agreement, it had an adverse effect on the sensitivity of the technique. 
iv) Use of a Decibel Threshold 
The typical characteristics of an ES as first detected have been described 
previously - with recorded intensity of ES up to 40 decibels. Again, from the 
table,(2.4) it can be seen that studies have varied in the minimum threshold used to 
define an ES from 3 to 9 dB. In response to the variable findings among centres, in 
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1995 the Consensus Committee of the Ninth International Cerebral Haemodynamic 
Symposium released a statement on the basic identification of Doppler microembolic 
signals124. They recommended that to constitute an ES, the signal should have the 
following basic features: 
1. a Doppler microembolic signal is transient, usually lasting less than 300 
milliseconds. Its duration depends on its time taken to pass through the Doppler 
sample volume. 
2. the amplitude of a Doppler microembolic signal is usually at least 3dB higher than 
that of the background blood flow signal and depends on the characteristics of the 
individual microembolus. 
3. within the appropriate dynamic range of bi- directional Doppler equipment, a signal 
is unidirectional within the Doppler velocity spectrum. 
4. depending on the equipment used and its own velocity, a microembolic signal is 
accompanied by a `snap', `chirp' or `moan' on the audible output. 
The typical appearance of an ES has been illustrated in Figure 2.1. 
From the technical aspects discussed above, it can be seen that variations in 
intensity may result from equipment used and recording settings - further differences 
may be produced by interpretation methods, which will be described below and in 
Chapter 3. Decibel thresholds need to be determined for each individual centre 
publishing results. 
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2.6 Use of Automated Embolus Detection Systems 
At present there is no reliable automated ES detection system - all analysis of 
recordings done off-line is therefore done manually - the recordings may be lengthy 
and may yield few ES. Some studies have been published having used commercially 
available automated systems, and the potential problems arising from such systems are 
considered in further detail in Chapter 4. 
Yet further variability may arise due to differences in patient populations and 
treatment regimes - it can be seen that even within studies there may be great 
variations in anti- platelet and anti -thrombotic therapy used. This effect can be 
minimised within study by standardising treatment protocols, but may not always be 
practical or ethical. 
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Chapter 3 
Methods: Transcranial Doppler Ultrasound 
In the previous chapter, technical and recording factors which may produce 
variability in reported results were discussed, with reference to previous studies in 
subjects with carotid artery stenosis. In this chapter, general methods used for all 
TCD recordings reported in this thesis will be described. 
3.1 Patient Recordings 
All patient recordings were performed using the commercially available 
TC4040 Pioneer (Nicolet EME Limited, Überlingen, Germany) with software version 
2.21, designed for diagnostic cerebral investigation and long -term unilateral or 
bilateral cerebrovascular monitoring. The `probe' referred to and used throughout is a 
2MHz transducer. 
In all cases, unilateral recordings were made from the MCA ipsilateral to the 
stenosed carotid artery via the transtemporal window. Once a satisfactory MCA signal 
was obtained the probe was held in place using an external fixation device, and 
recording commenced for the time selected. For initial studies the fixation device used 
was a Müller and Möll headset, though an updated headset, (Spencer Technologies, 
Marc500) was used in studies performed after June 1997. 
The MCA was selected as it supplies the majority of the circulation to its 
ipsilateral hemisphere. It is a direct continuation of the internal carotid artery and is its 
main branch, coursing in a horizontal plane, laterally and slightly anteriorly. It is the 
largest branch of the ICA, with a normal mean diameter of 2.5 -3.8mm 1225,126, and 
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forms an angle of <20° with the insonating probe. Identification of the MCA was 
made on a number of criteria as described below: 
1. ability to insonate the vessel via the transtemporal window. 
2. the depth in millimetres from the face of the transducer at which the sample volume 
is being recorded. This is taken in combination with the ability to trace the vessel 
along its length. 
3. the direction of flow in relation to the transducer - in the case of the MCA, flow 
will be seen towards the probe. 
4. the spatial relationship of the insonated vessel to the bifurcation of the internal 
carotid artery and ability to separately identify the posterior cerebral artery. 
5. relative flow velocity of the insonated vessel. 
It has been suggested that a sixth criterion should be used - that of the effect 
of common carotid artery compression manoevres on intracerebral flow. We did not 
apply this to our patient group, as all had significant carotid artery disease, and there 
are potential hazards associated127. 
In the case of the recordings made in the dissection phase of carotid 
endarterectomy, and following carotid PTA, the patient was examined in the supine 
position. Following carotid endarterectomy, patients were examined while sitting at an 
angle of 45 °. All other recordings were made with the patients sitting upright in a 
chair. 
During the recordings, patients were discouraged from speaking, as this 
produces artefact which may obscure ES. 
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Single depth recordings were made onto digital audio tape (DA -R120, TDK 
Limited, Japan) using a Sony DAT Walkman (Sony Corporation, Japan). Multi -gate 
recordings were made onto Hi8 videocassette (Maxell, Japan) using a TASCAM DA- 
88 digital multitrack recorder (TEAC UK Limited, Watford, Hefts, UK). All 
recordings were encoded at the time of their being made, and no patient data were 
recorded onto the tape packaging. This enabled further coding to be done at a later 
date and facilitated later off-line analysis to be carried out in a blinded fashion. 
3.1.1 Technical Settings 
i) Sample Volume: We initially aimed for a sample volume of 4mm, but as this did 
not provide sufficient power to obtain a satisfactory Doppler spectrum in the majority 
of patients, this was changed to 5mm at an early stage in the project. In those patients 
where 5mm proved insufficient, the sample volume was increased step wise to a 
maximum of 12mm giving a power of 53% (100% power = 675mW /cm2). 
ii) FFT Resolution: For all recordings a 128 -point FFT was used. 
iii) FFT Overlap: An FFT overlap of >50% was used in all recordings. 
iv) Dynamic Range: The Pioneer 4040 allows a dynamic range of 64 decibels. 
v) Filter Setting: The high -pass filter cut -off used in all recordings was 120 Hz. 
vi) Scale: The scale used for all recordings was such that the standard 
velocity range was 0 to 135 cm/second. Where this was insufficient, the baseline zero 
was shifted towards the base of the screen to increase the displayed velocity range. 
vii) Sweep Speed: This was kept constant at 5.1 seconds for all recordings. 
viii) Gain: All recordings were made at low gain settings. 
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ix) Depth: Depth settings used were between 46 and 56 millimetres in 
order to achieve the best possible signal. Where two -channel (multi- depth) recordings 
were made, recordings were standardised with the optimum signal set as the distal 
channel (proximal MCA) with the reference gate 4 millimetres distally (proximal 
channel, distal MCA). This protocol was decided on the basis of the multigate 
Doppler study described in Chapter 4. 
3.2 Validating Recording Protocols 
3.2.1 Recording Duration The consideration of duration of recording used 
will be discussed in detail in Chapter 6 - for all studies, recording times chosen will be 
explained in the relevant chapter. 
3.2.2 Recording Interpretation Prior to undertaking any definitive analysis of 
recordings for the presence of ES, it is first necessary to familiarise oneself with the 
usual characteristics of ES as recorded onto digital audio tape, and to then validate 
the analysis technique against a standard recording. Analysis of the standard recording 
referenced123 in Chapter 2 was therefore undertaken to determine the percentage 
agreement of my analysis technique against that of an experienced observer. 
A total of 1.75 hours of tape were analysed for ES, from a total number of 8 
patients. When an ES was detected, the time of onset of this signal was documented, 
and the Doppler spectrum at that time was saved to the hard drive for later review if 
necessary. Once analysis was completed the record of all ES detected was compared 
with that produced by another experienced observer (HSM). 
ES were identified on the basis of their characteristic appearance as described 
in Chapter 2. In total, Observer 1 (JM), observed a total of 89 signals felt to be 
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embolic in nature. The results for embolus detection were compared with Observer 2 
(HSM), who reported 85 embolic signals in all. The results were compared to give a 
figure for likelihood of agreement between the 2 observers. 
Normally comparison between observers is made using Cohen's kappa. This 
statistic cannot be applied in the situation described here, as analysis of the tape 
recording relies only on reporting of positive results - there are not any episodes 
where neither observer records an event (or 'abnormality'). Hence the number of 
occasions where neither observer records an abnormality is unknown, and is 
potentially infinite. If we apply the kappa statistic to the proportion of agreement from 













Table 3.1. Cross -tab table illustrating numbers used to calculate kappa co- efficient for 
proportion of agreement for the 2 observers as described above. Cohen's kappa from 
this table is -0.048, indicating extremely poor agreement - it is obvious however that a 
high degree of agreement had been attained. As there are only 2 observers, there are 
no 'negative' observations, and this affects the coefficient calculated. This problem is 
tackled in Bland and Altman, Statistical Approaches to Medical Measurement'28. 
Potentially there is an infinite number of 'negative' observations noted by both 
observers. To look at the effect of adding 'negative' observations to the kappa 





+ Row Total 
82 7 89 
3 18 21 
85 25 
Table 3.2. Effect of adding a small number of negative observations to the 
calculations - kappa coefficient here is = 0.726. 
The degree of agreement suggested by the kappa statistic will progressively 
improve as more and more theoretical negative observations are added as illustrated in 
Table 3.3 and Table 3.4. 
Observer 1 
Observer 2 + - Row Total 
+ 7 89 
- 3 408 411 
Column Total 85 415 










Table 3.4. Increasing the number of agreed negative observations further, kappa = 
0.940 - indicating a high level of agreement. 
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Instead of using the kappa coefficient, the most meaningful aspect of these 
observations (of ES) is the probability that if the first observer records an ES then the 
second observer will concur, because a proportion of agreement regarding negative 
observations will only be possible if the results are then compared with those of a 
third observer. 
From the original table (Table 3.1) the proportion of agreement of Observer 1 
(JM) with Observer 2 (HSM) is 0.97 (96.5 %); proportion of agreement of Observer 2 
with Observer 1 is 0.92 (92.1 %). This level of agreement compared favourably with 
the levels achieved in the paper quoted in Chapter 2. From this it was agreed that 
tapes from patient recordings could be analysed independently - initially all possible 
ES identified were saved to the machine hard -drive for review, and after continuing 
good levels of agreement as to what constituted an ES, analysis was continued 
independently. 
3.2.3 Setting a Decibel Threshold 
All studies described in the following chapters also use a decibel threshold, 
which was set at 7dB or above. The reasons for this are defined below. As mentioned 
above, one way of improving inter- observer reliability is to implement a decibel 
threshold to define an ES, though while this improves specificity it does at the same 
time decrease sensitivity. Use of a decibel threshold was inherent in the early 
Consensus Statement on embolus detection`'`, where an increase above the 
background spectrum of 3dB was used. The work that follows focuses on the use of a 
decibel threshold to aid in increasing the specificity of ES identification - intensity 
being just one of the criteria used to identify an ES. 
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Decibel thresholds were used in a number of early studies, varying between 3 
to 9 dB98.1o3_1'(Table 2.4). Some of the studies performed were done using intensity 
thresholds suggested by one investigator on one machine using particular settings - 
these criteria being then directly applied to either a different machine or to the same 
machine with different settings, without any re- assessment or validation. 
The use of differing decibel thresholds as a possible source of variability in 
study reports has been discussed (Chapter 2). Arising from concerns over 
generalisation of thresholds without any within- centre revalidation work, we further 
examined the effect of use of a decibel threshold and analysis techniques used in 
assessing intensity of an ES. 
The decibel scale is a means of expressing the ratios of intensities or powers - 
it is a logarithmic scale, therefore compressing the wide range of intensities and 
powers found in practice into a relatively small range of numbers. It is defined by the 
following equation129: 
Intensity ratio(dB) = l Ologio(I/Io) dB 
Where I is the intensity of the ES and Io is the power of the Doppler background 
spectrum in the absence of any embolic signal - both of these parameters can be 
measured in a number of ways. If the value of Io is a fixed reference level, then 
intensity or power levels can be quoted in dB. Two of these methods are outlined 




Using ES from the standard tape recordings as used in the interpretation 
validation, the intensity increase for each ES was calculated from the colour -coded 
intensity scale on the screen. This can be adjusted so that its intensity can be measured 
to the nearest decibel101 The gain was reduced until the colour of the adjacent cardiac 
cycle reached zero, and the intensity of the embolic signal was then determined. 
Method 2 
Using the same standard recording and the EME Pioneer, the intensity of each 
ES was calculated with the automatic embolus detection software supplied with the 
machine. The algorithm determines the power of the ES over the whole spectral line; 
the background power is also determined over the whole spectral line using a running 
average of background intensity over the preceding spectral lines. It is not possible to 
set a threshold using Doppler speckle for the second method, as the software should 
not detect speckle as opposed to ES. 
3.2.5 Results 
Comparing embolus intensity as measured by the two methods. 
The relationship between ES intensity measured by the two different methods 
described is demonstrated in Figure 3.1. There was a highly significant correlation 
between measurements made by the different techniques (r =0.70, P <0.0001). 
However, as seen in the graph (3.1), the absolute values of intensity for the same ES 
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Figure 3.1. Scatterplot illustrating relationship between ES intensity (decibels) as 
determined by the two reading methods. 
We estimated the effect of these differences on the proportion of ES detected 
using the same decibel threshold but with intensity measured in different ways. This is 
further illustrated in Table 3.5. The percentage of ES detected varied markedly; for 
example, using a threshold of 7dB would result in only 4.9% of signals being missed 
by method 1 but 51.4% being missed by method 2. 














Table 3.5. Demonstrating the effect of measurement of intensity on proportion of 
embolic signals detected with use of an intensity threshold. 
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3.2.6 Discussion 
The results demonstrate that the intensity of the same ES, recorded with the 
use of the same parameters, can be markedly different when analysed in different 
ways. This of course has important implications when employing a decibel threshold, 
and emphasises that criteria developed by one investigator on one machine cannot be 
generalised without initial re- evaluation. Such use of ES criteria can lead to great 
differences in the number of ES detected. For example, the use of a 7 dB threshold 
measured by method 1 resulted in 95% detection of ES, whereas the use of the same 
threshold with intensity measured with method 2 would result in approximately 50% 
of signals being missed. A wider discrepancy may be given in assessment of very low 
intensity embolic signals, such as are commonly seen in carotid artery disease. As the 
ES studied were only those previously detected by 4 observers, this in itself may have 
introduced an intensity threshold. 
Using an inappropriately low threshold for the measurement of intensity may 
lead to inadvertent inclusion of episodes of Doppler speckle as representing ES. 
The differences between the results obtained by the two methods may have a 
number of explanations. The power increase associated with the ES can be measured 
in a number of ways, including the peak increase at one velocity, the area under the 
power increase measured across both velocities and across time, or the power 
increase along the whole spectral line, which will include the power increase of the ES 
and also of the background Doppler spectrum at other velocities. The background 
power can also be measured in a number of ways - it can be measured at the same 
velocity or at all velocities, at the same point of the cardiac cycle or across the whole 
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cycle, and only within the Doppler spectrum or along the whole spectral line. The 
background intensity is higher in diastole than in systole, and therefore the position of 
the ES within the cardiac cycle will alter decibel measurements. If the whole spectral 
line is used, then for technically poor recordings with artefactual noise outwith the 
spectrum the background intensity will appear higher, reducing the effective intensity 
of the ES. 
As this study used a standard recording, it is possible to comment on the effect 
of the reading method on the intensities of the embolic signals recorded. It illustrates 
that in addition to factors at work in causing variation at the recording stage including 
sample volume, depth of insonation, patient anatomy and fast Fourier transformation 
effects, there is also potential for variability in result reporting at the analysis stage. 
3.3 Determining a Decibel Threshold for These Studies 
It has previously been suggested that an appropriate intensity threshold may be 
determined by measuring the intensity increase occurring with random episodes of 
Doppler `speckle' 107; these variations occur in the normal Doppler spectra and result 
from a number of factors, including non -uniformity of the ultrasound field and non - 
uniformity of the red blood cell scatterers. For this reason, the intensity increases 
associated with 200 episodes of random Doppler speckle using recordings from 
normal volunteers, made at the same depth, sample volume and gain were calculated. 
This level of intensity increase above baseline could therefore be expected to be seen 
at random - i.e. not necessarily in association with presence of an ES. 
The histogram demonstrating the intensity distribution of 200 episodes of the 
saved speckle measured using Method 1 is illustrated in Figure 3.2. From this it can 
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be seen if we apply the recommended decibel threshold of >_3dB to define an ES by 
this method then many episodes of speckle may be falsely recorded as representing an 
embolus. Instead the logical conclusion from reading this graph is to use >_7dB as the 
threshold - thus cutting down significantly on reporting of false positives, though at 
some expense to technique sensitivity. Accordingly, a decibel threshold of >_7dB is 
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Figure 3.2. Frequency histogram for the 200 episodes of Doppler `speckle', 
demonstrating increases in intensity above background occurring randomly in normal 
subjects in the absence of any ES. 
Having performed the validation studies above, both in terms of ability to 
successfully identify ES and the validity of the threshold used, it was possible to go on 
to perform patient recordings, as described in subsequent chapters. 
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Chapter 4 
Experimental Use of Multi -Gated Doppler 
A major hindrance to the wider clinical application of TCD is the lack of an 
automated embolus detection system - having to review recordings in real time is a 
lengthy process. A system for embolus detection where segments of interest of the 
recording are saved for review, as used presently in analysis of 24 hour 
electrocardiogram recordings, would be ideal. Until such time as a reliable system 
becomes available, the clinical usefulness of the technique is somewhat restricted. 
4.1 Automated Embolus Detection 
Any automated system developed for embolus detection must be both highly 
specific and sensitive for ES and able to distinguish these reliably from both patient - 
and probe- generated artefact. Previous work done in this field has included use of a 
computer algorithm to identify the characteristic bell- shaped relative intensity increase 
occurring with an embolus, and differentiating this from the bi- directional increase 
seen with an artefact. Using such a system, the investigating group were able to 
achieve high specificity and sensitivity off- line130, but results with on -line systems did 
not match up to their off-line promise131. An alternative is to train a neural network, 
and early work with such a system again showed promise, with a high specificity on- 
line, but with sensitivity only in the order of 70 %132. 
Unfortunately, artefact, such as may occur secondary to movements of the 
probe or patient, can also produce embolus -like signals, and therefore ES cannot be 
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distinguished on the basis of intensity and duration alone. Very high- intensity signals 
may result in receiver overload and aliasing - i.e. the received signal intensity is 
beyond the dynamic range or maximum amplitude of the receiver. According to the 
standard definition of an ES, these cannot be differentiated from artefact''' 
4.2 Principle of Multi -Gated Doppler 
Prior to 1994, multi -gate monitoring of the middle cerebral artery had been 
described as a method to assess blood velocity profiles and in monitoring 
autoregulation and reactivity133. The use of a multi -gate device in embolus detection 
was first proposed by Rune Aaslid at the 8th International Symposium on Cerebral 
Haemodynamics in Münster, Germany in September 1994. It utilises the `coincidence 
method', described by Bothe and Kohlhörster in 1929, that two events triggered by 
the same stimulus should occur within a certain time window. As emboli pass through 
the artery being studied, an embolus would be first detected in the deeper (distal) 
channel and then in the more shallow (proximal) channel after a time delay that should 
bear a relationship to the distance between the two channels. In contrast, signals of 
increased intensity resulting from artefact should appear in both channels 
simultaneously. 
Early studies with this technique using a time delay to define an embolus in a flow 
model gave a sensitivity of 100 %. Using the same method in patients gave a sensitivity of 
98.1% and specificity of 98.8 %134. This study used the FFT data, which has a relatively 
poor temporal resolution, from which to calculate the time delay between two channels. 
Better results would be expected from using the time domain data which provides much 
finer temporal resolution. In addition, the in -vitro validation for this study used only air 
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emboli - there had been no previous validation using solid or formed emboli such as 
thrombus which result in less intense signals and have been more difficult to detect in 
previous automated systems. Despite these reservations, the figures quoted were both 
seen to be an improvement on those produced with previous techniques, and multi -gated 
Doppler was felt to have some promise for incorporation into an automated ES detection 
system. 
In the following study, a multi -gated Doppler ultrasound system was evaluated in 
an in -vitro model using both thrombus and air emboli, and then applied to a group of 
patients with potential embolic sources. 
4.3 Evaluation of Multi -Gated Doppler in a Flow Model and in Man 
4.3.1 Subjects and Methods 
TCD recordings were made using the standard equipment (Chapter 2). The 
Doppler signal was saved with software that allows the pre -FFT time domain Doppler 
signal, the post -r'r'T spectra and the audio signal to be stored on the computer hard disk 
and replayed (SoundTrak, Nicolet EME, Überlingen, Germany). The initial increase in 
amplitude at the time of arrival of an embolus or artefact in each of the two channels was 
measured from the time domain data, allowing a time resolution of 1 millisecond or 
greater. 
4.3.1A In -Vitro Studies 
We constructed a flow circuit using polyethylene infusion tubing (4mm internal 
diameter, Codan Limited), driven by a programmable flow pump (University 
Developmental Co- operation Flow System) and filled with a proprietary blood analogue - 
a suspension of nylon filaments in machine oil that had been previously validated as 
having similar scatter properties to blood (Elf Atochem)135. A waveform similar to that 
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normally obtained from the MCA with relative preservation of diastolic flow was 
obtained; mean systolic flow velocity was 40 cm/s (peak 95 cm/s, diastolic 30 cm/s). Air 
was removed from the circuit through an in -built reservoir tank. A length of the tubing 
was fixed in a water bath and insonated at an incident angle of 35 °, such that there was a 
comparable waveform with equal gain settings at each depth. Channel 1 was set at a 
depth of 52 mm with the following parameters: sample size 5 mm, power 25% (100% 
power is equivalent to 675 mW/cm2); and gain, 8. Channel 2 was set at 42 mm depth, at 
the same settings of sample size, power and gain. 
We introduced emboli of 2 types through a transparent side -arm device, allowing 
visualisation of any accidentally introduced air: 181 air bubbles were introduced using a 
lml syringe to produce bubbles of maximum volume 0.01 ml; 193 thrombus emboli were 
prepared from fresh human blood which had been allowed to clot, cut in cuboid shapes 
with a maximum dimension of 0.5 mm, and then suspended in normal saline. In addition 
368 episodes of artefact were produced; 187 of these were produced by tapping the 
probe and 181 by tapping the tubing to mimic patient artefact. 
4.3.1B Patient Studies 
The patient studies had 2 aims: (1) to determine in what proportion of patients we 
could successfully insonate the MCA with satisfactory gate separation, and (2) to 
determine the sensitivity and specificity of the method in detecting ES and differentiating 
them from artefact. ES in patients with mechanical prosthetic cardiac valves are more 
intense than those in patients with carotid stenosis109 and have been easier to detect by 
previous automated systems; therefore, we evaluated the method in both patient groups 
separately. In the carotid group we also included ES recorded during the recovery phase 
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after carotid endarterectomy and carotid angioplasty; these ES have a similar intensity to 
those recorded in symptomatic carotid stenosis136 
Insonation of 35 MCAs in 24 patients was attempted; (16 men, 8 women; mean 
[SD, range] age, 66.5 years [10.39, 50 -86]). Of these patients, 14 had a known potential 
source of emboli. Six patients with metallic prosthetic cardiac valves were monitored 
bilaterally for 20 minutes. Eight patients with symptomatic carotid stenosis (mean 
stenosis 84.4 %, range 60 % -95 %) were monitored ipsilateral to the stenosis for 1 hour. 
Four patients later underwent carotid endarterectomy, and 1 patient underwent carotid 
angioplasty. In these patients more extensive postoperative recordings were made for a 
total of 300 minutes per patient. All these recordings were made following the procedure, 
either after catheter removal for percutaneous transluminal angioplasty, or in the recovery 
room for endarterectomy, and no recordings were made during the procedures when ES 
could represent air bubbles. In the additional 10 subjects recruited from hospital in- 
patients, monitoring was continued only for the time it took to obtain a satisfactory 
signal; this was to determine whether adequate gate separation could be obtained. 
Insonation was via the standard approach (Chapter 2). Once the MCA was 
identified, the depth in the two channels was adjusted, and the axial sample volume 
reduced while satisfactory visualisation of the Doppler spectra within the two samples 
was maintained. A standard protocol was used in siting the position of the two sample 
volumes; we aimed for a sample volume of 5 mm and a distance between the centre 
points of the sample volumes (i.e. between the two depths) of 10 mm. Episodes of 
artefact were also recorded for off-line analysis as above. These were produced by 
requesting that the patient cough, speak or swallow, and by tapping or moving the probe, 
probe holder, or headgear. 
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4.3.1C Signal Analysis 
For all ES, maximum relative intensity increase was determined according to 
Method 1 (Chapter 3). The pre -FFT time domain data from the two channels were used 
to determine whether the intensity increase was present in both channels; if so, the time 
delay for the onset of the intensity increase in the two channels was measured. The time 
of `arrival' of an ES was defined as the point at which the amplitude of the time domain 
signal was greater than twice background with a concomitant high intensity signal on the 
colour -coded display. Comparisons between groups were made with the use of Student's 
t test for unpaired data. 
4.3.2 Results 
4.3.2A In -Vitro Studies 
All 374 emboli were detected as high intensity signals. Air emboli resulted in more 
intense signals than thrombus emboli mean (SD, range) for air emboli 31.5 dB (11.8, 11 
to 39) versus 22.5 dB (4.8, 11 to 39) for thrombus emboli, p <0.0001. Forty -three air 
emboli but no thrombus emboli resulted in receiver overload and a bi- directional signal, 
as previously reported; these were included in the analysis. All emboli were detected in 
both channels (Figure 4.1A, 4.1B), in all cases first in the more proximal channel, with a 
mean (SD, range) time delay between the two channels of 17.56 ms (10.31, 3 to 53). The 
mean (SD, range) delay was 17.32 ms (9.94, 3 to 53) for air emboli and 17.78 ms (10.66, 
4 to 50) for thrombus emboli. In contrast artefact appeared simultaneously, or near 
simultaneously, in the two channels (Figure 4.1C) with a mean (SD, range) time delay of 
-0.01 ms (0.39, -4 to 2); p <0.0001 versus emboli. 
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Figure 4.1. Time domain Doppler signals 
for: A) air embolus in flow model; B) 
thrombus in flow model; C) artefact 
caused by probe tapping in the flow 
model; D) embolic signal from patient 
with prosthetic metallic cardiac valve; E) 
embolic signal from patient with carotid 
artery stenosis; F) lower amplitude signal 
embolic signal from subject with carotid 
artery stenosis. In each, the lower of the 
two traces represents the distal channel 
(proximal MCA). A time delay is present 
between the onset of the amplitude 
increase in the two channels in A,B,D,E 
and F. In contrast the artefact in C 
appears simultaneously in the two 
channels. The amplitude increase in the 
proximal channel for the carotid embolic 
signal in (F) is of low amplitude compared 
with the background Doppler signal (see 
text for further discussion). 
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Figure 4.2. Frequency histogram of the time delay between the onset of the 
amplitude increase in the two channels for air and thrombus emboli and artefact in the 
flow model. 
Time delays for air and thrombus emboli and artefact are shown in Figure 4.2. 
When we specified a cut -off time delay of more than 2 ms to define a signal as an 
embolus, could detect and differentiate them from artefact with a 
sensitivity of 100% and a specificity of 100 %; this was similarly good when either air 
emboli alone or thrombus emboli alone were considered. These values include the 43 air 
emboli which resulted in receiver overload and aliasing; for these cases analysed as a 
separate group, mean (SD, range) time delay between gates was 19.81 ms (9.61, 9 to 
53). 
There was a highly significant relationship between the velocity at which the 
embolic signal intensity increase occurred and the time delay between the two channels: 


























Time 8 0 
o $ 
delay o # o o y 30 o 0 
o o 0 
(ms) o 0 
o g g o 0 
O 0 °° o o o $ 
g 
o o 
O o g 
A 








8 o 8 8 
8 
o 

























8 8 8 
0 
20 40 60 80 100 120 
Embolic signal velocity (crn/s) 
THROMBUS EMBOLI 
r = -0.74, p < 0.0001 
o 
o 
o 0 8 o 
ó 8 0 
20 40 60 80 100 
Embolic signal velocity (cm/s) 
Figure 4.3b. 
The two scatter -plots (Figure 4.3a,ó) portray the relationship between the time delay seen 
for each embolus and the velocity of the embolus within the Doppler spectrum. 
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4.3.2B Patient Studies 
Successful insonation of the MCA was possible in 33 of 35 arteries (94.3 %). In 
the two failed cases this was due to unilateral absence of an acoustic temporal window. 
In all MCAs that could be insonated it was possible to record at 2 depths with a mean 
(SD, range) sample volume of 4.96 mm (0.20, 4 to 5) and mean (SD, range) gate 
separation of 4.71 mm (1.85, 1 to 9). 
Prosthetic Mechanical Cardiac Valves 
We recorded 125 ES, with a mean (SD, range) relative intensity increase of 31.1 
dB (7.7, 10 to 55). The mean (SD, range) time delay was 29.6 ms (28.2, 2 to 122). For 
30 ES, all in the same patient, the ES were heard and detected in both the time domain 
data and the post -FFT spectral display in the proximal channel, but were not audible or 
visible in the distal channel suggesting that some emboli may have passed into a 
branching artery between the two sample volumes. All other ES were visible and audible 
in both channels. The mean time delay for ES was significantly longer than that for the 
222 episodes of artefact which had a mean (SD, range) time delay of 0.0 ms (0.46, -2 to 
3, p <0.0001). Time delays for the ES and artefact are shown in Figure 4.4. When only 
the ES detected in both channels were included, and a threshold of a time delay of 2 
milliseconds between the two depths as the defining criterion for an ES were used, the 
sensitivity was 98.9 %, and specificity 99.0 %. However, if the ES visible in only one 
channel were also included the sensitivity fell to 75.2 %. On the whole, ES in patients with 
cardiac valves were clearly visible as a large amplitude increase in the time domain data, 
in contrast to some of the carotid ES (Figure 4.1D) 
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Figure 4.4. Frequency histogram of the time delay between the onset of the amplitude 
increase in the two channels for embolic signals in patients with carotid artery stenosis 
and mechanical cardiac valves and artefact in the same patients. 
Carotid Artery Stenosis 
We recorded 141 ES, with a mean (SD, range) relative intensity increase of 
19.3áB (5.9, 5 to 33). No ES were visible and audible in the proximal channel but not in 
the distal channel, unlike the valve ES. However, two ES audible and visible in the post - 
FFT spectra in both channels were identifiable in the time domain data of only one 
channel; one ES was detected only in the proximal but not the distal time domain data, 
while one ES was clearly audible and visible in the proximal channel post -FFT spectral 
display but not visible in the time domain data at that depth. This appeared to be a 
reflection of the fact that the amplitude increase in the time domain data was small for 
many ES, Figure 4.1E, and on occasion difficult to distinguish from the background 
Doppler signal; a typical example is shown in Figure 4.1F. The ratio of the maximum 
amplitude increase to the background Doppler signal amplitude in the time domain data 
was small for many carotid ES, and the mean value was significantly smaller than that for 
valve ES. (5.1 [2.5] versus 13.2[5.7]; p = <0.0001); individual values are shown overleaf 
in Figure 4.5. 
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For ES identifiable in both channels, the mean (SD, range) time delay between the 
two channels was 14.9 milliseconds (15.42, 0 to 90). The time delay was significantly 
longer than that of the 222 episodes of artefact, p = <0.0001. When the same 2 -ms cut- 
off was used, a sensitivity of 94.0 % and specificity of 99.0% was obtained when those 
signals identifiable in both channels were considered (Figure 4.4). The sensitivity fell to 
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Figure 4.5. The ratio of the amplitude increase in the pre -FFT time domain signal for 
embolic signals compared with that due to the background Doppler signal in the absence 




In this in -vitro model, the use of a multigated technique allowed the identification 
of ES and their discrimination from artefact with a very high sensitivity and specificity. Of 
particular note, it allowed detection of ES resulting in receiver overload with a similar 
high sensitivity and specificity - the first method to be able to identify such ES - which 
cannot be identified from the frequency spectral data alone either visually or with the use 
of a neural network132 or computer algorithm'30 This application may be particularly 
useful when it is used during operative procedures, when both echogenic air emboli and 
artefact may be common. In addition, the multigate data may allow the unambiguous 
identification of low -velocity ES, which can sometimes be difficult to separate from 
artefact on frequency spectral data alone. 
In all patients in whom an acoustic window could be obtained, it was technically 
possible to record using the multi -depth probe with adequate gate separation. We 
identified the sensitivity and specificity of the multigated system using ES identified 
according to conventional criteria and compared them with known episodes of artefact. 
The results in patients were encouraging but not as impressive as the in vitro data for a 
number of reasons. This was primarily because in some patients the ES did not appear in 
both channels. In one patient in the valve group, 30 ES (approximately 40% of the signals 
in this patient) were detected proximally but were not audible or visible distally in either 
the time domain data or in the post -FFT spectral data. This is likely because between the 
two sample volumes a proportion of the emboli passed down a branch vessel. Our 
protocol aimed for a gate separation of 10mm between the centres of each sample 
volume, and sometimes the distal gate was a fairly shallow depth of 42 mm; the problem 
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may be reduced with the use of a deeper distal gate, thereby lowering the chance that this 
gate may be sited beyond the branching of the MCA. 
Further studies are required to examine whether reduced gate separation allows 
such good discrimination between emboli and artefact. On the other hand, gate separation 
that is too narrow will reduce the time interval between detection of emboli in the 
proximal and distal gates and will reduce the specificity in differentiating emboli from 
artefact. Apart from this difficulty in a single patient, the use of a multigated probe in 
patients with prosthetic cardiac valves allowed detection of emboli and differentiation 
from artefact with a very high sensitivity, similar to that seen in the in -vitro model. This is 
a largely a reflection of the higher intensity of the more echogenic mechanical valve ES, 
as previously reported. This resulted in a large and clear amplitude increase in the time 
domain signal (Figure 4.1D). 
In contrast, for the less intense carotid ES, some signals were identifiable audibly 
and in the post -FFT spectral display but not in the time domain data. This occurred for 
low- intensity emboli, in which the power or intensity increase was small and lost in the 
background Doppler signal. It is possible that the total cross -sectional area of the MCA is 
not fully covered by the sample volume at both depths. This will be less of a problem for 
more echogenic emboli, which have a larger effective sample volume137. Separating the 
intensity increase at different frequencies by FFT analysis allowed identification of the ES 
since the intensity increase of an ES is maximal at one frequency. Although only two 
carotid ES were not detectable in the time domain data, a much larger number resulted in 
an amplitude increase only slightly greater than that of the background Doppler signal. 
This is illustrated by the relatively low ratio of the maximum amplitude to background 
amplitude for many carotid ES in the time domain data (Figure 4.1E; Figure 4.5). With 
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the use of off-line analysis in combination with the post -FFT spectral data, it is possible 
to determine the time delay for most carotid ES. However, it may prove difficult in 
automated on -line systems based on the time domain data alone to distinguish the small 
amplitude increase occurring with some carotid ES from amplitude fluctuations in the 
normal background Doppler signal. Further work is required to improve the sensitivity of 
the multigated technique for small- amplitude ES. 
The predominant factor determining the time taken to travel between the two 
channels was the velocity at which the ES was maximal, which presumably reflects the 
speed at which the embolus is travelling. However, in the model that there was a much 
greater range of time taken between detection in each channel than would be expected by 
simple mathematical principles. The theoretical distance travelled by an embolus as 
detected by the probe is 5 mm (i.e. distance between the edges of the axial sample 
volumes). If we correct for angle of insonation, an embolus travelling at the mean 
velocity (40 cm/s) would be expected to take 15.3 ms to cross between the two axial 
sample volumes. Any embolus travelling at the peak velocity for the system (95 cm/s) 
would be expected to give a time delay of 6.4 ms between the two depths. It is 
noteworthy that 46 of the emboli we produced traversed the distance in 6 ms or less. This 
reflects the fact that rather than being cylindrical in shape, with a sharp cut -off of the 
ultrasound beam at each end of the sample, there is a gradual weakening of the beam at 
each end. It follows that the effective sample volume will be greater for more echogenic 
emboli such as air embolii3'. In patient studies some ES took much longer to travel 
between the two sample volumes, and this was particularly so for some valve ES. This 
may be due to their passage being slowed by turbulence, non - laminar flow, and 
momentary adhesion to the vessel wall. 
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The results demonstrate that a multigated approach can detect ES and 
differentiate them from artefact, but, as with other methods, it has some inherent 
problems which need to be resolved before it is suitable for routine clinical use. The 
results are similar to those reported previously134, but show a lower sensitivity for low 
amplitude carotid ES. In the previous study carotid ES, a minority of all ES studied, were 
not separated from those from patients with heart valve replacements or left ventricular 
assist devices, and no analysis of the intensity of the ES was made. Our results 
demonstrate that in patients with the more intense mechanical valve ES, high sensitivity 
and specificity is likely to be obtained; the only major difficulty appeared to be passage of 
emboli down a branching vessel between the two sample volumes, and this may be 
improved by reduced gate separation. In patients with carotid ES, the less intense ES 
may be unclear in one or both channels. For these ES combining the multigated method 
with a method analysing the post -FFT spectral data may improve sensitivity; use of the 
frequency spectra may provide greater resolution because the intensity increase 
associated with an ES is usually centred on a narrow frequency band. 
4.5 Further Development 
From the above discussion it can be seen that the two situations causing 
reduced sensitivity of the technique occur: i) in association with a large gate 
separation distance, and ii) in subjects with low intensity ES, as seen in carotid artery 
stenosis. 
As a direct result from this work, future multi -gate recordings were made as 
follows: the reference depth was taken as the depth at which optimum spectral 
recording was possible. The second channel was set 4mm proximal to this (i.e. the 
reference recording was made from the proximal MCA with the second gate 
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recording from distal MCA). This was done in an attempt to minimise `loss' of an 
embolus via an artery side branch. 
The problem with low intensity ES is of a small increase in amplitude in the 
time domain signal against the background amplitude. A possible method of reducing 
this effect is to use a lower frequency probe, e.g. 1MHz, which would theoretically 
improve the background -to- signal ratio1'. 
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Chapter 5 
Embolic Signals in Carotid Artery Stenosis (I) 
Part I 
5.1 Correlation with Markers of Clinical Risk 
As discussed, cerebral embolism from extra -cranial internal carotid artery 
disease is an important mechanism of ischaemic stroke'38'40 and the increase in 
stroke risk conferred by presence of a significant internal carotid artery stenosis has 
been confirmed in two major trials64,65 At present, carotid endarterectomy is not 
routinely indicated in the management of asymptomatic CAS, on the basis of risk - 
benefit analysis141. Trials are ongoing to identify indicators of higher risk within this 
group taz 
For more than 30 years, case reports have existed of direct visualisation of 
embolic material within the retinal circulation'43,144 but it was not until 1990 that it 
was appreciated that particulate emboli could be detected in the intra- cranial vessels73. 
Since this time there have been a number of studies monitoring for ES in the setting of 
CAS, and ES have been shown to correlate with individual markers of stroke risk: 
they are more common in symptomatic than asymptomatic disease'o5107, and are more 
common soon after the appearance of symptoms108,145,146 ES have also been shown to 
be more frequent in association with the presence of plaque ulceration as determined 
both by imaging1 ' and on histological examinationl04 There are case reports of ES 
abating in response to treatment with antiplatelet or anticoagulant therapy 
107,147 while 
in a small prospective study in asymptomatic CAS, the presence of two or more ES 
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of two or more ES per hour was a highly significant independent predictor of stroke 
risk148. It may be that the rate of TCD- detected embolism may reflect to some extent 
the `disease activity' of the carotid lesionlo8 
In this study we determined the incidence and frequency of embolisation in a 
large series of patients with CAS and correlated the presence of ES with a number of 
markers of risk in order to further determine the clinical relevance of asymptomatic 
ES detection. 
5.1.1 Methods and Subjects 
One hundred and twenty -three (123) patients with >60% CAS as determined 
on Duplex criteria149 were recruited to the study. Of these, successful insonation of 
the ipsilateral MCA was possible in 111 (90.2 %). Symptomatic patients (n =69) were 
defined as having had symptoms (amaurosis fugax, TIA, or stroke) in the territory of 
the stenosed artery within the previous 12 months. Patients with a possible cardiac 
source of embolisation (atrial fibrillation, valve disease /prosthesis) were excluded 
from the study. All patients were maintained on anti -platelet/anti- thrombotic 
medication as prescribed at their time of entry into the study. 
Clinical data, including time lapsed since last symptoms where appropriate, 
were recorded for all subjects. 
In addition, 74 (66.7 %) patients underwent carotid angiography for clinical 
reasons. In 67 patients the resulting films were of sufficient quality as to ascertain 
presence or absence of plaque ulceration or irregularity. 88 patients (79.3 %) had brain 
imaging by CT scan. 
TCD recordings were made from the middle cerebral artery using the standard 
equipment and protocol (Chapter 2). Target sample volume initially was 4mm - as this 
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failed in many cases to deliver sufficient power for satisfactory recording this was 
changed after recruitment of the first 40 patients to 5mm. The axial sample volume 
was then increased further if necessary to obtain a suitable signal. The sample volume 
used for each patient was maintained on any subsequent recording. 
Analysis of all recordings was performed blind to patient clinical information 
according to the standard validated methods (Chapter 3). 
Each patient underwent recording for 1 hour, and 77 patients (69.4 %) 
attended for a second 1 -hour recording on a separate occasion. Mean (SD,range) time 
between recordings was 17.53 days (20.96, 1 -123). Median (range) depth of 
insonation was 52 nun (46 -56) for the first recording made. Median (mean, range) 
sample volume for all first recordings was 5 mm (5.56, 4 -12). Any recording 
containing 1 or more ES is described as ES positive. 
5.1.2 Results 
Comparing ES positive to ES negative subjects, there were no significant 
differences in vascular risk factors between the two groups - see Table 5.1. 
Factor ES positive(n=41) ES negative(n=70) P 
Mean age (SD, range) 66.3 (9.95, 42-81) 67.0 (8.9, 43-82) 0.72 
Male sex 30 (73%) 43 (61%) 0.21 
Hypertension 29 (71%) 46 (66%) 0.59 
Diabetes mellitus 7 (17%) 12 (17%) 0.99 
Hyperlipidaemia 18/40 (45%) 38/67 (57%) 0.24 
Ischaemic heart disease 15 (37%) 22 (31%) 0.24 
Peripheral vascular disease 17 (41%) 23 (33%) 0.36 
Current smoker 9 (22%) 22 (31%) 0.28 
Table 5.1. Patient characteristics comparing ES positive to ES negative subjects. 
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5.1.2A ES and Symptom Status 
Of the total 111 recordings made, 41(36.9 %) were ES positive. For the 69 
symptomatic patients, 29 (42.0 %) were positive, compared with 12 (28.6 %) positive 
records in 42 asymptomatic subjects, p =0.15. ES were more common in recently 
symptomatic patients: 27 of 57 (47.4 %) patients with symptoms in the last 6 months 
were ES positive (p= 0.058 versus asymptomatic). The effect of changing the time 
cut -off point to define symptom status is demonstrated in Table 5.2. 
Cut -off Point n Percent positive 
recordings 
p (compared with 
asymptomatic) 
1 year 69 42.0 0.15 
6 months 57 47.4 0.058 
3 months 50 48.0 0.057 
1 month 26 53.8 0.037 
Table 5.2. To illustrate the influence of selection of the cut -off point in defining 
symptomatic status in CAS. 
In patients in whom ES were detected, there was no difference in the numbers 
seen between the two groups - median (range) in symptomatic group was 3 (1 -45), 
and in asymptomatic, 4.5 (1 -23), p =0.69, Mann - Whitney U. 
For the 77 patients undergoing two single hour recordings, the two hour 
period was combined, such that effectively the patients had attended for a 2 -hour 
recording. In this group, there were 47 symptomatic and 30 asymptomatic patients. In 
the symptomatic group, 28/47 (59.6 %) recordings were ES positive, compared with 
12/30 (40 %) in the asymptomatic group, p =0.09. Where ES were detected, median 
(range) numbers were 2 (1 -60) and 1.5 (1 -51) respectively, p =0.76. 
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5.1.2B ES and Time Since Symptoms 
In symptomatic patients, mean (SD,range) time since last symptom at the time 
of the first recording, was 79.58 days (85.14, 1 -325). 
The correlation between ES per hour and time from last symptom was 
calculated using Spearman's Rho for non -parametric data. This showed a significant 
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Figure 5.1. Scatterplot illustrating the negative correlation between time since last 
symptom and ES per hour on first recording (y- axis). 
Forty -seven (47) of the symptomatic subjects attended on a second occasion, 
with documentation of time since last symptom - giving a total of 116 recordings in 
symptomatic patients. Considering this group, the relationship had increased 
significance with p= -0.3121, p =0.001 
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5.1.2C ES and Angiographic Appearance 
Angiography was performed in 74 patients. Of these films, 67 were of 
sufficient quality to determine degree of stenosis and plaque characteristics. All films 
were reviewed by a single observer (HSM), blind to the TCD recording results. 
Plaques were categorized as ulcerated, irregular or smooth, according to the criteria 
used in the NASCET trial'so 
Thirteen plaques (19.4 %) were classified as ulcerated, 23 (34.3 %) as irregular, 
and 31 (46.3 %) as smooth. In addition, 14 subjects were seen to have near occlusion 
of the affected internal carotid artery, as defined by collapse of the distal vessel. The 
association between stenosis morphology and ES status is summarized in Table 5.3. 
Plaque appearance n( %) ES positive ( %) 
Ulcerated 13 (19.4) 9(69.2) 
Irregular 23(34.3) 10(43.5) 
Smooth 31(46.3) 9(29.0) 
Near occlusion 14(20.9) 7(50) 
Table 5.3. Relationship between ES status and angiographic appearance of the 
plaque. 
Plaque ulceration was associated with ES - p= 0.025. Presence of ulceration on 
angiography gave an increased risk of embolisation - Odds Ratio 4.14 (95 %CI 1.12- 
15.26). 
5.1.2D ES and Degree of Stenosis 
Stenoses were classified on Duplex ultrasound as .79% (n =20) or 80 -99% 
(n =91) by standard criteria149. We found no association between degree of stenosis 
and embolisation - 6 (30 %) and 35 (38.5 %) were ES positive respectively - p =0.48. 
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5.1.2E ES and Therapy 
Of the total sample, 90 were taking aspirin alone - 44 at 75mg daily, 17 at 
150mg daily and 29 at 300mg daily. Two patients were taking no anti -platelet or anti - 
thrombotic medication. Patients taking any other antiplatelet or antithrombotic 
medication were excluded from this analysis. There was no correlation between ES 
and aspirin dose, p =0.23. 
Aspirin dose(mg) ES positive (n, %) 
75 13(29.5) 
150 9(52.9) 
300 10 34.5 
Table 5.4. Relationship between aspirin dosage and ES status. 
5.1.2F ES and CT Infarct 
89 subjects had brain imaging by computed tomography. 38(43 %) of these 
showed a relevant infarct. There was no difference in the numbers ES positive in each 
group - 42.1% vs. 37.3 %, p =0.64. 
5.1.2G Follow -up and Survival 
All study subjects were followed up from the time of the first recording to 
examine the relationship between presence of ES on MCA monitoring and risk of 
further events attributable to the studied stenosis. Survival analysis was undertaken, 
using the Kaplan-Meier log rank test. An event was defined as a focal cerebrovascular 
event attributable to the stenosis studied. Censor points included carotid 
endarterectomy, carotid angioplasty, carotid artery occlusion, non -stroke death and 
asymptomatic at time of last follow -up. Follow -up (days) was for a mean (SD,range) 
111.7 (190.13, 1 -774). 
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In the symptomatic group, mean (SD, range) time of follow -up was 22.55 
days (20.31, 1 -76). Within this group, 9 (13.0 %) had recurrent events during the 
course of follow -up (7 TIA, 2 stroke). Seven (77.7 %) of subjects within this group 
were ES positive at the time of the first recording, p =0.02, chi -squared. All had at 
least one ES positive recording during the total follow -up period. 
In the asymptomatic group, mean (SD, range) time of follow -up is 258.1 days 
(246.9, 2 -774). At this time, 32 patients continue to be asymptomatic, with recent 
follow -up either at Neurology Outpatients (n =25), or if not possible then by telephone 
(n =7). In this group, two (5 %) have developed symptoms attributable to their 
stenoses (1 TIA, 1 stroke) - both had ES detected at the time of first examination, 
p =0.02, chi -squared. 
The relationship of ES presence to outcome was assessed by Kaplan-Meier 
log rank test. A highly significant association was found between the two - p =0.02 in 
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Figure 5.2. Kaplan -Meier survival plots. A - symptomatic subjects. B - asymptomatic 
subjects. For each plot the top (broken) line represents subjects who were ES 
negative at the time of the first recording. Censored events include carotid 
endarterectomy, carotid angioplasty, carotid occlusion and non -stroke death. `Events' 
are all strokes and TIAs occurring in the distribution of the stenosed artery during the 
follow -up period. 
We analysed the data further to examine any possible link between ES `load' 
and outcome. In studies of ES during and following carotid endarterectomy, ES load 
has been found to be more important than ES status per se`s` To assess numbers of 
ES as a continuous variable against outcome, a Cox regression model must be fitted, 
allowing for the possible confounder of symptom status. As there were no events in 
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the asymptomatic patients with no ES, it was not possible to fit this model. On 
analysis of ES numbers alone, without stratification, there was a significant 
relationship to outcome events, p= 0.0006. This would suggest a trend in the 
relationship, but it would not be valid to quote this statistic more definitively without 
stratification. 
5.1.2H ES Characteristics 
In all, for the first recording alone a total of 316 ES were detected - 223 in 
symptomatic and 92 in asymptomatic subjects. 
Mean (SD) intensity increase seen in symptomatic patients was 12.39 dB 
(4.25) compared with 11.55 dB (3.54) in asymptomatics, p= 0.099. However, as there 
was a large range of ES frequency seen between subjects (1 -45 per hour) these results 
may be subject to skewing, and further analysis was carried out using weighted means 
- mean (SD) intensity increase in symptomatics was 11.2 dB (2.38), compared with 
11.04 dB (2.82) in asymptomatics, p =0.79. 
Comparison was made between symptom groups: there was no difference in 
mean intensity comparing patients within the four clinical groups. 
Group n Weighted Mean (SD) intensity 
increase (dB) 
Asymptomatic 13 10.88(2.76) 
Amaurosis fugax 6 11.16(2.34) 
TIA 9 10.53(2.77) 
Stroke 14 11.66(2.19) 
Table 5.5. Relating ES intensity to symptom category. 
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5.1.3 Conclusion and Discussion 
5.1.3A Clinical Factors 
The study was undertaken in a large series of patients, evaluating a number of 
clinical parameters in relation to embolic activity in carotid artery disease, in contrast 
with earlier studies which have examined individual markers of clinical risk. Small 
studies have already shown that ES are more common in patients with symptomatic 
disease and in such subjects are commoner soon after symptoms. 
A significant correlation was found between ES per hour and the time lapsed 
since the patient was last symptomatic, the association increasing in significance when 
further recordings were added to the analysis. 
Surprisingly, we did not find a significant association between symptom status 
per se and embolisation - an association reported reliably in earlier work. This may be 
explained in part by the time cut -off we used to define `symptoms' or absence of 
symptoms. Previous studies loa,ios,o,ios,n have defined a cut -off point of up to 6 
months to determine symptom status, and have found an association between this and 
embolisation. Indeed by `shifting ' our own cut -off point, first to 6 and then to 3 and 1 
month, the results achieve significance, though some of the power of the calculation is 
lost in this way by reducing numbers in the symptomatic group (as illustrated in Table 
5.2). The results may have been further influenced by our detection of much higher 
rates of embolisation in the asymptomatic group than have been reported previously, 
which was accompanied by a higher level of symptom emergence in the asymptomatic 
group. This is reflected in the survival data which will be discussed in more detail 
below. 
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There was a highly significant association of embolisation with plaque 
ulceration as demonstrated angiographically. Again this is in keeping with previous 
studies104'' 
11, and provides further indirect evidence of the importance of local factors 
at the level of the plaque influencing embolus formation. We found no correlation 
between embolisation and degree of Duplex -determined ipsilateral stenosis. 
Aspirin dose did not appear to significantly influence embolisation - if anything 
there was a trend towards higher incidence of ES on the higher doses of aspirin. It is 
possible that subjects at higher risk of recurrence may be maintained on a higher 
aspirin dose, with asymptomatic subjects more likely to be prescribed a lower dose. In 
addition, splitting the study group dosewise does give small numbers in each group 
which will itself influence the results. 
There was no association found between presence of a relevant infarct on CT 
and ES status. However, we did not exclude patients from this study who had had 
temporally distant symptoms, which may act to confound results. To investigate any 
relationship fully, a prospective study in the setting of asymptomatic CAS with initial 
normal CT brain scan would be necessary. 
5.1.3B Prospective Data 
It has already been discussed that we found much higher rates of embolisation 
in our asymptomatic patients than have been previously reported by other groups. To 
examine further the prognostic significance of ES, we looked at the prospective data 
in more detail, and found that of our series of 111 patients, 11 (9.9 %) had recurrent 
symptoms attributable to their CAS. Both in the symptomatic and the asymptomatic 
groups, there was a highly significant relationship between detection of ES at the first 
recording and symptom recurrence. 
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Taken in combination, the association of known clinical risk factors with the 
presence of ES, and the demonstration that ES predict future events provide 
considerable evidence for the clinical importance of ES in patients with CAS. Further 
reports from NASCET and ECST regarding allocation to endarterectomy of patients 
with moderate CAS suggest that there may be only certain subgroups who will benefit 
from surgery 69'70. It may be implied from our data that those with ES as recorded 
using transcranial Doppler may form an important subgroup in which early 
intervention may be necessary, underlining the importance of incorporation of TCD in 
prospective studies of asymptomatic CAS. However, the numbers in our prospective 




Embolic Signals in Carotid Artery Stenosis (I) 
5.2 Platelet Activation and Carotid Embolisation 
5.2.1 Background 
Previous clinical and pathologic studies have suggested that increased levels of 
platelet activation, or more reactive platelets may be found in the setting of acute or 
transient cerebral ischaemia and in cerebral infarction'522''53. Such platelet activation 
has also been described in the setting of other vascular disorders including unstable 
angina'54, myocardial infarction'", cardiopulmonary bypass156 and following coronary 
angioplasty157 and thrombolysis'58. Platelet hyperreactivity has been reported in 
association with vascular risk factors including hypertension'59, cigarette smoking160, 
diabetes mellitus161, and hyperlipoproteinaemia'62. Increased platelet reactivity has 
also been described in stress163 and following strenuous exercise164. 
Having implicated platelets in thrombo -embolism, one may also expect to find 
a relationship between asymptomatic embolisation and platelet activation. 
Demonstration of such a relationship would provide farther evidence of the clinical 
significance of asymptomatic ES. 
5.2.2 Measuring Platelet Reactivity - Relevance to Cerebrovascular Disease 
i. Platelet Aggregation 
The first available method for evaluation of platelet reactivity came in the 
1960's, with the development of the platelet aggregometer by Professor Born165, 
allowing ex -vivo investigation of platelet responses to physiological agonists. Post- 
88 
mortem studies have revealed circulating platelet aggregates in intra- myocardial 
vessels166 - this observation led to the development of the `Wu and Hoak' platelet 
count ratio method to assess the presence of circulating platelet aggregates167. Platelet 
hyperreactivity as detected by both these methods has been described in the setting of 
both acute ischaemic stroke'53 and transient ischaemic attack' 52'`53 
ii. Platelet Specific Proteins 
Platelet activation can also be measured indirectly by assays of platelet specific 
proteins released on activation. These include beta thromboglobulin (ßTG) and 
platelet factor -4 (PF- 4)168. However measurement of these markers is subject to in- 
vitro activation of platelets during phlebotomy and plasma processing. More recently 
it has been possible to measure urinary ßTG, which is not subject to such influence, 
but it has not been assessed on the scale of a large clinical or epidemiological study. 
Plasma ßTG has been found to be elevated in the acute phase of stroke, and 
independently related to increased mortality169 
iii. Non -specific Platelet Proteins 
Platelet activation is accompanied by thromboxane A2 synthesis. TXA2 is 
released into the circulation and is converted to TXB2, which is then further broken 
down into a series of compounds including 2,3- dinor -TXB2 and 11- dehydro -TXB2, 
which undergo urinary excretion. It is possible to measure urinary 2,3- dinor -TXB2 by 
gas chromatography -mass spectrometry - useful information regarding in -vivo TXA2 
synthesis by activated platelets. Levels of urinary 2,3- dinor -TXB2 are increased in 
cardio -, cerebro- and peripheral vascular disorders170'171. Use of serum TXB2 itself as 
a marker of platelet activation has not been examined in detail. 
89 
The non -specific platelet alpha - granule protein, soluble (circulating) P- selectin 
(sP -sel) may also be assayed in plasma using an ELISA. There are some limitations to 
interpretation of results from such assays, as a proportion of sP -sel is endothelium - 
derived - therefore elevation may represent either primary platelet activation, 
activation secondary to tissue damage or endothelial damage per se. It is argued that 
the failure of sP -sel levels to correlate with von Willebrand factor, an established 
endothelial cell marker, would imply that sP -sel is platelet derived ''. One advantage 
of this assay is that it is not subject to large variations by sampling technique13 
One recent study in the setting of acute ischaemic stroke, and in patients with 
recently ( <1 week) symptomatic CAS found sP -sei levels to be significantly 
elevated14. A second study of sP- selectin levels in patients with symptomatic CAS 
found no relationship - in contrast to subjects with extensive peripheral vascular 
disease.15. This study did not define any cut -off point to define `symptomatic', and 
this may provide a basis for explaining the difference in results. 
iv. Direct Markers 
There are activation -dependent surface membrane changes which occur on 
platelet activation, such that by assessing surface glycoprotein expression it is possible 
to distinguish activated from resting platelets. By using monoclonal antibodies 
(MoAbs) specific for these glycoproteins it is possible to detect activated platelets in 
vivo by flow cytometry 16'177. Changes include down- regulation of the glycoprotein Ib 
receptor, up- regulation and conformational change of the glycoprotein IIb -IIIa 
receptor178, and with release of platelet granule contents the alpha -granule membrane 
proteins are incorporated into the platelet outer membrane. To study activation 
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specific proteins, the two most commonly studied types of MoAb are those directed 
against the conformational change in the GPIIb -IIIa protein and those directed against 
granule membrane proteins. 
The GPIIb -IIIa complex (also known as CD41 /61) acts as a receptor for 
fibrinogen, von Willebrand factor, fibronectin and vitronectin, and is essential for 
platelet aggregation19. It is possible to assess the amount of this antigen expressed at 
the platelet surface using most MoAbs directed against this antigen, or to use an 
MoAb (PACT) directed against the fibrinogen binding site exposed by the 
conformational change in this complex18. Other GPIIb -IIIa -specific activation - 
dependent MoAbs are directed against either ligand- induced conformational changes 
in the complex ( ligand- induced binding sites - LIBS)180 or receptor -induced 
conformational changes in the bound ligand - fibrinogen, (receptor -induced binding 
sites - RIBS) "'. As well as GPIIb -Ilia- specific MoAbs, fluorescein- conjugated 
fibrinogen can also be used in flow -cytometric assays to detect the activated form of 
the platelet surface GPIIb -IIIa complex18' 
More widely studied are MoAbs directed against granule membrane proteins, 
particularly against P- selectin (also known as CD62P; formerly known as GMP -140, 
or PADGEM protein). P- selectin is involved in mediation of adhesion of activated 
platelets to neutrophils and monocytes, and is a component of the a- granule 
membrane of resting platelets only expressed at the platelet surface after a- granule 
secretion'82. 
Fluorescence- activated flow cytometry is advantageous above the other 
measures of platelet activation described, in that platelets are studied within their 
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physiological milieu and the test is specific for and sensitive to presence of activated 
platelets, able to detect a sub -population of as few as 1% partially activated 
platelets183. The technique of flow cytometry is discussed in further detail in 
Appendix 1 (page 156). 
v. Other markers 
Shortened platelet survival time may be used as a marker of increased platelet 
reactivity, as assessed by platelet scintigraphy184 this technique has been used in 
acute ischaemic stroke, confirming marked platelet activation in this setting185 
Increases in platelet volume have been reported in acute cerebral ischaemia 
186,187 
Mother marker, glycocalicin (the extramembranous portion of GPIb) has also been 
assayed, and may have some potential use as a marker of platelet damage' 88. The 
largest case series found no association between glycocalicin level and previous 
TIA189 
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Table 5.6 below provides a summary of platelet activation markers and 
detection methods (taken from Wu,K.K.. Platelet activation mechanisms and markers 




Agonist - induced aggregation Aggregometry 
Shear stress -induced aggregation Viscometer -flow cytometry 
Platelet aggregates Platelet -count ratio or flow cytometry 
Platelet activation products 
Beta -thromboglobulin (plasma or urine) RIA or EIA 
11- dehydro -TXB2 (urinary) RIA 
2,3- dinor -TXB2 (urinary) GC -MS 
Glycocalicin (plasma) EIA 
Activated platelets 








I "In or 51Cr platelet test 
EIA, enzyme immunoassay; GC -MS, gas chromatography -mass spectrometry; GPIIb- 
IIIa, platelet membrane glycoprotein IIb -IIIa; RIA, radioimmunoassay; SPA, 
spontaneous platelet aggregation; TXB2, thromboxane B2 
93 
5.2.3 Platelet Activation and Carotid Artery Stenosis 
From the above discussion, it can be seen that systemic platelet activation has 
been described in the setting of cerebral ischaemia and infarction and in conjunction 
with a number of vascular risk factors. Anti- platelet agents, such as aspirin, are 
proven in secondary prevention of stroke. By combining this knowledge it is 
reasonable to hypothesise that systemic platelet activation may occur in the setting of 
symptomatic CAS and furthermore that platelet activation may relate to development 
of asymptomatic ES - whether this occurs locally at the level of the plaque or as a 
systemic phenomenon. 
In a subgroup of CAS patients recruited to the study detailed in Part I of this 
chapter, we investigated platelet activation using both fluorescence activated flow 
cytometry and sP- selectin assay (ELISA), comparing a group of symptomatic patients 
with CAS to a group of population controls. The relationship between platelet 
activation levels and detection of asymptomatic ES was also investigated. 
5.2.4 Methods 
5.2.4A. Flow Cytometry 
40 subjects were recruited - 26 with CAS (18 symptomatic, 8 asymptomatic) 
from the above study and 14 normal controls. 
After discarding the first 2.5ml of blood, a 1.8ml blood sample was obtained 
for each subject, uncuffed, from an ante -cubital vein and drawn into a syringe 
containing 0.2ml of 3.15% trisodium citrate. Samples were processed immediately for 
flow cytometric analysis as over. 
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Samples were prepared into 5 separate test -tubes: tube 1 acted as a double 
negative control; tube 2 was a single- stained (FITC) preparation of MoAb to 
glycoprotein Ib (CD42b) to allow compensation settings to be made; tube 3 contained 
a single- stained (PE) preparation of MoAb to glycoprotein IIb/IIIa (CD41) allowing 
further compensation settings of the PE detector. Tubes 4 and 5 contained double 
stained preparations of FITC -labelled IgG to CD42b with PE- labelled CD41 and PE- 
labelled MoAb to P- selectin (CD62P) respectively. All MoAbs were supplied by 
Serotec Limited, Oxford, UK. After a 5- minute incubation period at room 
temperature, 50µ1 of cold HEPES buffered saline was added, and the samples 
incubated for 20 minutes longer at room temperature. Finally, samples were fixed with 
500µl of 0.2% formol saline, and flow cytometric analysis performed within 2 hours 
of collection. 
Sample analysis was performed using a FACScalibur flow cytometer (Becton 
Dickinson Limited, Oxford, UK) with CellQuest software (Becton Dickinson Ltd.). 
The cell sorter was calibrated monthly using fluorescent microbead standards (Becton 
Dickinson Ltd.) using FACSCompv2.0 software (Becton Dickinson Ltd.). The 
platelet population was analysed at a high flow rate, and identified on the basis of 
forward- and side- scatter characteristics obtained with gain settings in the logarithmic 
mode (see Appendix 1). As dual -colour analysis was used, a fluorescence threshold 
was set to analyse only those cells that had bound FITC -labelled anti -CD42b. Because 
erythrocytes and white blood cells do not bind this platelet -specific antibody they 
were effectively excluded from the analysis. Platelet -bound PE- labelled anti -CD41 or 
anti -CD62P was then determined by analysing 10,000 platelets for PE fluorescence. 
95 
CD62P (P- selectin) is expressed only at the surface of activated platelets - 
platelet activity as assessed by degree of CD62P expression can therefore be taken as 
the absolute percentage of platelets stained with PE at a level of >98% of those 
platelets incubated with non - specific PE- labelled antibody. CD41 is expressed on all 
platelets, active or resting, but the degree of CD41 expression increases per platelet 
on activation. Platelet activation as determined by CD41 expression (MoAb binding) 
was therefore taken as the geometric mean fluorescence intensity per platelet (in 
arbitrary fluorescence units), again for those cells having PE fluorescence >98% of 
those cells incubated with negative control MoAb. 
For both studies described below, subjects with CAS underwent a one -hour 
TCD recording on the day that blood was taken for assessment. Where results are 
related to presence or absence of ES, this refers to the recording done on the same 
day. 
5.2.4B. ELISA 
53 patients with >_70% symptomatic CAS from the main study described in 
Part I had blood drawn at the time of their TCD recording. Data from these patients 
were compared with those from 56 population controls, closely matched for age, sex 
and vascular risk factors. 
Blood Sampling 
Both patients and controls were asked to donate 35ml of blood for study use. 
Venesection was from the brachial vein, using a 21 -gauge needle, with blood drawn 
using the Vacutainer system. Blood for this study comprised 4.5ml drawn into 0.5ml 
of 0.129 mol trisodium citrate. Samples were transferred immediately to a refrigerator 
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and within 4 hours were spun down for 10 minutes at 4 °C at 1500g. Plasma was 
aspirated and stored at -80 °C until analysis. Analysis was then performed in duplicate 
at the end of the study by a single observer blind to group category. 
Laboratory Assays 
Soluble P- selectin levels were measured using a quantative sandwich 
enzyme - linked immunoassay (R & D Systems, Abingdon, UK) according to the 
manufacturers instructions. Assays were performed by N. Smith, Department of 
Medicine, King's College School of Medicine & Dentistry. 
Statistics 
Percentages of CD62P- positive platelets and geometric mean fluorescence 
intensity determining CD41 expression were not normally distributed, and hence a log 
transformation was carried out to produce a normal curve. Comparisons between 
groups were then performed by One -way ANOVA. 
sP- selectin levels as determined on ELISA were found to be normally 
distributed. Comparison of means therefore uses Student t -test unless otherwise 
indicated. Correlations are made using Pearson's test. Where multiple comparisons 
are to be made, one -way ANOVA is used as detailed in the text. 
5.2.5 Results 
5.2.5A. Flow Cytometry 






Normal Control p 
n 18 8 14 
Age(mean,SD) 67.17(8.98) 71.62(6.27) 62.71(7.49) 0.05 
Male sex 16 5 6 0.02* 
Hypertension 10 6 3 0.14 
Diabetes 3 1 0 0.29 
Ischaemic Heart 5 3 3 0.72 
Disease 
Peripheral Vascular 4 3 0 0.06 
Disease 
Current smoker 5 0 2 0.21 
Table 5.6. Clinical data for the three compared groups. There was an excess of 
males in the symptomatic group. 
There was no relationship between gender and platelet activation - for 
CD41 logGMI, mean (SD) in males was 2.32 (0.14) versus females 2.37 (0.17), 
p =0.36, t -test; for CD62P, log percentage positive patients mean (SD) was - 
0.22 (0.47) for males versus 0.17 (0.26) in females, p =0.17, t -test. 
Comparison was made of antigen expression in the three groups as 
measured by labelled antibody expression - the results are illustrated in Table 
5.7 below. Further comparison was made of platelet activation among ES 
positive and ES negative subjects - again shown in table form, Table 5.8. 
Antibody sCAS aCAS Controls p (one -way 
Expression mean(SD) mean(SD) mean(SD) ANOVA) 
CD62P 0.07(0.51) 0.07(0.34) -0.1(0.36) 0.87 
CD41 2.32(0.15) 2.26(0.09) 2.39(0.17) 0.12 
Table 5.7. Comparing platelet activation as determined by flow cytometric 
analysis between the three groups - figures given are in log units. 
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Antibody ES +ve ES -ve p (t-test) 
Expression mean(SD) mean(SD) 
CD62P 0.11(0.60) 0.04(0.33) 0.69 
CD41 2.30(0.16) 2.31(0. l D 0.79 
Table 5.8. Comparing platelet activation as determined by flow cytometric 
analysis between ES positive and ES negative groups - figures given are in log 
units. 
5.2.5B ELISA 
The demographic characteristics of the two groups are summarised in 
Table 5.9. There were no significant differences between the groups. 
Control Group Symptomatic CAS 
n 56 53 
Mean (SD) Age (years) 66.25(7.04) 67.04(8.94) 0.43f 
Sex M:F 40:16 36:17 0.69 
Diabetes* 6(11 %) 7(13 %) 0.69äk 
Hypertension ** 32(57 %) 35(66 %) 0.34f 
Current smoker 14(25 %) 12(23 %) 0.77f 
Table 5.9. Characteristics of patient and control gr 
insulin- dependent and non - insulin dependent diabetes 
U; f chi - squared. 
oups. ** - includes both 
mellitus; f Mann -Whitney 
There was no difference in sP- selectin levels between patients and 
controls: mean (SD, range) sP- selectin level in normal controls was 151.6 ng /ml 
(69.08, 33.19- 298.78), versus 135.71 ng/ml (55.57, 59.26 -281.24) in patients, 
p =0.12. 
In 48 patients with symptomatic CAS in whom TCD recordings were 
performed, ES were detected in 20 (41.7 %). There was no difference found 
between those with a positive versus those with a negative recording - in ES 
positive patients, mean (SD) sP- selectin 134.64 ng/ml (48.03) versus 140.73 
ng /ml (63.25), p =0.72. 
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The relationship between sP -sel levels found in the CAS group by 
symptom category - amaurosis fugax, hemispheric transient ischaemic attack 
and completed stroke was examined. The results are shown in Table 5.10 - by 
one -way ANOVA there was no detectable difference according to symptom 
categorisation, p =0.68. 
Symptom Category 
Amaurosis fugax (n =8) 
Hemispheric TIA (n =16) 
Completed Stroke (n =29) 
Table 5.10. sP- selectin level by symptom category. 





For the patient group, time lapsed in days since last symptom was 
recorded - mean(SD, range) 89.55 (93.95,1 -325). There was no correlation 
between sP- selectin levels and time since last symptom, (r = -0.002, p= 0.99). 
5.2.6 Discussion 
Both sets of results - flow cytometry and ELISA - are consistent with a 
lack of systemic activation in CAS. We did not find any evidence of raised sP- 
selectin levels in patients with symptomatic CAS. This is supported by one 
previous study "', and may be due to atherosclerosis in this group being less 
widespread, or due to the fact that subjects were well- matched for other 
vascular risk factors. We found no relation with other markers of clinical risk in 
CAS including time from symptoms, presence of an infarct on CT scan, 
symptom category or presence of ES on TCD examination. The range of time 
since last symptoms in our study however was variable, ranging from 1 to 325 
100 
days (mean 89.55, SD 93.95), and this may have had an influence on results. It 
is unclear whether the main source of sP- selectin in humans is the endothelium, 
where it is stored in the Weibel -Palade bodies of endothelial cells, or platelets, 
where it is released from the alpha -granules on platelet activationi9° As sP- 
selectin levels appear to correlate with extent of atherosclerotic disease, then 
either source would be a possibility. It has been suggested however that the 
failure of sP- selectin levels to correlate with von Willebrand factor, an 
established endothelial cell marker would imply that sP- selectin is mainly 
platelet- derived 17' -. 
It is likely that local factors at plaque level are of greater importance in 
embolisation in CAS - it may be that a more representative picture of platelet 
activation at plaque level could be obtained by sampling from the vessel in the 
region of the plaque, as has been the case in flow cytometric studies in coronary 
artery disease reported previously191 
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Chapter 6 
Embolic Signals in Carotid Artery Stenosis (II) 
6.1 Variability 
In Chapter 5, the importance of ES detection in CAS with regard to their 
value as a predictive factor in stroke was demonstrated and their presence correlated 
with indirect markers of stroke risk. As discussed in Chapter 3, previous studies have 
reported very different proportions of patients with CAS in whom ES can be 
detected. One reason for this may be the differing recording times used, which have 
ranged from 20 minutes to 1 hour - see Table 2.4. 
There has been little work done previously examining variability of embolic 
activity, though that which exists suggests that the presence of ES within an individual 
may be variablet°7'121 If there are to be any prospective studies of the significance of 
ES in predicting stroke risk, it is vital that recording protocols be standardised. Any 
such study would require large numbers of patients as there would be relatively few 
outcome events - by definition more than one centre would need to be involved, and 
again the importance of standardisation is great. Furthermore, to determine numbers 
required to power such a study, more information is needed about the degree of 
variability expected. 
To elucidate further the variable nature of embolisation, we determined the 
effect of both repeating and extending recording times in patients with symptomatic 
and asymptomatic carotid stenosis in a subgroup of the patients recruited as described 
in Chapter 5. 
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6.1.1 Subjects and Methods: 
Twenty symptomatic and twenty asymptomatic patients with >60% CAS as 
determined by Duplex criteria'49 were recruited and completed the study. 
Symptomatic patients were defined as having had symptoms (amaurosis fugax, 
transient ischaemic attack, or stroke) in the territory of the stenosed carotid artery 
within the last year. Patients with potential cardiac sources of emboli were excluded. 
Seven were considered but not included for the following reasons: 5 had no acoustic 
window, 1 underwent carotid endarterectomy before completion of the protocol, and 
1 had a major stroke while awaiting surgery. 
The demographic characteristics and treatment of the 40 patients are 
summarized in Table 6.1. 
Factor Symptomatic Asymptomatic 
Number 20 20 
Mean Age (SD, range) 66.75 (9.73, 42 -82) 70.4 (8.41, 43 -79) 
Male Sex 75% 65% 
Hypertension 55% 70% 
Diabetes 15% 20% 
Hyperlipidaemia 40% 30% 
Ischaemic Heart Disease 25% 25% 
Peripheral Vascular Disease 20% 40% 
Smoker 85% 70% 
Positive Family History 60% 60% 
Treatment - Aspirin* 95% 95% 
Treatment - Warfarin** 5% 
Table 6.1. Clinical data - patients completing variability study. * for symptomatic 
group on aspirin, doses are as follows:75mg,n =9; 150mg,n =4; 300mg,n =6. For the 
asymptomatic group :75mg,n= 13;150mg,n= 3;300mg,n =3. 
**only one patient was taking warfarin regularly, INR 2.0 -3.0, as he had repeated 
TIA's on aspirin alone. 
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For 39 of the 40 patients anti -platelet and anti -coagulant medication was left 
unaltered. The 40th patient suffered a gastrointestinal bleed and aspirin was stopped 
between the first and second recordings. There was no difference in the degree of 
carotid stenosis between the two groups of patients: symptomatic, 60 % -79 %, n =5; 
symptomatic, 80 % -99 %, n =15; asymptomatic, 60 % -79 %, n =3; asymptomatic 80- 
99%, n =17 (x2 =0.63, p= 0.43). 
TCD recordings were made from the middle cerebral artery according to the 
standard protocol (Chapter 3). Each patient was present on three occasions for a 1- 
hour recording, and on one occasion (but not always the first occasion) this was 
extended to a 2 -hour recording. Mean (SD) time between recordings was 11.48 days 
(10.09) in the symptomatic group and 18.78 days (10.09) in the asymptomatic group. 
Mean (range) depth of insonation was 52.6 mm (48 -56). Sample volume was kept 
constant for each patient for all three recordings. 
All recordings were analysed off-line, blind to clinical information and patient 
group, and ES identified on spectral and acoustic characteristics (Chapter 3). A 
second observer (NK, see Acknowledgements) performed some of the analysis in this 
study - hence interobserver reproducibility studies were performed for the two 
observers analysing the tapes. This was performed on a 2 -hour recording comprising 
six 20- minute recordings from the ipsilateral middle cerebral artery in six patients with 
symptomatic carotid stenosis. Observer 1 (JM) detected a total of 89 ES, compared 
with Observer 2 who detected a total of 95 signals. The probability of agreement128 of 
observer 2 compared with observer 1 was 0.93. 
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6.1.2 Statistical Analysis 
All statistical analyses were performed on a PC with the use of SPSS for 
Windows and Genstat. The number of ES per tape was recorded, with a positive 
recording defined as one containing one or more ES. We evaluated the effects of 
repeating or prolonging recordings in two ways. First, we determined the cumulative 
yield resulting from extending and repeating the recordings. Second, we determined 
which recording protocol resulted in the greatest agreement between different 
recordings. For this analysis we treated the data as if they were two reproducibility 
studies: one with two consecutive 1 -hour recordings (the 2 -hour recording) and one 
with two non -consecutive recordings (two 1 -hour recordings repeated on different 
days). Kappa statistics128 were calculated, and their 95% confidence intervals were 
derived with the use of the standard error of the kappa (x) statistic provided by SPSS. 
The agreement was considered excellent for x >0.75, fair for x =0.4 to 0.75, and poor 
for x <0.4. 
Neither numbers of ES or their intensity were normally distributed, and 
therefore differences were analysed with the use of non -parametric statistics. To 
compare the number of ES per hour in the symptomatic and asymptomatic subjects, 
we attempted to fit a Poisson distribution, but because the variance was much greater 
than the mean, it was more appropriately fitted by a super Poisson distribution to 
allow for a dispersion parameter. We therefore applied the Wald test192 with the 
addition of a heterogeneity factor into the model to compensate for the variance. 
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6.1.3 Results 
6.1.3A Effect of Repeating and Extending the Recording on the Cumulative 
Yield 
For the purpose of this analysis, the first hour section of the 2 -hour recording 
is treated as an individual 1 -hour record. In this way each patient effectively attended 
on three separate occasions for 1 -hour recordings. 
In symptomatic subjects, ten (50 %) were ES positive at the first examination. 
After two and three recordings, the cumulative proportion of ES- positive patients 
increased to 12 (60 %) and 15 (75 %) respectively. Detailed results for each patient 
and each recording are shown in Table 6.2. 
Patient Recording I Recording 2 Recording 3 2 hour recording 
1 0 0 0* 0 
2 6 13* 2 31 
3 0* 0 1 2 
4 1* 0 0 3 
5 16 4 1* 1 
6 4 11* 9 23 
7 0* 0 13 0 
8 0 0 1* 2 
9 0* 1 0 0 
10 2 0* 2 1 
11 1 0* 0 0 
12 0* 1 1 0 
13 0* 0 0 0 
14 0* 0 0 0 
15 0 0 0* 0 
16 0 0 0* 0 
17 10 0* 0 0 
18 2 1* 0 2 
19 1 0 0* 0 
20 1 0* 0 0 
Table 6.2. For all 20 symptomatic patients, showing number of ES detected per 
recording, where recording 1 is the first and recording 3 the third 1 hour recording 
made. An asterisk( *) denotes the first hour of the 2 hour recording. 
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In asymptomatic subjects, four (20 %) had a positive first recording. Single 
repetition of the recording gave a cumulative yield of 5 ES- positive patients (25 %). A 
third recording provided no further increase in yield. As for symptomatic subjects, 
some subjects who were ES- positive on one recording were ES- negative on the next 
recording. Again, results per patient are tabulated in detail in Table 6.3. 
Patient Recording 1 Recording 2 Recording 3 2 hour recording 
1 0* 0 0 0 
2 0* 0 0 0 
3 0* 0 0 0 
4 0 0 0* 0 
5 23 2* 7 6 
6 1 0* 1 1 
7 0 0* 0 1 
8 0* 0 0 0 
9 14* 1 0 26 
10 0* 0 0 0 
11 0 0* 0 1 
12 0* 0 0 0 
13 1* 1 0 1 
14 0* 0 0 0 
15 0* 0 0 0 
16 0 0* 0 0 
17 0 0* 0 1 
18 0 1 0* 0 
19 0* 0 0 0 
20 0 0* 0 0 
Table 6.3. For all 20 asymptomatic patients, showing number of ES detected per 
recording, where recording 1 is the first and recording 3 the third 1 hour recording 
made. An asterisk( *) denotes the first hour of the 2 hour recording. 
The effect of extending the recording time (by 15- minute increments up to 2 
hours) on the yield of ES- positive patients is shown in Table 6.4. In symptomatic 
patients during the 2 -hour recording, 6 patients (30 %) were ES- positive by 1 hour; 
extending the recording for a further hour increased the yield to 8(40 %). In 
asymptomatic patients during the 2 hour recording, 3 patients (15 %) were ES- 
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positive by 1 hour; extending the recording for a further hour increased the yield to 7 
(35 %). The values for the yield of the first hour of the two hour recording are not 
necessarily the same as those for the first single -hour recording because the 2 -hour 
recording was not always performed on the first occasion (see "Subjects and 
Methods "). 
Time from start of 
recording (minutes) 
Number of positive 
recordings ( %) 
Symptomatic 
Number of positive 
recordings ( %) 
Asymptomatic 
15 3 (15 %) 2 (10 %) 
30 5 (25 %) 3 (15 %) 
45 5 (25 %) 3 (15 %) 
60 6 (30 %) 3 (15 %) 
75 7 (35 %) 4 (20 %) 
90 7 (35 %) 4 (20 %) 
105 8 (40 %) 4 (20 %) 
120 8 (40 %) 7 (35 %) 
Table 6.4. For both symptomatic and asymptomatic patients showing cumulative 
percentage positive recordings broken down into 15 minute segments. 
6.1.3B Comparison Between the Different Recording Strategies 
This analysis was performed by treating the data as a "reproducibility" study. 
The comparisons between different recording strategies are presented in Figure 6.1 
and assessed by the kappa statistic. The greater the x value, the greater the agreement 
between the two recordings, and therefore the less informative the second recording. 
There was an excellent level of agreement between 2 consecutive hours of 
recording in symptomatic subjects (x =0.78, p= 0.0003)(Figure 6.1A) while there was 
no significant agreement between two single hour recordings performed on different 
days in symptomatic patients (x =0.22, p= 0.27)(Figure 6.1C). 
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In contrast, in asymptomatic patients there was a fair level of agreement 
between two consecutive 1 -hour recordings (x =0.49, p= 0.01)(Figure 6.1B) and 
between two single hour recordings performed on different days (K =0.48, 
p= 0.03)(Figure 6.1D). 
Using a similar method of analysis, we looked at levels of agreement between 
a two -hour recording performed at one visit and a two hour recording composed of 
two single hour recordings made at two separate visits. This was done to determine 
which recording strategy produces higher numbers of ES positive patients and 
therefore which may yield most information. For asymptomatic stenosis there was a 
fair level of agreement between the two methods of recording (x =0.53, 
P= 0.01)(Figure 6.1F), whereas for symptomatic recording there was poor agreement 
(K =0.15, p= 0.44)(Figure 6.1E). 
6.1.3C Comparison Between Symptomatic and Asymptomatic Patients 
When we considered all 1 -hour recordings, a higher proportion of recordings 
with ES was found among symptomatic recordings (24/60 versus 10 /60;x2 =8.04, 
p= 0.005). However, when we considered only those recordings in which ES were 
detected, there was no difference in the median (range) of the total number of ES in 
the two groups: symptomatic, 2 (1 -16); asymptomatic, 1 (1 -23) p =0.7. 
We found a significant difference in the intensities of ES found between the 
two groups - median (mean, range) in symptomatic subjects 12 dB (13.7, 7 -30) versus 
11 dB (11.7, 7 -30), p =0.01, Mann - Whitney U. As the number of patients positive for 
ES was small, with a range from 1 -23 per hour, intensity data are subject to skew, and 
the analysis was repeated using weighted means. Weighted mean data were normally 
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distributed - comparison was therefore made using t -test: for symptomatic subjects 
mean (SD) 12.26 (3.37) versus 10.84 (2.90) for asymptomatic group, p= 0.253. 
A. Symptomatic Consecutive 1 hour Recordings 
Kappa = 0.78, 95% CI 0.50 -1.06, p= 0.0003 
2nd hour 
ES + ES - 
1st hour 
ES + 6 0 
ES - 2 12 
C. Symptomatic Inconsecutive 1 hour Recordings 
Kappa = 0.22, 95% CI 0.17 -0.61, p =0.27 
2nd hour 
ES + ES - 
1st hour 
ES + 5 6 
ES - 2 7 
B. Asymptomatic Consecutive 1 hour Recordings 




ES + 3 0 
ES - 4 13 
D. Asymptomatic Inconsecutive 1 hour 
Recordings 




ES + 2 2 
ES - 1 15 
E. Symptomatic 2 hour Recordings 
Kappa = 0.15, 95% CI -0.22 -0.53, p =0.44 
F. Asymptomatic 2 hour Recordings 
Kappa = 0.53, 95% CI 0.14 -0.93, p =0.01 
inconsecutive 
ES + ES - 
consecutive 
ES + 6 2 
ES - 7 5 
inconsecutive 
ES + ES - 
consecutive 
ES + 4 3 
ES - 12 
Figure 6.1. Evaluation of the agreement between different periods of recording. For 
each comparison, the 2x2 tables show whether ES were detected (ES +) or not 
detected (ES -) during each of the recording periods, which are then compared with 
the kappa statistic, which is shown with its 95% confidence intervals. Top, agreement 
between the first hour and second hour of the consecutive 2 -hour recording is shown 
for (A) symptomatic and (B) asymptomatic stenoses. Middle, agreement between two 
nonconsecutive 1 -hour recordings (made at 2 separate visits) is shown for (C) 
symptomatic and (D) asymptomatic stenoses. Bottom, agreement between the 
consecutive 2 -hour recording and the nonconsecutive 2 -hour recording (made up of 
two single -hour recordings at different visits) is shown (E,F). 
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6.1.4 Discussion 
The study demonstrates that the recording protocol is crucial in determining 
the proportion of patients in whom ES can be detected. In common with previous 
pilot studies'°7,121, our results confirm the variability of asymptomatic embolisation 
over time. By repeating recordings on three separate occasions, the proportion of ES- 
positive patients increased from 50% to 75% in symptomatic patients and 20 to 25% 
in asymptomatic patients. 
If ES were detected in symptomatic stenosis patients during a 1 -hour period, 
they were usually detectable in the same subjects during a second consecutive 1 -hour 
recording, as reflected by excellent agreement between the two recordings (x= 0.78). 
Therefore, extending the recording time from 1 to 2 hours in symptomatic patients is 
of limited benefit. In contrast, there was no significant agreement between which 
patients were positive for ES on 1 hour of recording compared with a non- 
consecutive second hour separated by a number of days; the mean time between 
recordings was 11 days in the symptomatic group. These results demonstrate the 
variability of asymptomatic embolisation in patients with symptomatic stenosis; they 
also demonstrate that although within a 2 -hour period the process may be relatively 
constant, a few days later embolisation status may well have changed. 
In asymptomatic patients there was fair agreement between which patients 
were positive for ES during 1 -hour recordings compared with those positive during a 
second consecutive hour (x =0.49 versus x =0.78 for symptomatic stenosis). This was 
a level of agreement similar to that seen between two non -consecutive hours of 
recording separated by a few days (x= 0.48). This reflects in part the lower frequency 
of patients with asymptomatic stenosis in whom ES can be detected and demonstrates 
111 
the usefulness of either increasing the recording time or repeating recordings in 
patients with asymptomatic stenosis. 
We found a significantly higher proportion of recordings with ES in 
symptomatic than in asymptomatic patients, as reported previously105'107, though at 
odds with the findings reported in Chapter 5. This may be explained on the basis that 
this study considered only the first 40 CAS patients recruited for detailed analysis of 
recording protocols, forming the basis for further recordings made. When we 
considered only those recordings in which ES were detected, there was no difference 
in the frequency of ES between asymptomatic and symptomatic patients. Comparing 
individual emboli, there was a highly significant difference between the intensity 
increase of ES in the two groups, with those in symptomatic recordings having a 
higher relative intensity. Comparing mean ES intensity on a patient -by- patient basis, 
this significance was lost, though there was still an apparent trend which may be 
explored further with a larger sample size. Although there are many technical 
difficulties in deriving embolus size from the intensity of the ES as discussed earlier'', 
this difference may be consistent with emboli in symptomatic patients being larger or 
possibly of more echogenic material. 
In conclusion, in asymptomatic stenosis, recording for 1 hour would appear to 
be the minimum reasonable period, and detection of ES- positive patients will be 
increased to a similar extent by prolonging recording to 2 hours or repeating the 
recording. In contrast, in patients with symptomatic disease a single hour of recording 
at one time is probably sufficient, but repeating the recording on a second occasion 
will identify additional subjects in whom embolisation is occurring. 
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Chapter 7 
Models of Embolisation 
There are a number of mechanisms for thromboembolism in stroke, as was 
discussed in Chapter 1, and the composition of emboli varies. As aspirin, an anti - 
platelet agent, is proven in secondary prevention of strokel93, it is not unreasonable to 
assume that many emboli are composed of platelet aggregates, and visualisation of 
platelet emboli in the retinal circulation supports this194. 
Many strokes and thrombo- embolic events occur despite the use of aspirin, 
but other agents are now available, including ticlopidine, clopidogrel, anti - 
glycoprotein IIb/IIIa antagonists and nitric oxide donors. Current methods available to 
evaluate these agents' efficacy are not ideal - ex -vivo studies such as platelet 
aggregation provide an indicator of potential effectiveness but may not be totally 
representative of biological effectiveness in -vivo 195. Currently available animal 
models196 are not always representative of the situation in man. Large multi- centre 
trials using vascular events as primary endpoints are required. However, the number 
of outcome events in such studies may be small, hence recruitment of large numbers is 
needed, and may not always give a definitive result'''. 
It can be seen that what is needed is a reliable model in which to evaluate the 
efficacy of new agents in -vivo in man, using small patient numbers. This would be 
useful in bridging the gap between laboratory studies and clinical trials. Patients with 
frequent ES as detected by TCD may provide us with a 'model' of embolisation in 
which anti -platelet and anti -thrombotic agents may be trialled. 
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7.1 Potential Models 
Testing of a new anti -platelet agent was initially proposed in four distinct 
situations, all arising in patients with carotid artery stenosis. Each situation and 
possible modes of embolisation are considered below: 
7.1.1 Severe Carotid Artery Stenosis 
Intact endothelial cells play many physiological roles 197 including provision of 
a non -thrombogenic surface and maintenance of vascular tone by release of small 
molecules such as nitric oxide. 
It is widely accepted that atherosclerosis develops as a response to injury. 
Endothelial cell dysfunction may result from various sources of endothelial injury, 
including exposure to agents such as oxidated low density lipoproteins(oxLDL), shear 
stress, hyperhomocysteinaemia , immunologic mechanisms and infection198. Branch 
points of the arterial are particularly susceptible to this process, such as at the 
carotid bifurcation. Endothelial cell dysfunction may be manifest as increased trapping 
of lipoprotein within the artery and the appearance of adhesive glycoproteins on the 
endothelial cell surface. As this process continues, there is development of the fatty 
streak, composed of foam cells and accompanying lymphocytes199 -204 As the process 
continues, there is continued cell influx and proliferation leading to more advanced 
lesions and progressing ultimately to the fibrous plaque. The fibrous plaque increases 
in size and by projection into the arterial lumen may impede blood flow. They are 
covered by a dense cap of connective tissue with embedded smooth muscle cells 
usually overlying a core of lipid and necrotic debris. Endothelial cell loss means that 
there is decreased production of molecules such as prostaglandin I2(PGI2), nitric 
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oxide (NO) and heparan sulphate. Platelet thrombi may form at sites of endothelial 
disjunction and activated platelets release mitogenic factors perpetuating the 
development of the lesion198. 
Platelet activation may take place by exposure to sub -endothelial elements, 
particularly collagen, and via thrombin generated by interaction between the platelet 
and the vessel wall205. Platelet aggregate formation may then occur either at sites of 
endothelial loss - either by exposure to subendothelial elements or thrombin, by loss 
of the endothelial anti -thrombotic properties or by shear - stress induced aggregation. 
With the more advanced fibrous plaque there is more extensive endothelial 
loss, with the potential for ulceration, intra- plaque haemorrhage and thrombosis. 
There may be eventual plaque rupture with release of atheromatous debris as 
described above. Data have shown that most sudden deaths from myocardial 
infarction are due to ruptures or fissures, particularly at the margins of the fibrous 
cap, resulting in haemorrhage into the plaque, thrombosis and artery occlusion206 
Extrapolation of these data into the carotid artery setting might account for 
transformation from `inactive' to `active' plaque, with development of emboli. This 
would be supported by the finding that embolisation is seen more frequently in 
association with high grade148 and ulcerated" lesions. 
7.1.2 Carotid Endarterectomy - Dissection Phase 
The `dissection phase' of carotid endarterectomy includes the time from skin 
preparation to clamping of the internal carotid artery - during this time the arterial 
system has not been entered, and therefore any emboli detected can be assumed to be 
particulate. The first ever description of a particulate embolus being detected by 
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transcranial Doppler ultrasound was in this setting73. Further work has shown that 
asymptomatic embolic signals can indeed be detected during the dissection phase of 
carotid endarterectomy, and these have been shown to correlate with post- operative 
cerebral focal ischaemia. In one study, >10 ES during the dissection phase were 
shown to correlate with a significant deterioration in postoperative cognitive 
function207. In a second study, >10 ES during this phase was shown to correlate with 
postoperative cerebral complications and with the appearance of new hyperintense 
lesions on postoperative T2- weighted magnetic resonance imag ing208. 
Prior to arteriotomy, the situation as regards formation of platelet aggregates 
with the potential for embolisation is as described above at the surface of the 
advanced atherosclerotic plaque. In addition, many ES seen during the dissection 
phase occur in association with handling of the artery209, such as occurs during 
slinging - these may in part represent emboli produced by dislodgment of plaque 
rather than platelet aggregates alone, and may be particularly important with friable, 
ulcerated plaques or those with associated thrombus2°9. 
7.1.3 Carotid Endarterectomy - Post- Operative Phase. 
Asymptomatic embolic signals are frequent following carotid 
endarterectomy'45'207, and recent studies demonstrate that a high frequency of embolic 
signals during the early post- operative phase correlates with early stroke risk15 
21°'2" 
One of the earlier studies published also demonstrated a correlation between 
persistent particulate embolisation and development of neurological deficit207. It is 
important to note that these studies have all made recordings following skin closure, 
and hence record beyond the time when air embolisation is a possibility. 
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Technically successful carotid endarterectomy involves removal of the plaque 
at the level of the superficial media. Hence post -operatively there is a large area 
denuded of endothelium - presumably the mechanism of platelet aggregate formation 
in this situation is via the same pathways as at the intact plaque, but with the previous 
microscopic areas of endothelial loss magnified to a macroscopic scale. 
7.1.4 Carotid Angioplasty 
Though carotid endarterectomy is the accepted treatment for symptomatic 
carotid artery stenosis, there has been a recent trial examining the safety and feasibility 
of applying percutaneous angioplasty to the carotid and vertebral arteries'`. Possible 
advantages of percutaneous transluminal angioplasty (PTA) include a shorter 
admission time, avoidance of a general anaesthetic and surgical incision and an ability 
to dilate surgically inaccessible lesions such as stenoses high in the internal carotid". 
The mechanisms by which PTA increases the size of the luminal diameter have 
been studied in both animals and cadavers. Balloon -induced barotrauma causes 
endothelial denudation; cracking, splitting and disruption of the atherosclerotic 
plaque; dehiscence of the intima and plaque from the underlying media; and stretching 
and tearing of the media and adventitia with resultant aneurysmal dilatation12'213. 
Balloon inflation may also be deleterious, causing plaque haemorrhage, extensive 
dissection (causing luminal compromise), platelet deposition or thrombus 
formatio n2 1 3,21 4. The endothelial loss causes increased thrombogenicity, which in 
animal models has been shown to return to near normal thrombogenicity within 24 
hours215. 
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It can be seen that both the therapeutic aims and unwanted effects provide a 
situation for development of embolisation - of dislodged atherosclerotic material, 
platelet aggregates and thrombus. In one study of patients treated by PTA with use of 
a distal occlusive balloon, debris released after deflation of the proximal angioplasty 
balloon was retrieved, and cholesterol crystals found in over 60% of cases216. 
One previous study found evidence of embolisation by transcranial Doppler 
monitoring in 90% of patients immediately after balloon inflation - this figure fell to 
80% after femoral catheter removal and 20% 48 hours following the procedure'36 
There is no published evidence relating asymptomatic ES to clinical outcome in this 
setting. 
Having postulated that much of the embolisation in the above four `model' 
situations as detected using TCD arises secondary to platelet adherence and 
subsequent aggregation, we aimed to influence embolisation rates using a new anti - 
platelet agent - S- Nitrosoglutathione, GSNO. To prove any effect of this agent, we 
needed subjects in whom ES could be reliably detected in sufficient numbers to 
provide the power needed to demonstrate a therapeutic effect. 
Before any study could start in looking at modification of the embolisation 
process, it was first necessary to look at the natural incidence of embolisation in the 
proposed groups, such that decisions could be made concerning feasibility. As a 
result, the first of the models described above was rejected as unsuitable, the reasons 
for this being detailed below. 
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7.1.1A Severe Carotid Artery Stenosis - Comment 
We recruited 114 patients with >60% CAS on Duplex ultrasound, each of 
them undergoing at least 1 hour of TCD recording from the ipsilateral MCA. This 
work is described in Chapter 5. In a smaller group of patients (n =40), we also 
investigated the variability of ES over time and within recordings, as described in 
Chapter 6. 
From our studies we concluded that ES in CAS may be infrequent, and are 
highly variable. Though information about embolisation in these patients may be of 
interest, and possible application in longitudinal studies of risk, we concluded it 
would not be feasible to undertake longitudinal or crossover studies of efficacy of 
therapy in this group in the small numbers permitted by my time- scale. 
We therefore went on to study embolisation in the setting of carotid 
endarterectomy - both dissection phase and post -operatively - and carotid angioplasty 
(PTA). In these situations the use of GSNO was investigated as a possible means of 
reducing the incidence of ES, which have been shown to be clinically relevant as 
above. 
7.2 S-Nitrosoglutathione, GSNO 
The agent we used - GSNO, S- Nitrosoglutathione - is a possibly targeted 
nitric oxide (NO) donor with specific anti -platelet action. In addition to its effects on 
vascular tone, nitric oxide inhibits platelet aggregation by stimulating soluble 
guanylate cyclase, thereby increasing cyclic guanosine monophosphate21 which leads 
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C O O H molecular weight = 340.8 grams 
Organic nitrates, which act through releasing NO, reduce platelet deposition 
and thrombus formation after angioplasty in pigs, but often at doses causing 
Similarly in man organic nitrates induce hypotension at doses hypotension219,220 
required for an anti- platelet effect'''. 
S- Nitrosoglutathione (GSNO) is a stable S- nitrosothiol from which NO is 
released by the action of enzymes associated with platelet membranes'''. In animals 
and humans GSNO has significant anti -platelet action at doses which cause less 
haemodynamic effect than conventional NO donors'''. In a previous study it has been 
demonstrated that platelet activation occurs following coronary angioplasty and that 
this activation can be prevented by administration of GSNO191. GSNO has also been 
shown to inhibit platelet activation in the setting of acute myocardial infarction and 
unstable angina22a. 
7.3 Carotid Endarterectomy Study 
7.3.1 Subjects & Methods 
The methods described below were used for all patients undergoing carotid 
endarterectomy, whether recordings were made during the dissection phase, post- 
operatively or both. 
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We studied a total of 37 patients undergoing carotid endarterectomy for 
symptomatic internal carotid artery stenosis of >70% determined angiographically 
using the ECST method of measurement'''. Of these, 30 patients had recordings made 
during the dissection phase, and twenty -four patients had recordings made during the 
post- operative phase. Demographic characteristics for the two groups are detailed in 
the Results section. There was an overlap between the two groups, with 17 patients 
having studies performed during both phases of the surgery. 
All patients were pre -treated with aspirin 300mg once daily for at least one 
week prior to operation and all were given 5000IU sodium heparin intravenously 2 
minutes to carotid clamping. 
7.3.1A Methods - GSNO 
GSNO was supplied in powder form (prepared by Dr. Dave Madge, Wolfson 
Institute for Biomedical Research, London). Infusions were prepared for each 
individual patient on the morning of surgery according to the weight of the patient. 
The amount used was 5.4x10-3g/kg, reconstituted with 100m1 of normal saline, 
prepared under sterile conditions and drawn into 50m1 syringes via a 0.2µm filter 
(Gelman Sciences, Michigan, USA). Once prepared, both syringes and the infusion 
tubing were wrapped in aluminium foil, as exposure to light accelerates spontaneous 
release of NO, and hence loss of GSNO activity. 
For each group, GSNO was administered as an intravenous infusion, 
commenced at induction of anaesthesia at 2.2nmol/kg/minute, and, if tolerated, 
increased to 4.4nmol/kg/minute at 10 minutes and continued until the arteriotomy was 
made. The criterion for terminating the infusion was a drop in mean arterial pressure 
(MAP) of 1OmmHg or greater. If blood pressure returned to the pre -GSNO level a 
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further test infusion was given and maintained at the lower rate. If once more there 
was a blood pressure drop of 10mm or greater in MAP, the infusion was stopped 
permanently. The dose used was chosen from work done showing effective reduction 
of platelet activation in the setting of acute myocardial infarction and unstable angina 
using GSN0224. Using a standardised weight of GSNO for each patient facilitated the 
use of constant infusion rates of 7.5m1/h rising to 15m1h if tolerated. 
7.3.1B Methods - Dissection Phase 
Patients were allocated to treatment with either GSNO (n =15) or no 
additional treatment (n =15). For the first 17 patients allocation was done on an open 
basis due to concerns over potential side effects of the GSNO (hypotension, bleeding) 
- however, side effects seen in this initial phase were minimal, and subsequently 
patients were randomised between GSNO or normal saline, drawn up and 
administered under the same protocol as the active treatment, with both the surgeon 
and anaesthetist blind to the treatment group. 
The GSNO infusion was commenced at the time of induction of anaesthesia 
and stopped at the time of cross -clamping, excepting those patients who also had 
recordings done for the post- operative phase. In this group 12 received GSNO, which 
continued as per the protocol below. 
In all patients a one hour recording was made in the 24 hours preceding 
surgery. Further TCD recording was started at the start of the procedure (`knife to 
skin') and stopped at the time of cross -clamping of the common carotid artery, i.e. 
before any arteriotomy was made. All data analysis was done by the treatment 
administrator,(JM), off-line and blind to treatment group, at a later date. 
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7.3.1C Methods - Post -Operative Phase 
Patients were allocated to treatment with either GSNO (n =12) or no 
additional treatment (n =12). In view of the potential side of ects of the GSNO 
(hypotension, bleeding), and our limited experience of its clinical use, allocation to 
treatment or control group for the first 17 subjects was done on an open basis as 
described above. 
GSNO was commenced as per the above protocol at the time of induction of 
anaesthesia and continued until 2 hours from skin closure. 
Post -operative TCD recordings were made for 3 hours commencing 30 
minutes from skin closure, and for 1 hour at 6 and 24 hours after skin closure. 
7.4 Carotid Angioplasty Study 
7.4.1 Subjects and Methods 
From January 1996 to April 1997, a total of 6 carotid angioplasties were 
performed at our centre. Of these, 1 patient had no acoustic window, and was unable 
to be included in TCD studies. For the remaining patients, 4 were allocated to no 
additional treatment, and 1 received GSNO. 
GSNO was prepared as detailed above - commencing at the time of femoral 
puncture at a rate of 7.5m1/hour, increased at 10 minutes to 15m1/hour to continue to 
2 hours from catheter withdrawal. 
All patients had TCD recordings made for 1 hour in the 24 hours preceding 
the procedure from the ipsilateral MCA. On the day of the angioplasty, recordings 
were made for 3.5 hours commencing at 30 minutes from catheter withdrawal, then 
for a further hour at 6 and 24 hours from catheter withdrawal. 
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All TCD recordings were made and analysed according to the methods 
described in Chapter 3. 
For all 3 studies, all patients were taking aspirin 300mg daily for at least one 
week prior to the procedure. Patients taking any other anti -platelet or anti -thrombotic 
medication were excluded. In addition, all patients received 5000IÚ of heparin during 
the procedure - during endarterectomy 2 minutes prior to the cross -clamp being 
applied, during angioplasty 2 minutes prior to first balloon inflation. Angioplasty 
patients were also given 300 -600µg of atropine immediately prior to the first balloon 
inflation. 
7.5 Statistical Methods 
As the numbers in the carotid angioplasty group are so small, results are 
merely presented in table form, and no statistical analysis is made. For both carotid 
endarterectomy studies, the numbers and intensity of ES in each group were not 
normally distributed and therefore comparisons between groups were performed using 
the Mann - Whitney U test for non -parametric data. 
7.6 Results 
7.6.1 Results - Dissection Phase 
All 30 patients underwent technically successful carotid endarterectomy. Their 
clinical data are summarised in Table 7.1. 
Of the 15 patients allocated to receive GSNO, 12(80 %) tolerated the full dose 
with no clinically apparent side effects - in one patient the infusion was continued at 
half dose, in the other 2 the infusion had to be stopped - all due to hypotension which 
reversed on stopping the infusion. When applying the same criteria to patients 
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receiving normal saline prepared by the same method, the infusion had to be stopped 
in one subject on the advice of the anaesthetist, again secondary to hypotension. 
Factor 
Sex M:F 












Dissection time, minutes 
mean(SD) 
ES per hour, dissection 









































Table 7.1. Patient - and GSNO -treated groups - dissection 
phase. *Hypertension is defined as systolic pressure of >160mmHg or diastolic 
>90mmHg or on anti -hypertensive treatment. tDefined by ECST criteria. All cases of 
diabetes were of NIDDM type. 
In the control group receiving either no GSNO or normal saline, the median 
(range) number of ES detected per hour was zero (0- 62.26) versus 3.6 (0 -28) in the 
treatment group, p =0.17, Mann Whitney U. In the control group, 6 patients were ES 
positive, compared with 12 in the GSNO group, p =0.03. A summary of the results for 
each patient illustrating dissection time and ES detected per hour for each patient is 
shown in Table 7.2. 
125 
Patient number Group Dissection 
time(minutes) 
Total ES detected ES /hour 
1 Control 27 0 0 
2 Control 75 0 0 
3 Control 32 0 0 
4 Control 77 8 6.23 
5 Control 66 0 0 
6 Control 32 0 0 
7 Control 40 0 0 
8 Control 36 2 3.3 
9 Control 41 0 0 
10 Control 60 0 0 
11 Control 53 55 62.26 
12 Control 70 1 0.86 
13 Control 43 27 37.67 
14 Control 66 0 0 
15 Control 41 22 32.2 
16 GSNO 60 5 5 
17 GSNO 30 14 28 
18 GSNO 38 12 18.95 
19 GSNO 92 6 3.91 
20 GSNO 43 1 1.4 
21 GSNO 48 3 3.75 
22 GSNO 50 1 1.2 
23 GSNO 61 1 0.98 
24 GSNO 50 0 0 
25 GSNO 53 5 5.66 
26 GSNO 48 1 1.25 
27 GSNO 30 0 0 
28 GSNO 52 0 0 
29 GSNO 50 3 3.6 
30 GSNO 30 5 10 
Table 7.2. For each patient monitored during dissection phase - according to group - 
showing the length of the dissection period and numbers of ES per hour detected. 
From the scatterplot, Figure 7.1, it can be seen that one patient in the control 






Figure 7.1. Scatterplot of numbers of ES per hour found in each group during 
dissection phase. 
A total of 172 ES were detected in the dissection phase: 115 in the control 
group versus 57 in the GSNO group. Mean (SD) intensity of ES in the control group 
was 17.51 dB (8.31) compared with 12.52 dB (4.90) in the GSNO group, p= 0.0001. 
However, near half of the ES found in the control group were detected in just 1 
patient. In view of the small numbers, further comparison was made using weighted 
means to smooth the distribution: for controls mean (SD) was 16.01 (6.35) versus 
13.21 (4.47) in the treatment group, p= 0.40, Mann Whitney U. 
7.6.2 Results - Post- Operative Phase 
In all patients a one hour recording was made in the 24 hours preceding 
surgery. All underwent technically successful carotid endarterectomy. Of the 12 
patients allocated to receive GSNO, 10 tolerated the full dose with no clinically 
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apparent side effects. In two patients there was a fall in MAP of >10mmHg, and the 
infusion was suspended. The infusion was tolerated at the half -maximum dose in one 
patient, but in the second case even this infusion rate caused hypotension and the 
GSNO was stopped. Clinical data for all patients are summarised in Table 7.3. 











62.3 (8.6) 0.54 
Diabetes 3 0 0.18 
Hypertension* 5 7 0.49 
Current smoker 1 4 0.2 
Hypercholesterolaemiat 8 6 0.47 
Table 7.3. Patient characteristics - control and GSNO- treated groups - post- operative 
study group. *Hypertension is defined as systolic pressure of >160mmHg or diastolic 
>90mmHg or on anti -hypertensive treatment. tHypercholesterolaemia is defined as 
fasting cholesterol of >6.0mmo1/1 or treatment. All cases of diabetes were of NIDDM 
type. 
In the control group receiving no GSNO, the median (range) number of ES 
detected during the 3 hour postoperative recording period was 38.5 (1 -219). At 6 
hours the median (range) number of ES per hour had fallen to 5.5 (0 -105). By 24 
hours, median (range) ES per hour had fallen to zero (0 -30). 
The results for each patient in the study are shown in Table 7.4. 
On intention to treat analysis, there was a significant reduction in 
asymptomatic embolisation in the GSNO group during both the initial 3 hour 
recording period and during hour 6 (Figure 7.2). The median (range) number of ES 
detected in the first 3 hour recording was 7.5 (0 -61) (p =0.018 v controls). During 
hour 6 the median (range) number of embolic signals was zero (0 -41)(p =0.014 versus 
controls). By 24 hours the rate of embolisation in both groups was low and there was 
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no difference between control and treatment groups: median (range) was zero (0 -37) 
(p =0.74 vs. controls). 
Patient Group ES pre - 
op 
ES1 ES2 ES3 ES6 ES24 
1 Control O 13 O 38 50 1 
2 Control O 62 69 48 48 30 
3 Control O 46 51 28 7 O 
4 Control O 1 0 1 1 O 
5 Control O 16 4 3 11 0 
6 Control O 5 14 12 1 O 
7 Control O 12 5 3 3 3 
8 Control O 2 0 O O O 
9 Control O 3 0 O 0 0 
10 Control O 3 1 4 4 0 
11 Control O 10 6 61 105 1 
12 Control O 26 7 15 13 0 
13 GSNO O 3 5 O 0 0 
14 GSNO O 1 O O O O 
15 GSNO O O O O O O 
16 GSNO O 6 13 9 7 1 
17 GSNO O 6 1 3 3 0 
18 GSNO O 1 3 1 0 0 
19 GSNO O 2 3 0 O O 
20 GSNO O 0 O 0 1 0 
21 GSNO 1 1 O O O O 
22 GSNO 1 1 3 2 O 3 
23 GSNO 2 0 O O O O 
24 GSNO 1 11 29 2 41 37 
Table 7.4. ES per hour for each patient in the post- operative study - ES1, ES2 and 
ES3 designate ES detected in the first, second and third hours recordings following 
skin closure. ES6 and ES24 represent ES detected in the hours recordings taken at 6 











Figure 7.2. Box and whiskers plot - ES per hour against time from skin closure 
according to treatment group. Median value is shown as solid black line, boxes 
represent 25th to 75th percentile and lines delineate range. 
Individual numbers of embolic signals in the two groups during the first three 
hours are shown in Figure 7.3. The two patients with frequent embolic signals in the 
GSNO group were the two in whom a full dose of GSNO could not be given due to 
hypotension. Exclusion of both patients who did not tolerate full dose would increase 
the difference between the two groups: at 3 hours in the GSNO group median (range) 
number of embolic signals was 5.5 (0 -20)(p =0.005 versus controls); at 6 hours 
median was zero (0 -7)(p= 0.003) and at 24 hours zero (0 -3)(p= 0.47). 
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ES detected 












Control group GSNO group 
Figure 7.3. Scatter distribution of total embolic signals detected in each patient 
during 3 hour post- operative recording according to treatment group. *denotes 
patient in whom infusion was stopped. * *denotes patient receiving half -maximum 
dose. 
A total of 715 ES were detected in the initial 3 hour post- operative recording 
in the control group compared with 197 in the GSNO group. During this period 
embolic signals in the GSNO group were significantly less intense than those in the 
control group: mean (SD) 12.30 dB (4.30) versus 14.27 dB (4.71), p <0.0001. 
In the control group three patients suffered peri- operative ischaemic events. 
One patient suffered a stroke at 20 hours post -operation in the ipsilateral internal 
carotid artery territory with right facial and arm weakness and dysphasia; this 
recovered fully over three days and CT brain scan showed a cortical infarct. Two 
further control patients, who both had contralateral carotid occlusion, had strokes in 
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the contralateral internal carotid artery territory. In one patient aphasia and 
hemiparesis was noted on recovery from anaesthesia and he was left with a residual 
deficit; CT scan showed a large area of infarction in the internal carotid artery 
watershed areas. The second patient developed left hemiparesis and coma on three 
days post- operation and died; brain CT scan showed an intracerebral haemorrhage. 
There were no strokes or transient ischaemic attacks in the GSNO group but one 
patient was noted to have developed internal carotid artery occlusion on the side of 
the endarterectomy on repeat carotid duplex prior to discharge. 
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7.6.3 Results - Carotid Angioplasty 
The results are shown in table form below: 
Patient 1 Patient 2 Patient 3 Patient 4 Factor Patient 5 
Age 72 61 74 63 70 
Sex F M F M F 
Diabetes Normal NIDDM Normal Normal Normal 
(diet) 
Hypertension Normal Untreated Treated Normal Normal 
Smoking Non Current Ex Ex Ex 
Time since 
symptoms 
41 111 233 2 86 
Symptom 
type 
Stroke Stroke Stroke TIA TIA 
Treatment 
group 
Control Control Control Control GSNO 
Treated 
stenosis ( %) 
93 85 89 84 79 
Residual 
estimated 
stenosis ( %) 
20 60 0 50 40 
Balloon 
inflations 
3 3 1 3 3 
ES/hour pre- 
op 
0 14 0 1 0 
ES1 0 28 23 41 0 
ES2 0 8 3 15 0 
ES3 0 13 0 20 0 
ES6 2 2 0 1 0 
ES24 0 0 0 0 0 
Table 7.5. Summary clinical data for the 5 studied patients undergoing percutaneous 
transluminal carotid angioplasty. ES1, ES2, ES3 = number of embolic signal detected 
in the first, second and third hours of recording post -procedure. ES6 - number 
detected in the hour 6 hours from catheter withdrawal, ES24 - number in the hour 24 
hours from removal of catheter. 
The patient receiving GSNO had to have the infusion stopped 30 minutes early 
secondary to hypotension - though this occurred late, at 135 minutes from 
commencement. Hypotension in this case persisted despite stopping the infusion, and 
did not respond well to fluid replacement. 
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7.7 Discussion 
7.7.1 Dissection Phase 
GSNO did not reduce embolisation rates in the dissection phase of carotid 
endarterectomy in this study. In one patient receiving the normal saline control the 
infusion was stopped on the advice of the anaesthetist due to hypotension, illustrating 
the fact that operative and anaesthetic factors may confound results. Possible 
explanations for the lack of efficacy of the agent in this situation may be in part 
accounted for as follows: 
i) timing of the infusion and agent pharmacokinetics may be such that there is 
insufficient time for the agent to act within the time window given 
ii) platelet activation at the surface of an intact plaque may act via a different receptor 
system to cGMP 
iii) the degree of endothelial loss is smaller at an intact plaque - there is therefore 
endogenous endothelial NO production, the system may be saturated, and addition of 
further exogenous NO will not affect embolisation 
iv) most importantly, many ES seen during the dissection phase occur in association 
with handling of the artery209, such as occurs during slinging, and may be of different 
composition to those seen post -operatively. As their frequency was not influenced by 
treatment with an anti -platelet agent, this would be consistent with their not 
comprising platelet aggregates. 
The dissection phase of carotid endarterectomy does provide a model of 
embolisation - i.e. reliably provides sufficient numbers of ES for assessment of 
therapeutic agents. The association of ES occurrence with handling of the artery may 
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provide information that can be used in surgical training in endarterectomy 
technique 9 
7.7.2 Post -Operative Phase 
GSNO resulted in a highly significant reduction in the frequency of 
embolisation following carotid endarterectomy. This reduction was maintained at 6 
hours post- operatively, even though the infusion was stopped 2 hours post- 
operatively. In the majority of patients GSNO was well tolerated, but in two 
individuals it resulted in a drop in blood pressure. In one case it could be continued at 
half the maximum dose but in the other case it had to be stopped. Our data provide 
further evidence for the importance of nitric oxide in preventing platelet adhesion and 
aggregation in -vivo, and illustrate the potential use of platelet specific NO donors 
which may have relatively less hypotensive effect, for a given anti -platelet effect, than 
conventional NO donors such as nitroglycerin. GSNO has only been given as an 
intravenous infusion, but in the future oral analogues, or other platelet specific NO 
donors, may be effective in preventing thromboembolism. Our results also 
demonstrate that pre- operative aspirin and intra- operative heparin fail to prevent many 
embolic events. 
The patient numbers were too small, and the study was not designed, to 
determine whether there was a significant reduction in clinical events. However there 
were no clinical ischaemic events in the GSNO group. There was one minor stroke in 
the control group in the ipsilateral internal carotid territory, and two strokes in the 
contralateral internal carotid artery territory. However the latter were in patients with 
contralateral occlusion and in one the pathogenesis was probably intraoperative 
haemodynamic ischaemia, while in the other it was haemorrhage probably due to a 
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hyperperfusion syndrome. Nevertheless there was certainly no increase of events in 
the GSNO treated group. 
In addition to the lower frequency of ES in the GSNO treated group the mean 
intensity of the individual ES was lower in the GSNO group. Theoretically embolic 
signal intensity would be expected to increase with increasing embolic size, and this 
has been confirmed in experimental models87. ES intensity also depends on embolus 
composition with thrombi resulting in more intense ES than platelet aggregates in 
experimental models87. Assuming embolus composition was similar in the GSNO 
treated and untreated group our results are consistent with emboli in the GSNO 
treated group representing smaller platelet aggregates. However there are a number of 
technical difficulties associated with interpreting ES composition or size from 
intensity alone87. 
This study demonstrates that ultrasonic ES detection allows the in -vivo 
efficacy of anti -platelet agents to be evaluated in relatively small numbers of patients. 
In the study the ability of GSNO to reduce embolisation from an arterial luminal 
surface surgically denuded of endothelium was tested. 
The use of this model may allow effective initial evaluation of new anti -platelet 
therapies in small studies prior to their assessment in large and expensive clinical 
trials, and should also allow dose -response studies to be performed before embarking 
on such trials. 
7.7.3 Carotid Angioplasty 
As the numbers studied are small, we cannot draw any statistical inferences 
from our results. 
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7.8 Future Potential 
It can be seen that combining TCD monitoring with administration of new 
therapeutic agents following carotid endarterectomy provides us with in -vivo models 
of embolisation in which new agents can be assessed. It is possible that carotid 
angioplasty would provide a further suitable model, but this work is still at an early 
stage, as discussed above. 
By combining a knowledge of the molecular action of new anti -platelet agents 
with TCD monitoring we can gain further information as to the mechanism of 
production and composition of the embolic material. 
This same work may be taken further with assessment of other agents, 
particularly new anti -platelet agents such as the glycoprotein IIb/IIIa antagonists to 
reduce embolisation in the same situations. 
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Chapter 8 
Final Conclusion and Discussion 
In Chapter 1, the purpose of this thesis was set out - to outline the importance 
and implications of embolisation in carotid artery stenosis and explore the use of 
transcranial Doppler ultrasound as a tool in such patients. 
Detailed discussion is given at the end of each chapter - here I will present a 
broad overview and possible future directions for the work contained here. 
Areas investigated were: 
i.) Chapter 4 - multi -gated Doppler. The wider clinical application of TCD is 
hampered by the lack of an effective on- or off -line analysis programme such that 
lengthy recordings can be evaluated for ES counts with high specificity and sensitivity 
without the need for a trained human observer. The possible incorporation of multi - 
gated Doppler into such a system had been suggested. To address this possibility, we 
evaluated multi -gated Doppler in both a flow model and in patients. The results 
suggested that the technique is useful in differentiating ES from artefact - however, it 
loses sensitivity for low amplitude ES, such as those typically seen in patients with 
CAS - the patient group in which we are particularly interested. 
Future Implications - two factors may be altered to improve the sensitivity of the 
technique. Firstly, narrower gate separation can be employed - these results influenced 
our own practice in subsequent studies. To improve the signal:background ratio, a 
lower frequency probe (e.g. 1MHz) can be employed. 
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ii) Chapter 5 - identification of individuals at highest risk of stroke. Previous 
studies have shown that embolisation, as assessed using TCD, correlates with a 
number of clinical markers of stroke risk in CAS, and one small prospective study had 
suggested an association between presence of ES and future stroke risk. 
We have confirmed the association between ES and presence of plaque ulceration as 
detected angiographically. A significant correlation was shown between time since last 
symptom attributable to the stenosis and ES. In a series of over 100 CAS patients, we 
found further evidence of an association between ES and risk of future TIA and 
stroke both for asymptomatic and symptomatic CAS. 
Future Implications - the results lend further support to the importance of ES 
presence as a predictor of stroke and need to be confirmed in large multi- centre 
studies. Ongoing trials are assessing risk stratification in asymptomatic CAS - TCD 
monitoring should be included in such trial protocols. 
iii) Chapter 6, Chapter 3 - recording protocols, variability and generalisability. 
Though much work had been done previously using TCD in CAS evaluation, the sum 
of the work done was less than all its parts - to be able to combine studies there have 
to be set basic criteria. Twenty -four hour recordings had shown that over prolonged 
recording times there was a great degree of variability, both inter- and intra- subject. 
To address these issues we have studied variability in greater detail, validated our own 
use of ES identification criteria and from this have generated our own recording 
protocols. 
Future Implications - the work was important in providing recommendations for 
future work in ES detection in CAS. If utilised in future work by other groups, then 
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results may be combined and further collaborative work set up. International studies 
of ES as a possible long -term predictor of stroke will need to employ such 
generalisable criteria if coherent results are to be produced. 
iv) Chapter 7 - models of embolisation. Having accepted that ES represent embolic 
material in the middle cerebral artery, then it is possible to speculate as to the nature 
of the material by assessing its response to pharmacological intervention. We have 
shown these ES to be frequent in both carotid endarterectomy and carotid 
angioplasty, and have assessed a new anti -platelet agent in the context of each of 
these situations. The work in carotid angioplasty is incomplete, but the data from 
carotid endarterectomy shows a striking reduction in ES numbers detected following 
endarterectomy when S- nitrosoglutathione is used. No change in ES numbers is seen 
when the agent is used during the dissection phase, which allows us to speculate 
further that the mechanism of embolisation may be different in this situation. 
Future Implications - the work with carotid endarterectomy subjects can be taken 
further in the evaluation of other anti -platelet agents as they emerge - allowing such 
drugs to be piloted in small numbers of subjects. In the setting of angioplasty, GSNO 
is being evaluated in further patients. Long -term monitoring of the angioplastied 
lesion using Doppler ultrasound will also allow conclusions to be drawn regarding 
effects of treatment on restenosis rates. 
In conclusion - we have addressed major issues in the evaluation and 
development of transcranial Doppler ultrasound. We have shown that the 
incorporation of multi -depth monitoring into automated ES detection systems may be 
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advantageous. The predictive value of ES in stroke and TIA risk has been 
strengthened, and a new in vivo model for the evaluation of anti -platelet and anti - 
thrombotic agents has been developed. Each of these developments provides a 
platform for further work in patients with CAS, in working towards improved 
decision - making in both those with symptomatic and asymptomatic disease. 
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A1.1 Technical Background 
Membrane changes accompanying platelet activation have been described in 
Chapter 5. In 1987, Shattil et al reported the use of dual -colour flow cytometry to 
develop an assay to detect activated platelets in whole blood, exploiting knowledge of 
these specific changes. 
Flow cytometry is a technique for making measurements on particles or cells 
as they flow in a fluid stream one by one through a sensing point. Thus measurements 
are made on each particle within the suspension in turn, and values produced are not 
just average values for the whole population. The technique depends upon the sample 
being presented as a suspension of single particles, stained in a specific way, that will 
pass through the detection system without any disruption of fluid flow or blockage of 
orifices. It is possible to analyse whole cells, cell organelles or specific clumps of 
tissue in this way. Platelets are relatively simple to prepare as they exist normally as 
single particles within a suspension. The cells must be stained by incubation with a 
fluorescent dye or fluorescent -conjugated antibody or ligand. For accurate 
interpretation of results it is important that the staining is specific for and proportional 
to the feature to be measured. 
Flow cytometers make measurements based on light as the excitation source. 
As cells are small and pass rapidly through the detection point, intense illumination is 
required. Cells are fluorophore- labelled - the light source must be capable of exciting 
the fluorescent dye by production of specific wavelengths. The scattered fluorescent 
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light generated by the passage of cells through the illuminating beam is collected by 
photodetectors which convert the photon pulses into electronic signals. 
As the laser hits the particle suspension, the light is scattered, and is collected 
at both forward (FSC) and side (SSC) collection optics. The forward collection lens 
gathers scattered light from approximately 1 -20 degrees off the laser beam axis. The 
light collected at this angle is dependent on particle size. The right angle (side 
collection) lens is designed to measure light over the greatest cone possible, and 
provides a measure of fluorescence intensity. Particles can be identified from the 
scatter plot produced as they will appear in a specific region according to their size 
and intensity. 
The mixture of forward and side- scattered light will be of a particular range of 
wavelengths, depending on the fluorophore used to label the cells or particles. The 
two most commonly used fluorophores are fluorescein isothiocyanate (FITC, green) 
and phycoerythrin (PE, red). The absorption and emission spectra for these two 
fluorophores both overlap to some extent - this is discussed further below, and 
illustrated in Figure A1.6 
The results obtained are most commonly displayed as the frequency histogram 
and the dual- parameter correlated plot or `dot plot'. The frequency histogram is a 
direct graphical representation of the number of events occurring. The dot plot is a 
two -dimensional extension of the frequency histogram - with each detected cell 
represented by a dot at the coordinates of fluorescence intensity. Typical frequency 
histograms and dot plots accompany the stepwise description of the technique as used 
for our studies. 
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A1.2 Method Illustration 
Figure A1.1. Dot -plot from an unstained sample - the platelet population is identified 
on the basis of forward and side -scatter characteristics alone. 
A `gate' is drawn around the `region of interest' as shown above - this region 
can then be selected for the staining studies that follow. The x -axis shows the degree 
of forward scatter (FSC) while the y -axis represents the degree of side scatter (SSC). 
For our studies, FSC was set at E00 and SSC at 350. 
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Figure A1.2. Dot -plot - unstained sample. 
Having selected the region of interest, all cell counting events outwith this 
area are excluded from the analysis, leaving the plot as shown above. The cell counter 
is set to count 10000 events within this area. Axis labelling applies as for Figure 
A1.l. 
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Figure A1.3. Dot -plot - sample incubated with both FITC- and PE- labelled negative 
control antibodies. 
Some of the fluorescence detected will arise from `unbound' fluorophore, i.e. 
be non -specific. To minimise the effect of this on results from specific staining, a 
preliminary sample may be studied using fluorophore bound to a negative control 
antibody. In the study described here, a sample was incubated with phycoerythrin 
(PE)- and fluoroisothiocyanate (1,'1TC)- labelled antibody raised to a rat cell marker. 
FITC- derived fluorescence is detected at the FL1 detector, with that from PE 
detected at the FL2 detector. The detector sensitivity was then adjusted such that 
>98% of the cells within the region of interest were negative for either fluorophore, 
and hence appear in the lower left quadrant of the plot above. Positive' cells are 
those demonstrating >101 fluorescence at either the FL1 (FITC) or FL2 
(PE) 
detectors. Therefore a singly positive PE- labelled cell would appear in 
the upper left 
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quadrant, a singly positive FITC -labelled cell would appear in the lower right 
quadrant, and a double -stained cell would appear as an event in the upper right 
quadrant. The results can alternatively be displayed as frequency histograms - 
illustrated below. In Figure A1.4, the frequency histogram is shown for FITC staining 
while in Figure A1.5 the same results are shown for PE staining. Both these 
histograms accompany and are derived from Figure A1.3. 
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Figure A1.4. Frequency histogram for all FITC staining using the double- negative 
control. The number of cells `positive' for FITC is <2% of the total 10 000 events 
(number of cells lying within the gate M1) as explained above. 
101 102 
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Figure A1.5. Similarly, the above histogram shows that using the PE- stained non- 
specific antibody <2% of the total cells studies are positive for PE. 
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Having set the detectors as above, the next step is to define which cells within 
the region of interest are truly platelet- derived and not other cell particles of similar 
FSC and SSC characteristics. To do this, a platelet -specific stain may be used - in this 
study, FITC -labelled anti -CD42b was employed - this being an antibody to platelet 
glycoprotein Ib (CD42b). The singly- stained FITC cells may then be studied by 
setting a threshold of >101 at the FL1 detector to define a platelet - this will be 
illustrated in Figure A1.7. 
Once this threshold has been set to define a platelet, the next step is to 
determine `compensation' settings for the FL1 and FL2 detectors, to minimise cross- 
talk between the detectors. 
In reality there is significant overlap between the emission and absorption 
spectra of fluorescein isothiocyanate and phycoerythrin. This means that the emissions 
from the two fluorochromes will overlap such that some fluorescence from one 
fluorochrome will pass to the detector set to measure fluorescence from the other and 
vice versa. The effects of this may be minimised by optical filtration, or application of 
a bandpass filter. By this method light wavelengths greater than 560nm are reflected 
towards the PE fluorescence detector, through a filter centred at 578nm while shorter 
wavelengths 500 -560nm pass to the FITC fluorescence detector through a 530nm 
filter. The spectral overlap may be corrected further during signal processing. This is 
illustrated in Figure A1.6, shown overleaf. 
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Figure A1.b. The fluorescence emission spectra for FITC (left) and PE (right) are 
shown above. The bandpass filters applied are outlined with the heavy black lines. It 
can be seen that some degree of overlap persists even after signal filtration. 
Wavelength is in nanometres. 
Using a single- stained FITC - labelled sample, it is possible to adjust the 
compensation settings, to minimise the effects of the crosstalk between the two 
detectors due to the emission spectra overlap. To set compensation of FL2:FL1, the 
single -stain FITC -labelled antibody to human CD42b was used. The compensation is 
adjusted such that the majority of cells lie within the lower right quadrant. For our 
studies this was invariably set at 45 %. The typical dot -plot obtained is shown on the 
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Figure A1.7. Dot -plot from single- stained FITC -labelled CD42b (platelet 
glycoprotein Ib). 
As platelet glycoprotein Ib is not expressed on any other cell line, cells 
expressing this antigen are identified as platelets. With this knowledge it is possible to 
set a threshold to look at platelets alone within the region of interest, by only 
examining cells positive for FITC staining with this antibody. Cells, or `events', in the 
lower right quadrant alone would therefore be included in the analysis, and again, 
10000 events are counted per sample. 
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To set compensation settings for FL1:FL2, a single- stained PE- labelled sample 
is used. For our studies, we used a single- stained PE- labelled monoclonal antibody to 
CD41, or platelet glycoprotein IIb/IIIa. Again this is expressed on all platelets, but 
degree of expression is increased on platelet activation. The compensation settings are 
adjusted such that the majority of cells lie within the upper left quadrant - invariably 
this was set at 0.2 %. The result obtained is shown in Figure A1.8. 
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Figure A1.8. Dot -plot from single - stained PE- labelled CD41 (platelet glycoprotein 
IIb/IIIa) 
Having set the threshold and compensation settings, it was then possible to 
examine the double stained populations to assess degree of platelet activation for each 
subject. The first double -stained sample examined was the FITC -labelled CD42b 
and 









Figure A1.9. Dot -plot from double -stained sample incubated with FITC - labelled 
CD42b and PE- labelled CD41. 
As a threshold has been set, identifying the cells of interest on the basis of 
FITC -positivity, no events appear in either left -hand quadrant. All cells in the upper 
right hand quadrant are taken to be positive for both FITC and PE, i.e. to express 
both CD42b and CD41. As CD41 is ubiquitous in platelets, we cannot take a 
percentage of cells expressing this marker as being the number activated - instead we 
must look at the degree to which they express the antigen - the geometric mean 
intensity (GMT, in arbitrary fluorescence units) is taken. In the result printout this is 
easily read from the upper right quadrant statistics for each sample run. The higher 
the 
GMI, the more activated platelets are present within the sample studied. 
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The second double -stained sample run uses FITC -labelled CD42b again to 
identify the platelet population, with the second, PE- labelled antibody used being 
directed at CD62P (platelet -surface P- selectin). Again, a typical dot -plot is illustrated, 
Figure A1.10. 
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Figure A1.10. Dot -plot from double - stained sample incubated with FITC- labelled 
CD42b and PE- labelled CD62P. 
P- selectin is usually contained within the alpha -granules of platelets, and is 
only expressed at the cell surface following activation and degranulation. Hence any 
platelet positive for P- selectin is assumed to be activated and therefore all 
events 
appearing in the upper right quadrant (i.e. double positive stained 
cells) represent 
activated platelets. The absolute numbers of positive cells can be 
taken to calculate 
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`percentage activated' for each sample studied as a percentage of the total of 10000 
events. 
The results reported in Chapter 5 therefore take GMI PE -CD41 and 
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S- Nitrosoglutathione Reduces the Rate of 
Embolization in Humans 
Jane Molloy, MRCP; John F. Martin, FRCP; Paul A. Baskerville, FRCS; 
Simon C.A. Fraser, FRCS; Hugh S. Markus, DM 
Background Antiplatelet agents presently used in the secondary prevention of cardiovascular disease fail to prevent the 
majority of cases of recurrent stroke and systemic embolization. An evaluation of the efficacy of new agents is hampered 
by a lack of in vivo models in humans. Asymptomatic cerebral embolic signals (ES) may be detected with the use of 
transcranial Doppler ultrasonography. These signals are particularly common after carotid endarterectomy, and this 
provides a situation in which new antiplatelet agents can be evaluated. With this model, we determined the effectiveness 
of S- nitrosoglutathione (GSNO), a nitric oxide donor with relative platelet specificity, in reducing cerebral embolization. 
Ylethods and Results -Transcranial Doppler ultrasound recordings from the ipsilateral middle cerebral artery were made 
after carotid endarterectomy in 12 control patients and 12 patients receiving intravenous GSNO from the induction of 
anesthesia until 2 hours after skin closure. Recording times were 0.5 to 3.5, 6 to 7, and 24 to 25 hours after skin closure. 
The Doppler signal was recorded onto tape, and analysis for ES was performed, with the investigators blinded to 
treatment group. All patients received aspirin 300 mg /d before surgery and 5000 IU of heparin during surgery. The 
median (range) number of ES detected during the initial 3 -hour postoperative recording was markedly reduced in the 
GSNO group compared with the control group: 7.5 (0 to 61) versus 38.5 (1 to 219) (P = 0.018). This difference persisted 
until 6 hours after surgery. 
r'onclusions- Despite the administration of aspirin and heparin, frequent embolization occurred and was markedly 
reduced after the administration of GSNO. This demonstrates the potential use of platelet -specific nitric oxide donors 
in the treatment of thromboembolic disease. This model of cerebral embolism may allow determination of the 
effectiveness of new antiplatelet agents in humans. (Circulation. 1998;98:1372 -1375.) 
Key Words: ultrasonics drugs platelet aggregation inhibitors endothelium- derived factors 
A ]though aspirin is effective in the secondary prevention 
of thromboembolic disease,' many strokes and systemic 
mbolic events occur despite its use, and there is a need for 
lore effective antiplatelet agents. Potential agents include 
Iclopidine, clopidogrel, the new generation of glycoprotein 
lb /Illa antagonists, and nitric oxide (NO) donors. Current 
iethods available for the evaluation of such agents are not 
lea]; ex vivo studies such as platelet aggregation provide an 
idicator of potential efficacy but may not be completely 
presentative of biological effectiveness in vivo.' Presently 
vailable animal models' are not always representative of the 
tuation in humans. Because of the low incidence of outcome 
vents, large, expensive, multi -center clinical trials are re- 
uired in which as many as 19 000 patients may need to be 
:cruited.4 A reliable model in which to evaluate the efficacy 
f new agents in vivo in humans, with small patient numbers, 
'ould be useful in bridging the gap between laboratory 
udies and clinical trials. 
Recently, it was demonstrated that circulating cerebral 
inboli can be detected with the use of transcranial Doppler 
ultrasonography.5 Emboli appear as high- intensity transient 
signals with typical acoustic characteristics. This technique 
has been shown to be highly sensitive and specific in 
validation studies both in vitro and in animal models!' 
Embolic signals (ES) have been reported in a wide variety of 
patient groups with potential embolic sources such as carotid 
artery disease, atrial fibrillation, and cardiac valvular disease.' 
At carotid endarterectomy, endothelial denudation takes 
place, and the outer layers of the arterial media are exposed, 
resulting in a potent thrombogenic surface on which platelet 
adherence and aggregation occur. Asymptomatic ES are 
frequent after carotid endarterectomy,y "' and recent studies 
demonstrate that a high frequency of ES during the early 
postoperative phase correlates with early stroke risk.'''12 This 
situation provides a potential model in which to test 
the 
efficacy of new antiplatelet agents. The frequency of ES in 
this situation may provide sufficient power to allow 
the 
evaluation of therapies in relatively small numbers of 
patients. 
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62.3 ±8.6 0.54 
Diabetes, n 3 0 0.18 
Hypertension,* n 5 7 0.49 
Current smoker, n 1 4 0.2 
Hypercholesterolemia,t n 8 6 0.47 
*Hypertension is defined as systolic pressure of >160 mm Hg or diastolic 
pressure of >90 mm Hg or antihypertensive treatment. 
tHypercholesterolemia is defined as a fasting cholesterol level of >6.0 
mmol /L or as receiving treatment. All cases of diabetes were non- insulin- 
dependent diabetes mellitus. 
In addition to its effects on vascular tone, NO inhibits 
platelet aggregation by stimulating soluble guanylate cyclase, 
thereby increasing cGMP," which leads to reduced platelet 
adhesion and aggregation.' Organic nitrates, which act 
through the release of NO, reduce platelet deposition and 
thrombus formation after angioplasty in pigs but often at 
doses that cause hypotension.1"6 Similarly, in humans, or- 
ganic nitrates induce hypotension at doses required for an 
antiplatelet effect." S- Nitrosoglutathione (GSNO) is a stable 
S- nitrosothiol from which NO is released by the action of 
enzymes associated with platelet membranes.' In animals 
and humans, GSNO has significant antiplatelet action at 
doses that cause less hemodynamic effect than conventional 
NO donors.19 In a previous study, we demonstrated that 
platelet activation occurs after coronary angioplasty and that 
this activation can be prevented by the administration of 
GSNO 2 GSNO has also been shown to inhibit platelet 
activation in the setting of acute myocardial infarction and 
unstable angina.21 In the present study, we examined the 
hypothesis that GSNO prevents platelet aggregation and 
adherence and therefore subsequent cerebral thromboembo- 
lism, as determined with Doppler ultrasound, immediately 
after carotid endarterectomy. 
Methods 
We studied 24 patients who were undergoing carotid endarterectomy 
for symptomatic internal carotid artery stenosis of >70% determined 
angiographically with the European Carotid Surgery Trial method of 
naeasurement.22Their demographic characteristics are summarized in 
the Table. The study was approved by the King's Healthcare Ethical 
Committee, and informed consent was obtained from all subjects. All 
patients were pretreated with aspirin 300 mg /d for ?1 week before 
surgery and were administered 5000 IU of sodium heparin intrave- 
nously during the operation and before carotid clamping. Patients 
were allocated either to treatment with GSNO (r=12) or to no 
additional treatment (n =12). In view of the potential side effects of 
GSNO (eg, hypotension and bleeding), neither the surgeon nor the 
anesthetist was blinded to treatment, but all data analysis was 
performed with the investigator blinded to the study group. 
GSNO was administered as an intravenous infusion beginning at 
Me induction of anesthesia at a rate of 2.2 nmol kg -' min' and, 
if tolerated, increasing to a rate of 4.4 nmol kg-' min' at 10 
minutes and continuing until 2 hours after skin closure. The criterion 
For tennination of the infusion was a drop in mean arterial pressure 
,MAP) of?l0 mm Hg. If MAP returned to the pre -GSNO level, an 
additional test infusion was administered and maintained at the lower 
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rate. If again there was a drop in MAP of --10 mm Hg, the infusion 
was stopped permanently. 
A commercially available transcranial Doppler machine (TC 
4040; EME/Nicolet Ltd) was used to record from the ipsilateral 
middle cerebral artery. A sample volume of 5 mm and a mean 
recording depth of 52.77 mm (range, 48 to 56 mm) were used. 
Recordings were made to digital audiotape for off -line analysis. In 
all patients, a I -hour recording was made in the 24 hours preceding 
surgery. Postoperatively, recordings were made for 3 hours, begin- 
ning 30 minutes from skin closure, and for I hour at 6 and 24 hours 
after skin closure. 
Analysis of recordings was performed by an observer (J.M.) who 
was blinded to the clinical details, time of recording, and study 
group. ES were identified by their characteristic visual appearance 
and chirping sound. An intensity threshold of >7 dB was used 
because previous studies have shown that this improves interob- 
server reproducibility in the detection of ES.Z''24 The intensity of the 
ES was calculated by comparison with the built -in intensity scale on 
the Doppler as previously described.24 Interobserver reproducibility 
of ES detection was determined by 2 observers who independently 
analyzed 4 hours of tape recording from 6 patients with symptomatic 
carotid artery stenosis. The proportion of specific agreement' 
between observer I and observer 2 (H.S.M.) was 0.98 and that 
between observer 2 and observer I was 0.92. For both validation and 
patient studies, the timing of all ES was noted, and each signal was 
saved to the hard drive for an analysis of intensity. 
The number of ES in each group was not normally distributed, and 
therefore comparison between the number of ES detected in each 
group was performed with the Mann -Whitney U test for nonpara- 
metric data. For comparison of ES intensity, an unpaired! test was 
used. 
Results 
Details of the patient groups are given in the Table. All 
patients underwent technically successful carotid endarterec- 
tomy. Of the 12 patients allocated to receive GSNO, 10 
tolerated the full dose with no clinically apparent side effects. 
In 2 patients, there was a fall in MAP of >10 mm Hg, and the 
infusion was suspended. The infusion was tolerated at the 
half -maximum dose in 1 patient, but in the second patient, 
even this infusion rate caused hypotension, and GSNO 
administration was stopped. 
In the control group receiving no GSNO, the median 
(range) number of ES detected during the 3 -hour postopera- 
tive recording period was 38.5 (1 to 219). At 6 hours, the 
median (range) number of ES per hour had fallen to 5.5 (0 to 
105). By 24 hours, the median (range) number of ES per hour 
had fallen to 0 (0 to 30). 
On an intention -to -treat analysis, there was a significant 
reduction in asymptomatic embolization in 
the GSNO group 
during both the initial 3 -hour recording period 
and hour 6 
(Figure 1). The median (range) number 
of ES detected in the 
first 3 -hour recording was 7.5 (0 to 61) 
(P =0.018 versus 
controls). During hour 6, the median (range) 
number of ES 
was 0 (0 to 41) (P =0.014 versus controls). 
By 24 hours, the 
rate of embolization in both groups was low, 
and there was no 
difference between control and treatment 
groups: the median 
(range) was 0 (0 to 37) (P =0.74 
versus controls). 
Individual numbers of ES in the 2 groups 
during the first 3 
hours are given in Figure 2. The 
2 patients with frequent ES 
in the GSNO group were the 
2 in whom a full dose of GSNO 
could not be given because of hypotension. 
Exclusion of both 
patients who did not tolerate 
a full dose increased the 
difference between the 2 groups: 
at 3 hours in the GSNO 
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Figure 1. ES per hour versus time from skin closure according 
:o treatment group. Solid line indicates median value; boxes, 
25th to 75th percentile; and vertical lines, range. 
group, the median (range) number of ES was 5.5 (0 to 20) 
:P =0.005 versus controls); at 6 hours, the median (range) 
was 0 (0 to 7) (P= 0.003); and at 24 hours, the median (range) 
was 0 (0 to 3) (P= 0.47). 
A total of 715 ES were detected in the initial 3 -hour 
7ostoperative recording in the control group compared with 
197 in the GSNO group. During this period, ES in the GSNO 
group were significantly less intense than those in the control 
group: the mean (SD) was 12.30 (4.30) versus 14.27 (4.71) 
113 (P<0.0001). 
In the control group, three patients experienced perioper- 
itive ischemic events. One patient had a stroke 20 hours after 
iurgery in the ipsilateral internal carotid artery territory with 
ight facial and arm weakness and dysphasia; this patient 
.ecovered fully over a 3 -day period, and a CT brain scan 
showed a cortical infarct. Two additional control patients, 
loth of whom had contralateral carotid occlusion, had strokes 
n the contralateral internal carotid artery territory. In I 
)atient, aphasia and hemiparesis were noted on recovery from 
lnesthesia, and he was left with a residual deficit; a CT scan 
howed a large area of infarction in the internal carotid artery 
watershed areas. The second patient developed left hemipa- 
esis and coma 3 days after surgery and died; a brain CT scan 
ES detected 
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igure 2. Scatter distribution of total ES detected in each 
atient during 3 -hour postoperative recording according to 
eatment group. Patient in whom infusion was stopped. 
=Patient receiving half -maximum dose. 
showed an intracerebral hemorrhage. There were no strokes 
or transient ischemia attacks in the GSNO group, but 1 patient 
was noted to have developed internal carotid artery occlusion 
on the side of the endarterectomy on repeat carotid duplex 
before discharge. 
Discussion 
GSNO resulted in a highly significant reduction in the 
frequency of embolization after carotid endarterectomy. This 
reduction was maintained at 6 hours after surgery, even 
though the infusion was stopped 2 hours after surgery. In the 
majority of patients, GSNO was well tolerated, but in 2 
individuals, it resulted in a drop in blood pressure. In 1 
patient, it could be continued at half the maximum dose, but 
in the other, it had to be stopped. Our data provide further 
evidence for the importance of NO in preventing platelet 
adhesion and aggregation in vivo and illustrate the potential 
use of platelet -specific NO donors that may have relatively 
less hypotensive effect, for a given antiplatelet effect, than 
conventional NO donors such as nitroglycerin. GSNO has 
been administered only as an intravenous infusion, but future 
oral analogs, or other platelet -specific NO donors, may be 
effective in preventing thromboembolism. Our results also 
demonstrate that aspirin alone fails to prevent many embolic 
events. 
The patient numbers were too small and the study was not 
designed to determine whether there was a significant reduc- 
tion in clinical events. However, there were no clinical 
ischemic events in the GSNO group. In the control group, 
there was 1 minor stroke in the ipsilateral internal carotid 
territory and 2 strokes in the contralateral internal carotid 
artery territory. The latter occurred in patients with contralat- 
eral occlusion; in 1 patient, the pathogenesis was probably 
intraoperative hemodynamic ischemia, whereas in the other, 
it was hemorrhage, probably due to a hyperperfusion syn- 
drome. Nevertheless, there certainly was no increase of 
events in the GSNO- treated group. 
In addition to the lower frequency of ES in the GSNO- 
treated group, the mean intensity of the individual ES was 
lower in the GSNO group. Theoretically, ES intensity would 
be expected to increase with increasing embolic size, and this 
has been confirmed in experimental models.' ES intensity 
also depends on embolus composition, with thrombi resulting 
in more intense ES than platelet aggregates in experimental 
models.` Assuming the embolus compositions were similar 
in 
the GSNO- treated and untreated groups, our 
results are 
consistent with emboli in the GSNO- treated group 
represent- 
ing smaller platelet aggregates. However, there are 
a number 
of technical difficulties associated with the interpretation 
of 
ES composition or size on the basis of intensity alone.' 
The present study demonstrates that ultrasonic 
ES detec- 
tion allows the in vivo efficacy of antiplatelet 
agents to be 
evaluated in relatively small numbers 
of patients. In this 
study, we tested the ability of GSNO to reduce 
embolization 
from an arterial luminal surface surgically 
denuded of endo- 
thelium. However, the salve 
technology may allow the 
effectiveness of agents to be tested 
on embolism resulting 
fi-om other clinical situations, such 
as percutaneous translu- 
minal coronary angioplasty. The 
use of this model may allow 
affective initial evaluation of new antiplatelet therapies in 
;mall studies before their assessment in large and expensive 
;linical trials. It should also allow dose -response studies to be 
Jerformed before such trials are begun. 
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Temporal Variability of Asymptomatic Embolization in 
Carotid Artery Stenosis and Optimal Recording Protocols 
Jane Molloy, MRCP; Naheed Khan; Hugh S. Markus, DM 
lackground and Purpose- Although asymptomatic embolization can be detected in patients with carotid artery stenosis, 
its temporal variability is unclear. An understanding of this is important in designing optimal recording protocols for 
future prospective studies of the predictive value of embolic signals (ES). We determined the effect of repeating and 
extending recording times in patients with symptomatic and asymptomatic carotid stenosis. 
Methods -In 20 asymptomatic and 20 symptomatic subjects with >60% carotid stenosis, we used transcranial Doppler 
ultrasound to record for ES in the ipsilateral middle cerebral artery. Three 1 -hour recordings were performed on three 
separate days, and on one occasion (not necessarily the first) the recording was extended to 2 hours. The recordings were 
saved onto digital tape for subsequent blinded analysis. 
tesu /is- Marked temporal variability was seen in symptomatic patients in whom the cumulative proportion of subjects with ES 
increased from 10 (50 %) after a single hour of recording to 12 (60 %) and 15 (75 %) after two and three recordings, 
respectively. Extending the recording to 2 hours increased the yield of ES- positive patients from 6 (30 %) to 8 (40 %). In 
symptomatic patients there was excellent agreement between whether patients were positive for ES during each of two 
consecutive 1 -hour recordings ( K =0.78, P= 0.0003) but poor agreement between the results of two single -hour recordings 
performed on different days ( K =0.22, P= 0.27). In asymptomatic patients, 4 (20 %) were ES positive during the first hour; this 
increased to 5 (25 %) after the recording was repeated once, with no further increase after the third recording. Extending the 
recording to 2 hours increased the yield from 3 (15 %) to 7 (35 %). In contrast to symptomatic stenoses, in patients with 
asymptomatic stenoses there was fair agreement between whether patients were ES positive on two consecutive 1 -hour 
recordings (K =0.49, P =0.01) or two single -hour recordings performed on different days ( K =0.48, P= 0.02). Symptomatic 
subjects were more likely to have ES (when all 1 -hour recordings were considered, 24/60 versus 10/60; P= 0.0046). ES in 
symptomatic subjects had a higher relative intensity increase than in asymptomatic subjects (P = 0.01). 
'onclusions -The temporal variability of ES needs to be taken into account in the design of optimal recording protocols and 
comparisons of results from different studies. Extending the duration of recording beyond an hour in symptomatic stenoses 
is of less value, but repeating the recording on a different day will often identify additional subjects with ES. In intervention 
studies in symptomatic patients, the time since last symptoms must be considered. In asymptomatic stenosis, extending the 
duration of recording beyond an hour will increase the proportion of patients positive for ES. (Stroke. 1998;29:1129- 1132.) 
Key Words: carotid artery diseases cerebral embolism ultrasonography, Doppler 
ith the use of transcranial Doppler ultrasound (TCD), 
embolic signals (ES) can be detected in patients with 
'rotid artery stenosis (CAS). Although in this group of 
tients the value of ES as a predictive factor in stroke is not 
tablished, their presence correlates with a number of indi- 
ct markers of stroke risk. They are more frequent in 
mptomatic than in asymptomatic subjects,'z and in symp- 
matic patients they are more frequently detected soon after 
e appearance of symptoms.' They are more frequent in 
tients with histologically proven plaque ulceration and 
rombosis determined on carotid endarterectomy specimens' 
[d in patients with plaque ulceration demonstrated 
geographically.' 
Previous studies have reported very different propor- 
rns of patients with CAS in whom ES can be detected. 
One reason for this may be the differing recording times 
used, which have ranged from 20 minutes to 2 hours.'2'47." 
Furthermore, pilot studies have suggested a marked vari- 
ability in the frequency of ES over time.29 Before larger 
prospective studies are performed, it is important to 
determine an optimum recording protocol. Both recording 
and subsequent data analysis are time consuming, increas- 
ing the importance of using a protocol that will maximize 
the possibility of ES detection without prolonging record- 
ing times unnecessarily. 
Therefore, in this study we examined the incidence of ES 
in asymptomatic and symptomatic patients with CAS. We 
determined the effect on the proportion of patients 
in whom 
ES were detected by both repeating a recording and 
extending 
the recording time. 
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Mean age (SD, range), y 







Hyperlipidemia 40% 30% 
Ischemic heart disease 25% 25% 
Peripheral vascular disease 20% 40% 
Smoker 85% 70% 
Positive family history 60% 60% 
Aspirin treatment* 95% 95% 
Warfarin treatment 5% 
*For symptomatic group on aspirin, doses are as follows: 75 mg, n=9; 150 
mg, n =4; 300 mg, n =6. For asymptomatic group: 75 mg, n =13; 150 mg, 
n =3; 300 mg, n =3. 
Subjects and Methods 
Twenty symptomatic and 20 asymptomatic patients with >60% 
CAS as determined by TCD criteria l'iwere recruited and completed 
the study. Symptomatic patients were defined as having symptoms 
(amaurosis fugax, transient ischemic attack, or stroke) in the territory 
of the stenosed carotid artery within the last year. Patients with 
potential cardiogenic sources of emboli were excluded. Seven 
patients were considered but not recruited for the following reasons: 
5 had no acoustic window, I underwent carotid endarterectomy 
before completion of the protocol, and I had a major stroke while 
awaiting surgery. 
The demographic characteristics and treatment of the 40 patients 
are summarized in Table I . For 39 of the 40 patients, antiplatelet and 
anticoagulant medication was left unaltered. The 40th patient suf- 
fered a gastrointestinal bleed, and aspirin was stopped between the 
first and second recordings. There was no difference in the degree of 
carotid stenosis between the two groups of patients: symptomatic, 
60% to 79 %, 5; symptomatic, 80% to 99 %, 15; asymptomatic, 60% 
to 79 %, 3; asymptomatic, 80% to 99 %, 17 (x2=0.63, P= 0.43). 
TCD recordings were made from the middle cerebral artery 
ipsilateral to the carotid stenosis by the transtemporal route. A 
commercially available TCD machine (EME Pioneer4040) was used 
with a 2 -MHz probe held in place with an external fixation device. 
Each patient was present on three separate occasions for a 1 -hour 
recording, and on one occasion (but not always the first occasion) 
this was extended to a 2 -hour recording. Mean (SD) time between 
recordings was I I.48 (10.09) days in the symptomatic group and 
18.78 (10.09) days in the asymptomatic group. Mean (range) depth 
of insonation was 52.6 (48 to 56) mm. We aimed for an axial sample 
volume of4 mm; when this delivered insufficient power for adequate 
recording, the sample volume was increased. Median (mean, range) 
sample volume was 5 mm (5.38, 4 to 12). Sample volume was kept 
constant for each patient for all three recordings. The Doppler audio 
signal was recorded onto digital audiotape. It was subsequently 
played back through the signal processor of the same TCD machine 
with the use of a 128 -point fast Fourier transform and a fast Fourier 
transform overlap of >50 %. All analyses were performed blinded to 
the clinical information or patient group. ES were identified by their 
typical visual appearance on the spectral display and their charac- 
teristic sound. In addition, an intensity threshold of >7 dB was used. 
The intensity was calculated from the color -coded intensity scale on 
the screen. This can be adjusted so that its intensity can be measured 
to the nearest decibel. The gain was reduced until the color of the 
adjacent cardiac cycle reached 0, and the peak intensity of the 
embolic signal was then determined. lnterobserver reproducibility 
studies were performed for the two observers analyzing the tapes. 
TABLE 2. Increase in Proportion of ES- positive Patients 
Resulting From Increasing the Recording Time From 
15 Minutes to 2 Hours for Both Symptomatic and 
Asymptomatic Patients 
Time From Start of 
Recording, min 
No. of Positive Recordings ( %) 
Symptomatic Asymptomatic 
15 3 (15) 2 (10) 
30 5 (25) 3 (15) 
45 5 (25) 3 (15) 
60 6 (30) 3 (15) 
75 7 (35) 4 (20) 
90 7 (35) 4 (20) 
105 8 (40) 4 (20) 
120 8 (40) 7 (35) 
This was performed on a 2 -hour recording comprising six 20- minute 
recordings from the ipsilateral middle cerebral artery in six patients 
with symptomatic carotid stenosis. The probability of agreement "of 
observer 2 compared with observer I was 0.93. 
Statistical Analysis 
All statistical analyses were performed on a PC with the use of SPSS 
for Windows and Genstat. The number of ES per tape was recorded, 
with a positive recording defined as one containing one or more ES. 
We evaluated the effects of repeating or prolonging recordings in 
two ways. First, we determined the cumulative yield resulting from 
extending and repeating the recordings. Second, we determined 
which recording protocol resulted in the greatest agreement between 
different recordings. For this analysis we treated the data as if they 
were two reproducibility studies: one with two consecutive I -hour 
recordings (the 2 -hour recording) and one with two nonconsecutive 
recordings (two I -hour recordings repeated on different days). 
Kappa statistics' were calculated, and their 95% confidence inter- 
vals were derived with the use of the approximate standard error of 
the kappa statistic provided by SPSS. The agreement 
was considered 
excellent for K >0.75, fair for K =0.4 to 0.75, and poor 
for K <0.4. 
The distribution of the number of ES or their intensity was not 
normally distributed, and therefore differences were 
analyzed with the 
use of nonparainetric statistics. In the symptomatic group, 
the relation- 
ship between time from last symptoms and the 
number of ES per hour 
was determined with Spearman's correlation 
coefficient. To compare 
the number of ES per hour in the symptomatic 
and asymptomatic 
subjects, we attempted to fit a Poisson distribution, 
but because the 
variance was much greater than the mean, 
it was more appropriately 
fitted by a super Poisson distribution to allow 
for a dispersion parame- 
ter." We therefore applied the Wald 
test with the addition of a 
heterogeneity factor into the model 
to compensate for the variance. 
Results 
Effect of Repeating and Extending the 
Recording 
on the Cumulative Yield 
For the purpose of this analysis, the 
first hour section of the 
2 -hour recording is treated as 
an individual 1 -hour record. In this 
way, each patient effectively 
attended three separate occasions 
for I -hour recordings. In symptomatic 
subjects, 10 (50 %) were 
ES positive at the first examination. 
After two and three 
recordings, the cumulative 
proportion of ES- positive patients 
increased to 12 (60 %) and 
15 (75 %), respectively. In asymp- 
tomatic subjects, 4 (20 %) 
had a positive first recording. Single 
repetition of the recording gave 
a cumulative yield of 5 ES- 
positive patients (25 %). A third 
recording provided no further 
increase in yield. As for symptomatic 
subjects, some subjects 
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Figure 1. Evaluation of the agreement between different periods 
of recording. For each comparison, the 2x2 table documents 
whether ES were detected (ES +) or not detected (ES -) during 
each of the recording periods, which are then compared with 
the kappa statistic, which is shown with its 95% confidence 
intervals. Top, Agreement between the first hour and second 
hour of recordings of the consecutive 2 -hour recording is shown 
for symptomatic (A) and asymptomatic (B) stenoses. Middle, 
Agreement between two nonconsecutive 1 -hour recordings (on 
different days) is shown for symptomatic (C) and asymptomatic 
(D) stenoses. Bottom, Agreement between the consecutive 
2 -hour recording and the nonconsecutive 2 -hour recording 
(made up of two single -hour recordings on different days) is 
shown (E, F). 
who were ES positive on one recording were ES negative on the 
next recording. 
The effect of extending the recording time (by 15- minute 
increments up to 2 hours) on the yield of ES- positive patients is 
shown in Table 2. In symptomatic patients during the 2 -hour 
recording, 6 patients (30 %) were ES positive by 1 hour; 
extending the recording for a further hour increased the yield to 
8 (40 %). In asymptomatic patients during the 2 -hour recording, 
3 patients (15 %) were ES positive by 1 hour; extending the 
recording for an additional hour increased the yield to 7 (35 %). 
The values for the yield in the first hour of the 2 -hour recording 
are not necessarily the same as those for the first single -hour 
recording because the 2-hour recording was not always per- 
formed on the first occasion (see "Subjects and Methods "). 
Comparison Between the Different 
Recording Strategies 
This analysis was performed by treating the data as a 
"reproducibility" study. The comparison between different 
recording strategies is presented in Figure I and assessed by 
the kappa statistic. The greater the K value, the greater is the 
agreement between the two recordings, and therefore the less 
informative is the second recording. There was an excellent 
level of agreement between 2 consecutive hours of recording 
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Figure 2. Relationship between time since last symptoms and 
number of ES per hour for the sixty 1 -hour recordings in symp- 
tomatic patients. Data include the two 1 -hour recordings and 
the first hour of the 2 -hour recording. 
in symptomatic subjects (K =0.78, P= 0.0003). In contrast, 
there was no significant agreement between two hour -long 
recordings performed on different days in symptomatic pa- 
tients (K =0.22, P= 0.27). In contrast, in asymptomatic pa- 
tients there was a fair level of agreement between two 
consecutive I -hour recordings (K =0.49, P =0.01) and be- 
tween two hour -long recordings performed on different days 
(K =0.48, P= 0.02). 
Using a similar method of analysis, we determined whether it 
is more useful to perform a single 2 -hour recording or two 
1 -hour recordings on separate days. We compared which pa- 
tients were ES positive during the consecutive 2 -hour recording 
with those detected during the summed 2 -hour recording made 
up of the two single -hour recordings performed on different days 
(Figure 1). For asymptomatic stenosis there was a fair level of 
agreement between the two methods of recording (K =0.53, 
P= 0.01), whereas for symptomatic recording there was poor 
agreement (K =0.15, P= 0.44). 
Comparison Between Symptomatic and 
Asymptomatic Patients 
When we considered all 1 -hour recordings, a higher propor- 
tion of recordings with ES was found among symptomatic 
recordings (24/60 versus 10/60; x2=8.04, P= 0.0046). How- 
ever, when we considered only those recordings in which 
ES 
were detected, there was no difference in the mean 
(variance) 
of the total number of ES in the two groups: symptomatic, 7.1 
(136.3); asymptomatic, 3.6 (93.8) (b =0 to 0.09, 
P <0.l). 
However, there was a significant difference in 
the intensity of 
ES between the two groups, with median (mean, 
range) 
values as follows: symptomatic, 12 (13.73, 
7 to 30) dB; 
asymptomatic, 11 (11.86, 7 to 30) 
dB (P =0.01, Mann - 
Whitney U test). 
The relationship between the time since 
last symptoms and 
the number of ES per hour is shown in 
Figure 2. Recordings 
made on each of the first, second, and 
third occasions are 
shown separately. For the 2 -hour 
recording, only the results 
from the first hour are shown. 
There was a negative relation - 
ship between time since symptoms 
and the number of ES per 
hour, which reached significance 
for two of the three record- 
ing periods: first recording, p= -0.25, 
P =0.1; second record- 
ing, p= -0.42, P =0.03; third recording, 
p= -0.37, P =0.05. 
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Discussion 
This study demonstrates that the recording protocol is crucial in 
determining the proportion of patients in whom ES can be 
detected. In common with previous pilot studies,49 our results 
confirm the variability of asymptomatic embolization over time. 
By repeating recordings on three separate occasions, the propor- 
tion of ES- positive patients increased from 50% to 75% in 
symptomatic patients and 20% to 25% in asymptomatic patients. 
If ES were detected in symptomatic stenosis patients 
during a 1 -hour period, they were usually detectable in the 
same subjects during a second consecutive 1 -hour recording, 
as reflected by excellent agreement between the two record- 
ings (K= 0.78). Therefore, extending the recording from 1 to 
2 hours in symptomatic patients is of limited benefit. In 
contrast, there was no significant agreement between which 
patients were positive for ES on 1 hour of recording corn - 
pared with a nonconsecutive second hour separated by a 
number of days; the mean time between recordings was 11 
days in the symptomatic group. These results demonstrate the 
variability of asymptomatic embolization in patients with 
symptomatic stenosis; they also demonstrate that although 
within a 2 -hour period the process may be relatively constant, 
a few days later embolization status may well have changed. 
In asymptomatic patients there was fair agreement between 
which patients were positive for ES during 1 -hour recordings 
compared with those positive during a second consecutive hour 
(K =0.49 versus K =0.78 for symptomatic stenosis). This was a 
level of agreement similar to that seen between two nonconsec- 
utive hours of recording separated by a few days (K= 0.48). This 
reflects in part the lower frequency of patients with asymptom- 
atic stenosis in whom ES can be detected and demonstrates the 
usefulness of either increasing the recording time or repeating 
recordings in patients with asymptomatic stenosis. 
We found a significantly higher proportion of recordings with 
ES in symptomatic than in asymptomatic patients, as reported 
previously.' 2 When we considered only those recordings in 
which ES were detected, there was no difference in the fre- 
quency of ES between asymptomatic and symptomatic patients. 
However, there was a highly significant difference between the 
intensity increase of ES in the two groups, with those in 
symptomatic recordings having a higher relative intensity. Al- 
though there are many technical difficulties in deriving informa- 
tion on embolus size from the intensity of the ES,14 this 
difference is consistent with emboli in symptomatic patients 
being larger or possibly of niore echogenic material. In addition, 
our results confirm a significant inverse relationship between the 
number of ES per hour and time since last symptoms.3.4 It is 
important that this relationship be taken into account in any 
studies determining the predictive value of ES in patients with 
asymptomatic stenosis or the effect of any therapeutic interven- 
tion in this group of patients. Patients would need to be matched 
for time since last symptom. 
Substantial indirect evidence suggests that ES in patients 
with carotid stenosis may be an important predictor of disease 
risk. They correlate with clinical parameters, as described in 
our study, and are also associated with plaque ulceration and 
degree of stenosis, which are both markers of increased stroke 
risk.`r' In individual case reports they have responded to 
treatment with antiplatelet or anticoagulant therapy, while in 
a small prospective study in asymptomatic CAS, the presence 
of two or more ES per hour was a highly significant 
independent predictor of stroke risk.' However, before the 
routine clinical use of this technique in predicting stroke risk, 
further large prospective studies are required to determine 
this association. Our results will be useful in determining 
optimal recording protocols for such studies. In patients with 
asymptomatic carotid stenosis, recording for 1 hour appears 
to be the minimum reasonable period, and detection of 
ES- positive patients will be increased to a similar extent by 
prolonging recording to 2 hours or repeating the recording. In 
contrast, in patients with symptomatic disease a single hour of 
recording at one time is probably sufficient, but repeating the 
recording on a second occasion will identify additional 
subjects in whom embolization is occurring. 
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Use of a Decibel Threshold in Detecting 
Doppler Embolic Signals 
Hugh S. Markus, DM; Jane Molloy, MRCP 
Background and Purpose To improve reproducibility and 
reliability in the identification of embolic signals detected with 
the use of Doppler ultrasound. many studies have used an 
intensity threshold. However, variable thresholds between 3 
and 12 dB have been used. and often the method of measure- 
ment of intensity is not stated. Potentially different methods of 
measurement could result in different intensity measurements 
for the same embolic signal. We determined the effect of these 
differences using commercial transcranial Doppler systems. 
Methods We analyzed 81 embolic signals recorded from the 
middle cerebral arteries of patients with carotid artery disease 
using three different methods of measuring intensity that had 
been previously used in research studies. In method 1 individ- 
ual time frames of the frequency spectra were analyzed. in 
method 2 a color -coded intensity scale was used and in method 
3 automated software was used. 
Results There was a highly significant correlation between 
measurements made by the different techniques (method 1 
versus method 2: r =.68. P <.0001; method 1 versus method 3: 
r =.66. P <.0001; method 2 versus method 3: r =.70. P<.0001). 
However, the absolute values of intensity for the same embolic 
signals varied markedly for the different methods. For example. 
a 4-dB threshold according to method 1 was equivalent to an 
approximately 7 -dB threshold measured by method 2. These 
differences had major effects on the proportion of embolic 
signals detected with the use of the same decibel threshold but 
with intensity measured in the different ways. For example. 
using a threshold of 7 dB would result in only 4.9% of simtals 
being missed by method 2 but 42.2% and 51.4% being missed 
by methods 1 and 3. respectively. 
Conclusions Our results demonstrate that the intensities of 
the same embolic signals_ recorded with the same parameters. 
are markedly different when analyzed in the different ways used 
in previous studies. This has important implications when a 
decibel threshold is used and emphasizes that criteria devel- 
oped by one investigator on one machine cannot be used lb!, 
another investigator without initial reevaluation. This could 
account for some of the differences in frequencies of embolic 
signals reported in previous clinical studies. (Stroke. 
199728:692 -695.) 
Res Fiords carotid stenosis cerebral embolism 
ultrasonics 
Cerebral embolus detection with the use of Dopp- 
ler ultrasound has many potential applications 
in the management of patients with cerebrovas- 
cular disease. In certain conditions, such as carotid 
artery stenosis, the presence of embolic signals appears 
to correlate with indicators of disease activity.12 How- 
ever, initial studies have produced widely varying pro- 
portions of patients in whom embolic signals can be 
detected. For symptomatic carotid stenosis this has 
varied between 20% and more than 90 %.=-7 Reproduc- 
ibility studies within one center or between two centers 
have shown that good interobserver reproducibility can 
be obtained but there may be disagreement, particularly 
for signals of low intensity,7-9 and studies between larger 
groups of observers have resulted in less agreement. 
Many researchers in this field have found that often 
patients with clear embolic signals also exhibit very small 
increases in relative intensity accompanied by a charac- 
teristic sound, and deciding which to count as definite 
embolic signals can be difficult. The use of a decibel 
threshold is one way of resolving this problem. Only 
signals above a certain intensity will then be recorded as 
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embolic signals. This results in greater interobserver 
agreement since disagreement usually occurs for low- 
intensity signals.` Many recent studies have included the 
use of a decibel threshold. which has varied from 3 to 12 
dB. 7.-17 However. few of these state how the intensity 
was calculated. A number of studies have been per- 
formed in which an intensity threshold suggested 
by one 
investigator on one machine with certain settings 
is 
applied to either a different machine or to 
the same 
machine with different settings, without 
any revalidation. 
Intensity is calculated from the logarithm 
of the ratio 
of the power of the embolic signal to 
that of the Doppler 
spectrum in the absence of any embolic 
signal. However. 
each of these two parameters can 
be measured in a 
number of ways. We determined 
whether three different 
methods employed in clinical studies 
in which commer- 
cially available transcranial Doppler 
equipment was 
used resulted in significant differences 
in the analysis of 
embolic signals from patients 
with carotid artery disease. 
We specifically chose this patient 
group because the 
embolic signals in patients 
with carotid stenosis are of 
lower intensity than those 
detected in patients with 
prosthetic heart valves" or 
during cardiopulmonary 
bypass and present greater 
diagnostic difficulty. 
Subjects and Methods 
Recordings were made 
from the middle cerebral 
artery 
ipsilateral to a symptomatic 
carotid stenosis in eight patients. 
Recordings were made 
on an EME TC 2000 transcranial 
Doppler machine with 
a 2 -MHz transducer. a sample 
volume 
of 10 mm, and a depth 
of 45 to 52 mm. The recordings 
had 
pl 
'previously been blindly evaluated by four observers from two 
centers in an interobserver reproducibility study.9 Eighty-one 
embolic signals that had been detected by all four observers 
Fywere used for the subsequent analysis. One method (method 3 
below) of determining the relative intensity increase of an 
embolic signal required that the embolic signal was detected 
with the use of an automated detection system. Even when a 
Flow detection threshold was used, 9 embolic signals were not 
!detected with this method; therefore, only 72 are included in 
analyses in which this method is used. 
The Doppler audio signal was recorded on digital audiotape 
libefore any fast Fourier transform processing and subsequently 
played back into two transcranial Doppler systems: (1) the 
same EME TC2000 and (2) an EME Pioneer 4/40 system. The 
intensity of each Doppler embolic signal was determined by 
CPthree methods used in previously published studies, as de- 
, l scribed below. 
Method 1 
Individual time frames of the fast Fourier transform were 
analyzed on the TC2000 according to a previously described 
method.19 The maximum relative power amplitude (RPA) 
?associated with the embolic signal was recorded. The back - 
;ground RPA in the absence of an embolic signal was measured 
from a Doppler spectrum of the previous or next cardiac cycle, 
at the same point in the cycle and at the same velocity. A mean 
-.of three background readings was taken. Intensity was then 
calculated from the following equation: Intensity Increase =10 
iog (Maximum RPA of Embolic Signal /RPA in Absence of 
Embolic Signal). 
Method 2 
With the use of the EME Pioneer, the intensity was calcu- 
lated from the color -coded intensity scale on the screen. This 
'can be adjusted so that its intensity can be measured to the 
nearest decibel.'' -0 The gain was reduced until the color of the 
adjacent cardiac cycle reached 0, and the intensity of the 
embolic signal was then determined. 
Method 3 
With the use of the EME Pioneer, the intensity of each 
embolic signal was calculated with the automatic embolus 
software supplied with the machine. The algorithm determines 
the power of the embolic signal over the whole spectral line; 
similarly, the background power is calculated over the whole 
spectral line using a running average of background intensity 
ever the preceding spectral lines. 
Previously it has been suggested that an appropriate intensity 
threshold may be determined by measuring the intensity in- 
:tease occurring with random episodes of Doppler "speckle "; 
hese variations in intensity occur in the normal Doppler 
pectra and result from a number of factors, including nonuni- 
ormfty of the ultrasound field and nonuniformity of the 
listribution of red blood cell scatterers. For this reason, the 
ntensity increases associated with 200 episodes of random 
)oppler speckle using recordings from normal volunteers, 
wade at the same depth, sample volume, and gain, were 
alculated with intensity measured as in methods 1 and 2. It was 
of possible to perform this analysis with the automated 
mbolic signal detection software used in method 3. 
Results 
The relationship between embolic signal intensity 
easured by the different methods is demonstrated in 
ig 1. There was a highly significant correlation between 
easurements made by the different techniques (meth- 
1 versus method 2: r =.68, P <.0001; method 1 versus 
ethod 3: r =.66, P <.0001; method 2 versus method 3: 
'.70, P <.0001). However, as can be seen in Fig 1, the 
solute values of intensity for the same embolic signals 
varied markedly for the different methods, with intensity usually being higher for method 2. A 4 -dB threshold according to method 1 was equivalent to an approxi- mately 7 -dB threshold measured by method 2. We estimated the effect of these differences on the propor- tion of embolic signals detected using the same decibel threshold but with intensity measured in different ways 
(Table). The percentage of embolic signals detected 
varied markedly; for example, using a threshold of 7 dB would result in only 4.9% of signals being missed by 
method 2 but 42.2% and 51.4% being missed by methods 
1 and 3, respectively. A similar difference was apparent 
when an appropriate threshold was determined from 
analysis of the relative intensity increase associated with 
episodes of Doppler speckle. The use of an upper limit 
of 2 SD above the mean resulted in a threshold of 
greater than 4 dB for method 1 and greater than 7 dB for 
method 2 (Fig 2). 
Discussion 
Our results demonstrate that the intensity of the same 
embolic signals, recorded with the use of the same 
parameters, can be markedly different when analyzed in 
different ways. This has important implications when a 
decibel threshold is used and emphasizes that criteria 
developed by one investigator on one machine cannot be 
used by another investigator without initial reevaluation. 
Such use can lead to great differences in the number of 
detected embolic signals. For example, the use of a 7 -dB 
threshold measured by method 2 resulted in 95% detec- 
tion of embolic signals, whereas the use of the same 
threshold with intensity measured with method 1 or 3 
would result in approximately half of the embolic signals 
being missed. The figures may be even more discrepant 
if very-low- intensity embolic signals are used. We only 
studied embolic signals that four observers had agreed 
were present, and this by definition introduced a detec- 
tion threshold. Furthermore, using an inappropriately 
low threshold for the method of measurement of inten- 
sity may lead to many episodes of Doppler speckle being 
inappropriately counted as embolic signals. This may 
account for the detection of "embolic signals" in 100% 
of patients in a recent study when a low- intensity thresh- 
old was used.21 
The differences between the results obtained by the 
three methods may have a number of explanations. The 
power increase associated with the embolic signal can be 
measured in a number of ways. These include the peak 
increase at one velocity, the area under the power 
increase measured both across velocities and across 
time, or the power increase along the whole spectral 
line, which will include the power increase of the em- 
bolic signal and also of the background Doppler spec- 
trum at other velocities. Similarly, the background 
power may be measured in a number of ways. The 
background power can be measured at the same velocity 
or at all velocities, at the same point of the cardiac cycle 
or averaging across the whole cardiac cycle, and only 
within the Doppler spectrum or along the whole spectral 
line. For example, the background intensity is higher 
in 
diastole than in systole, and therefore the position 
of the 
cardiac cycle will alter measurements. Similarly, 
if the 
whole spectral line is used, for technically poor record- 
ings with artifactual extraspectral noise, the background 
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power will appear higher, resulting in a lower intensity 
increase of the embolic signal. 
In this study we used the same recordings to measure 
intensity in three ways. In practice there are additional 
Effect of Method of Measurement of Intensity on 
Proportion of Embolic Signals Detected With Use of an 
Intensity Threshold 
Method of Analysis 
1 
2 
Proportion of Embolic Signals Detected 
Using Each Threshold, % 
4 dB 5 dB 6 dB 7 dB 
95.1 81.5 74.1 57.8 
100 98.8 98.8 95.1 
91.7 86.1 72.2 48.6 
12 
problems with comparing intensity measurements from 
one study to another study. The intensity of an embolic 
signal will be highly dependent on the recording param- 
eters used. For example, the shorter the length of the 
sample volume, the greater will be the ratio of the power 
of the embolic signal to the background 
spectra and 
therefore the higher the intensity of the embolic 
signal. 
The intensity may vary if the depth of 
insonation is 
varied because of differences in sample volume 
width for 
focused ultrasound beams at different 
depths. Differ- 
ences may arise even with the same 
apparatus and 
settings if, for example, the middle cerebral 
artery lies in 
the center of the sample volume in 
one patient, but if it 
is not centrally insonated in another patient. 
Additional 
problems may arise if the degree of 
fast Fourier trans- 
0-1 1. -2 
method 1 
method 2 
2.1 -3 3.1-4 4.1 -5 5.1.6 
Relative Intensity Increase (dB) 
6.1 -7 7.1 -8 
Relative intensity increase of 200 episodes of Doppler 
de from middle cerebral artery recordings of normal control 
cts measured by methods 1 and 2. The results obtained by 
od 2 are significantly higher. 
I overlap is inadequate.22 The intensity increase will 
;neater if the embolic signal is processed in the 
Ile of one time window rather than falling between 
adjacent time windows. Nevertheless, in practice 
differences can be reduced by using standardized 
igs and recording parameters, as in this study. Some 
lese difficulties suggest that the use of a decibel 
hold is inappropriate. However, different investiga- 
have different thresholds at which they interpret a 
l intensity increase as an embolic signal, and there - 
we believe that an intensity threshold may aid in 
)aring data from different studies. We suggest that 
)proximate threshold can be determined by analyz- 
áe intensity increases resulting from random Dopp- 
peckle, as in this study, but that this should be 
(rmed by each center on its equipment and at its 
I settings, and the equipment setting should then be 
constant for subsequent recordings. An additional 
of ensuring the use of an appropriate intensity 
hold is to analyze mixed data from patients and 
al control subjects while blinded to the source of an 
idual recording. Embolic signal detection depends 
atures other than intensity increase alone, such as 
nidirectional velocity of the signal and the charac- 
ic sound. Further technological advances such as 
mitigate technique23.24 may allow more unambigu- 
letection of embolic signals and determination of 
1 low- intensity signals result from circulating 
di. 
e marked difference in intensity measurements with 
se of commercially available transcranial Doppler 
ines has important implications for clinical studies 
[bolic signal detection. If an intensity threshold is to 
lablished, this should be determined by each center 
its own equipment. Wherever possible, all record - 
ihould then be made at a similar depth with a 
it sample volume and settings. These findings also 
important implications if intensity measurements 
be used to gain information about the composi- 
lf the underlying embolic material. 
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Multigated Doppler Ultrasound in the 
Detection of Emboli in a Flow Model 
and Embolic Signals in Patients 
Jane Molloy, MRCP; Hugh S. Markus, DM 
Background and Purpose The ability to detect asymptom- 
atic circulating cerebral emboli may contribute to the manage- 
ment of patients with stroke, but its clinical usefulness will de- 
pend on effective systems for automatically detecting embolic 
signals (ES) and differentiating them from artifact. A new method 
involves the use of a multidepth probe that allows recording from 
both distal and proximal sample volumes along the same vessel. 
Theoretically, an embolus should appear sequentially, with a time 
delay, between the two channels, whereas an artifact should ap- 
pear simultaneously in the two channels. 
Methods We evaluated this method in an in vitro flow model 
and in patients. In an in vitro model, with a flow pattern mimick- 
ing intracerebral flow, 181 air bubbles and 193 thrombus emboli 
were compared with the signals resulting from 368 episodes of 
artifact; a sample volume of 5 mm and a channel separation of 
10 mm were used. ES from two groups of patients -those with 
carotid artery stenosis (141 ES) and those with mechanical pros- 
thetic cardiac valves (125 ES) -were studied and compared with 
222 episodes of artifact produced in the same patients. 
Results In the model the mean (SD) time delay was 17.32 
(9.94) ms for air emboli and 17.78 (10.66) ms for thrombus em- 
boli compared with -0.0] (0.39) ms for artifact (air and thrombus 
emboli versus artifact, P <.0001). A sensitivity of 100% and 
specificity of 100% were obtained when a cutoff of >2 ms was 
used for an embolus. The method allowed equally good detection 
of those air emboli that resulted in receiver overload and aliasing. 
In patients the mean (SD) time delay was 29.6 (28.2) ms for valve 
ES and 14.9 (15.42) for carotid ES compared with 0.00 (0.46) 
for artifact (carotid and valve ES versus artifact, P <.0001). Con- 
sidering only those signals that were visible in both Doppler time 
domains resulted in a sensitivity for valve ES of 98.9% and for 
carotid ES of 94.0 %, with a specificity of 99.0 %. However, in 
one patient in the valve group some ES were visible only in the 
proximal channel, possibly because of passage of emboli down 
branch vessels between the two sample volumes. In addition, for 
the less intense carotid ES some signals were unclear or absent 
in one or both of the time domain signals at either depth, although 
visible in the post -fast Fourier transform spectra. Including those 
ES visible in only one channel reduced the sensitivity to 75.2% 
for valve ES and 92.6% for carotid ES. 
Conclusions The multigated technique offers a new method 
of detecting ES and differentiating them from artifact and is the 
first reliable method for differentiating intense ES resulting in 
receiver overload from artifact. Occasionally its sensitivity is re- 
duced when ES do not appear in the distal channel. probably 
because they pass down a side branch; this may be reduced by 
reducing gate separation. Some less intense carotid ES can be 
difficult to detect if the amplitude increase is small compared with 
the amplitude of the background Doppler signal. (Stroke. 
1996;27:1548-1552.) 
Key Words carotid artery diseases cerebral embolism 
heart valve prosthesis ultrasonics 
Stroke is the third leading cause of death and a major 
cause of disability. Cerebral embolism is the un- 
derlying pathogenic mechanism in many cases of 
stroke. Emboli may arise from the heart, carotid plaques, 
aortic plaques, intracranial atherosclerotic stenoses, or 
from systemic venous thrombosis in the presence of a 
venous to arterial shunt. The ability to detect asymptom- 
atic circulating cerebral emboli offers important potential 
advances in the localization of an actively embolizing 
source, the selection of high -risk patients for appropriate 
treatment, monitoring of the effectiveness of anticoagu- 
lant and antiplatelet therapy, and perioperative monitor- 
ing. Embolic signals (ES) appear as a unidirectional fre- 
quency- focused intensity increase, usually within the 
background spectral pattern and occurring at random 
within the cardiac cycle, accompanied by a characteristic 
harmonic sound. The technique has been demonstrated to 
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be highly sensitive and specific in both in vitro' and an- 
imal2'3 models. ES have been detected in patients 
with a 
variety of embolic sources, including carotid stenosis, 
atrial fibrillation, and prosthetic cardiac valves,4.6 and 
during and after operative procedures such as carotid 
end - 
arterectomy' and carotid angioplasty.' One of the 
major 
factors hindering the wider clinical application 
of the 
technique is the time taken to analyze off -line 
recordings 
from patients. Although the optimal recording 
time has 
not yet been defined for each separate 
patient subgroup, 
recordings are normally made for 
a minimum of 30 
minutes, with much longer periods 
being used by some 
groups. If embolic detection with 
transcranial Doppler 
ultrasonography is to become clinically 
useful, a reliable 
automated detection system is 
required. Such a technique 
should be both highly specific 
and sensitive for ES and 
be able to differentiate these 
from both patient and probe 
artifact. Previous investigators 
have used a computer al- 
áorithm to identify the characteristic 
bell- shaped relative 
intensity increase occurring 
with an ES and to differen- 
tiate this from the characteristic 
bidirectional intensity in- 
crease seen with an artifact. 
High sensitivity and speci- 
ficity were achieved in an 
off -line system,' but results 
with on -line systems have 
not yet been as good.10 An 
alternative approach is to 
train a neural network; 
such a 
Molloy and Markus Use of Multigated Doppler to Detect ES 1549 
;vstem has been shown 
to identify ES on -line with a high 
,specificity, but its sensitivity 
is only in the order of 70%. 
;nfortunately, 
artifact may also occasionally produce 
embolus -like signals 
and therefore cannot always be dif- 
ferentiated 
on the basis of intensity, duration, and direc- 
°rionality of the signal 
alone. Furthermore, in cases in 
,vhich ES cause receiver overload, 
aliasing occurs and 
bidirectional signals may be 
produced; these cannot be 
,,iifferentiated from artifact on the basis of previous em- 
tolus- defining criteria. 
A very promising method that involves the use of mul- 
tigated Doppler ultrasound has recently been described 
Aaslid. Since an embolus is in motion in the direction 
,if blood flow within the vessel being studied, if record- 
nip are made at two depths along the vessel length, there 
,should be a time delay between the ES seen at the distal 
'lepth and that seen more proximally. In contrast, signals 
Froduced by external interference would be expected to 
be seen simultaneously in both channels. Results with 
Ftuch a system have been recently reported"; however, 
his study used the post -fast Fourier transform (FFT) 
spectra from which to calculate the time delay, and even 
,getter results would be expected when the time domain 
'iata with their much higher temporal resolution are used. 
urthermore, the in vitro validation in this study 12 used 
air emboli, and there has been no validation when solid 
"'tr formed emboli, such as thrombus, are used, which re- 
Alt in less intense signals and have been more difficult 
to detect in previous automated systems. 
In this study we initially evaluated a multigated Dopp- 
er ultrasound system in an in vitro flow model using both 
,hrombus and air emboli, and we then applied it to a 
group of patients with potential embolic sources. 
Subjects and Methods 
In all studies the same transcranial pulsed Doppler machine 
was used (Pioneer 4040, EME Ltd) with a multidepth 2 -MHz 
Transducer. The Doppler signal was saved with software that gl- 
ows the pre -11-1 time domain Doppler signal. the post-F.F. 1 spec- 
tra, and the audio signal to be stored on the computer hard disk 
tad replayed. The initial increase in amplitude at the time of 
rrival of an embolus or artifact in each of the two channels was 
teasured from the time domain data, allowing a time resolution 
of l ms or greater. 
Vitro Studies 
We constructed a flow circuit using polyethylene infusion tubing 
14 mm ID, Codan Limited), driven by a programmable flow pump 
'University Developmental Cooperation Flow System) and filled 
vith a Proprietary blood analogue. a suspension of nylon filaments 
In machine oil that has been previously validated to have scatter 
Properties similar to those of blood (Elf Atochem).'a A waveform 
¡pillar to that normally obtained from the middle cerebral artery 
\,ICA) with relative preservation of diastolic flow was obtained; 
.mean systolic flow velocity was 40 cm/s (peak, 95 cm/s; diastolic, 
cm's). Air was removed from the circuit through a built -in res- 
n'oir tank. A length of the tubing was fixed in a water bath and 
asonated at an incident angle of 35 °, such that there was a compa- 
able waveform with equal gain settings at each depth. Channel 1 
vas set at a depth of 52 mm with the following parameters: sample 
lee, 5 mm; power, 25% (100% power is equivalent to 675 mW/ 
m1' and gain, 8. Channel 2 was set at a depth of 42 mm at the 
game settings of sample size, power, and gain. 
We introduced emboli of two types through a transparent side - 
nn device, allowing visualization of any accidentally introduced 4r:181 air bubbles were introduced with a 1 -mL syringe to pro - luce bubbles of 0.01 mL in volume (diameter, 0.64 mm); 193 
thrombus emboli were prepared from fresh human blood that had been allowed to clot, cut in cuboid shapes with a maximum di- mension of 0.5, and then suspended in normal saline. In addition, 368 episodes of artifact were produced; 187 of these were pro- duced by tapping the probe and 181 by tapping the tubing to mimic patient artifact. 
Patient Studies 
The aim of the patient studies was twofold: (1) to determine 
in what proportion of patients we could successfully insonate the 
MCA with satisfactory gate separation and (2) to determine the 
sensitivity and specificity of the method in detecting ES and dif- 
ferentiating them from artifact. ES in patients with mechanical 
prosthetic cardiac valves are more intense than those in patients 
with carotid stenosis" and have been easier to detect by previous 
automated systems; therefore, we evaluated the method in both 
patient groups separately. In the carotid group we included ES 
recorded during the recovery phases after carotid endarterectomy 
and carotid angioplasty; these ES have an intensity similar to 
those recorded in symptomatic carotid stenosis.8 
Insonation of 35 MCAs in 24 patients was attempted (16 men, 8 
women; mean [SD, range] age, 66.5 years [10.39, 50 to 86]). Of 
these patients, 14 had a known potential source of emboli. Six pa- 
tients with metallic prosthetic cardiac valves were monitored bilat- 
erally for 20 minutes. Eight patients with symptomatic carotid ste- 
nosis (mean stenosis, 84.4 %; range, 60% to 95 %) were monitored 
ipsilateral to the stenosis for 1 hour. Four patients later underwent 
carotid endarterectomy, and 1 patient underwent carotid angioplasty. 
In these patients more extensive postoperative recordings were 
made, for a total of 300 minutes per patient. All these recordings 
were made following the procedure, either after catheter removal for 
percutaneous transluminal angioplasty or in the recovery room for 
endarterectomy, and no recordings were made during the procedures 
when ES could represent air bubbles. In the additional 10 subjects 
recruited from hospital inpatients, monitoring was continued only 
for the time it took to obtain a satisfactory signal; this was to deter- 
mine whether adequate gate separation could be obtained. 
Insonation was achieved by the transtemporal route, with the use 
of a 2 -MHz probe held in place with an external fixation device. 
Once the MCA was identified, the depth in the two channels was 
adjusted, and the axial sample volume width was reduced 
while 
satisfactory visualisation of the Doppler spectra within the two 
sam- 
ples was maintained. A standard protocol was used in siting 
the 
position of the two sample volumes; we aimed for a sample 
volume 
of 5 mm and a distance between the center points of 
the sample 
volumes (ie, between the two depths) of 10 mm. Episodes 
of artifact 
were also recorded for off -line analysis as above. 
These were pro- 
duced by requesting that the patient cough, speak, 
or swallow and 
by tapping or moving the probe, probe holder, 
or headgear. 
Signal Analysis 
For all ES, maximum relative intensity 
increase was deter- 
mined. The intensity was taken from 
the intensity color -coded 
spectral display. The background intensity 
was calculated from 
a similar point in the preceding or following 
cardiac cycle. The 
pre -NF I' time domain data from the 
two channels were used to 
determine whether the intensity increase 
was present in both 
channels; if so, the time delay in the 
onset of the intensity increase 
in the two channels was measured. 
Comparisons between groups 
were made with the use of Student's 
t test for unpaired data. 
Results 
In Vitro Studies 
All 374 emboli were detected 
as high-intensity signals. 
Air 
emboli resulted in more intense 
signals than thrombus emboli 
(mean [SD, range] for air 
emboli, 31.5 dB [11.8, 
11 to 39] 
versus 22.5 dB [4.8, 11 
to 39] for thrombus 
emboli; 
P<.0001). Forty-three air emboli 
but no thrombus emboli 
resulted in receiver overload 
and a bidirectional signal, 
as 
previously reported; these 
were included in the analysis. 
All 
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emboli were detected in both channels (Fig lA and 1B), in 
all cases first in the more proximal channel, with a mean (SD, 
range) time delay between the two channels of 17.56 ms 
(10.31, 3 to 53). The mean (SD. range) delay was 17.32 ms 
(9.94. 3 to 53) for air emboli and 17.78 ms (10.66, 4 to 50) 
for thrombus emboli. In contrast, artifact appeared simulta- 
neously or near simultaneously in the two channels (Fig 1C), 
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FIG 2. Frequency histogram of the time delay between the onset 
of the amplitude increase in the two channels for air and throm- 
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FIG 1. Time domain Doppler signals for air embolus in 
flow model (A); thrombus in flow model (B); artifact 
caused by probe tapping in flow model (C); embolic sig- 
nal from patient with prosthetic metallic cardiac valve 
(D); and embolic signal from patient with carotid artery 
stenosis (E). The lower of the two tracings represents 
the distal channel. A time delay is present between 
the 
onset of the amplitude increase in the two channels 
in 
A, B, D, and E. In contrast, the artifact in 
C appears 
simultaneously in the two channels. The amplitude 
in- 
crease in the proximal channel for the carotid 
embolic 
signal in E is of low amplitude compared 
with the back- 
ground Doppler signal (see text for discussion). 
with a mean (SD, range) time delay 
of -0.01 ms (0.39, -4 
to 2: P <.0001 versus emboli, t test). 
Time delays for air and thrombus 
emboli and artifact 
are shown in Fig 2. When we specified 
a cutoff time delay 
of more than 2 ms to define a 
signal as an embolus, the 
method could detect emboli 
and differentiate them from 
artifact with a sensitivity of 
100% and a specificity of 
100 %; this was similarly 
good when either air 
emboli 
alone or thrombus emboli 
alone were considered. 
These 
values include the 43 air emboli 
that resulted in receiver 
overload and aliasing; for 
these cases analyzed as 
a sepa- 
rate Er.roup, mean (SD, range) 
time delay between gates 
was 19.81 ms (9.61, 9 to 53). 
There was a highly significant 
relationship between 
the 
velocity at which the ES 
intensity increase occurred 
and 
the time delay between 
the two channels: 
air emboli. 
r = -.77. P <.0001; thrombus, 
r = -.74, P <.0001. 
Patient Studies 
Successful insonation 
of the MCA was possible 
in 33 
of 35 arteries (94.3 %). 
In the two failed cases 
this was due 
to unilateral absence 
of an acoustic temporal 
window. In 
all MCAs that could 
be insonated, it 
was possible to record 
Molloy and Markus Use of Multigated Doppler to Detect ES 1551 
Kl 
attwodepths, 
with a mean (SD, range) sample volume of 
1.96 mm (0.20, 
4 to 5) and mean (SD, range) gate sepa- 
4rration of 4.71 
mm (1.85, 1 to 9). 
Prosthetic Mechanical 
Cardiac Valves 
We recorded 125 ES, with 
a mean (SD, range) relative 
r- intensity increase 
of 31.1 dB (7.7, lÒ to 55). The mean 
.(SD, range) time delay 
was 29.6 ms (282, 2 to 122). For 
30 ES, all in the same patient. 
the ES were heard and 
detected in both the time domain 
data and the post -FFT 
spectral display in the proximal channel 
but were not au- 
dible or visible in the distal channel, suggesting that some 
emboli may have passed into a branching artery between 
nihe two sample volumes. All other ES were visible and 
audible in both channels. The mean time delay for ES was 
'significantly longer than that for the 222 episodes of arti- 
fact, which had a mean (SD, range) time delay of 0.0 ins 
',(0.16, -2 to 3; P<.0001). Time delays for the ES and 
artifact are shown in Fig 3. When we included only the 
ES detected in both channels and used a threshold of a 
rrr:ime delay of 2 ms between the two depths as the defining 
criterion for ES, the sensitivity was 98.9% and specificity 
99.0 %; however, if the ES visible in only one channel were 
also included, the sensitivity fell to 75.2 %. On the whole, 
the ES in patients with cardiac valves were clearly visible 
as a large amplitude increase in the time domain data, in 
contrast to some of the carotid ES (Fig ID). 
Carotid Artery Stenosis 
We recorded 141 ES, with a mean (SD, range) relative 
intensity increase of 19.3 dB (5.9, 5 to 33). No ES were 
risible and audible in the proximal channel but not in the 
iistal channel, unlike the valve ES. However, two ES au- 
dible and visible in the post -F1 1 spectra in both channels 
were identifiable in the time domain data of only one chan- 
sel; one ES was detected only in the proximal but not the 
'distal time domain data, while one ES was clearly audible 
and visible in the proximal channel post -l-± 1 spectral dis- 
Play but not visible in the time domain data at that depth. 
îhis appeared to be a reflection of the fact that the ampli- 
tude increase in the time domain data was small for many 
FES and frequently difficult to distinguish from the back - 
;round Doppler signal; a typical example is shown in Fig 
.E. The ratio of the maximum amplitude increase to the 
aackground Doppler signal amplitude in the time domain 
'OM was small for many carotid ES, and the mean value 
'tas significantly smaller than that for valve ES (5.1 [2.5] 
.versus 13.2 [5.7]; P <.0001); individual values are shown 
p;n Fig 4. For ES identifiable in both channels, the mean 
,n 
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FIG 4. The ratio of the amplitude increase in the pre -fast Fourier 
transform time domain signal for embolic signals (ES) compared 
with that due to the background Doppler signal in the absence 
of an ES. Channels at both recording depths have been included. 
(SD, range) time delay between the two channels was 14.9 
ms (15.42, 0 to 90). The time delay was significantly 
longer than that of the 222 episodes of artifact (P <.0001). 
When the same 2 -ms cutoff was used, a sensitivity of 
94.0% and specificity of 99.0% were obtained when those 
signals identifiable in both channels were considered (Fig 
3). The sensitivity fell to 92.6% when all ES, including 
those visible in only one channel, were considered. 
Discussion 
In our in vitro model, the use of a multigated technique 
allowed the identification of ES and their discrimination 
from artifact with a very high sensitivity and specificity. 
Of particular note, it allowed detection of ES that resulted 
in receiver overload with a similar high sensitivity and 
specificity; this is the first method to be able to identify 
such ES, which cannot be identified from the frequency 
spectral data alone either visually or with the use of a 
neural network" or computer algorithm. 'This application 
may be particularly useful when it is used during operative 
procedures, when both echogenic air emboli and artifact 
may be common. In addition, the multigate data may allow 
the unambiguous identification of low- velocity ES, which 
can sometimes be difficult to separate from artifact on fre- 
quency spectral data alone. 
In all patients in whom an acoustic window could be 
obtained. it was technically possible to record using the 
multidepth probe with adequate gate separation. We 
iden- 
tified the sensitivity and specificity of the multigated 
sys- 
tem using ES identified according to conventional 
criteria 
and compared them with known episodes of artifact. 
The 
results in patients were encouraging but not 
as impressive 
as the in vitro data for a number of reasons. 
This was 
primarily because in some patients the ES 
did not appear 
in both channels. In one patient in the 
valve group, 30 ES 
(approximately 40% of the signals in 
this patient) were 
detected proximally but were not audible 
or visible distally 
in either the time domain data or in 
the post -FFT spectral 
data. This is likely because between 
the two sample vol- 
umes a proportion of the emboli pass 
down a branch ves- 
sel. Our protocol aimed for a gate 
separation, between the 
centers of each sample volume, of 
10 mm, and sometimes 
the distal gate was a fairly shallow 
depth of 42 mm; the 
problem may be reduced with 
the use of a deeper distal 
gate, thereby lowering the 
chance that this gate may 
be 
sited beyond the branching 
of the MCA. Further studies 
are required to examine whether 
reduced gate separation 
allows such good separation 
between emboli and artifact. 
On the other hand, gate separation 
that is too narrow 
will 
reduce the time interval between 
detection of emboli in 
the 
t' 
1552 Stroke Vol 
27, No 9 September 1996 
proximal and distal gates 
and will reduce the specificity in 
differentiating emboli 
from artifact. Apart from this diffi- 
culty in a single patient, 
the use of a multigated probe 
allowed detection of emboli 
and differentiation from arti- 
fact with a very high sensitivity, 
similar to that seen in the 
in vitro model. This is largely 
a reflection of the higher 
intensity of the more echogenic 
mechanical valve ES, as 
previously reported. This resulted in a large 
and clear am- 
plitude increase in the time domain signal (Fig 1). 
In contrast, for the less intense carotid ES, some signals 
were identifiable audibly and in the post-FFI spectral dis- 
play but not in the time domain data. This occurred for 
low- intensity emboli, in which the power or intensity in- 
crease was small and lost in the background Doppler 
signal. An additional possible explanation is that the total 
cross -sectional area of the MCA is not fully covered by 
the sample volume at both depths. This will be less of a 
problem for more echogenic emboli, which have a larger 
effective sample volume.15 Separating the intensity in- 
crease at different frequencies by an NN-1 analysis allowed 
identification of the ES since the intensity increase of an 
ES is maximal at one frequency. Although only two ca- 
rotid ES were not detectable in the time domain data, a 
much larger number resulted in an amplitude increase only 
slightly greater than that of the background Doppler signal. 
This is illustrated by the relatively low ratio of the maxi- 
mum amplitude to background amplitude for many carotid 
ES in the time domain data (Figs lE and 4). With the use 
of an off -line analysis in combination with the post-H.1 
spectral data, it is possible to determine the time delay for 
most carotid ES. However, it may prove difficult in auto- 
mated on -line systems based on the time domain data 
alone to distinguish the small amplitude increase occurring 
with some carotid ES from amplitude fluctuations in the 
normal background Doppler signal. Further work is re- 
quired to improve the sensitivity of the multigated tech- 
nique for small -amplitude ES. 
The predominant factor determining the time taken to 
travel between the two channels was the velocity at which 
the ES was maximal. which presumably reflects the speed 
at which the embolus is traveling. However, in the model 
there was a much greater range of time taken between 
detection in each channels than would be expected by sim- 
ple mathematical principles. The theoretical distance trav- 
eled by an embolus as detected by the probe is 5 mm (ie. 
distance between the edges of the axial sample volumes). 
If we correct for angle of insonation, an embolus traveling 
at the mean velocity (40 cm/s) would be expected to take 
15.3 ms to cross between the two axial sample volumes. 
Any embolus traveling at the peak velocity for the system 
(95 cm/s) would be expected to give a time delay of 6.4 
ms between the two depths. It is noteworthy that 46 of the 
emboli we produced traversed the distance in 6 ms or less. 
This reflects the fact that rather than being cylindrical in 
shape, with a sharp cutoff of the ultrasound beam at each 
end of the sample, there is a gradual weakening of the 
beam at each end. It follows that the effective sample vol- 
ume will be greater for more echogenic emboli such as air 
emboli.1S In patient studies some ES took much longer to 
travel between the two sample volumes, and this was par- 
ticularly so for some valve ES. This may be due to their 
passage being slowed by turbulence. nonlaminar flow, and 
momentary adhesion to the vessel wall. 
Our results demonstrate that a multigated approach can 
detect ES and differentiate them from artifact. but as with 
other methods, it has some inherent problems that need to 
be resolved before it is suitable for routine clinical use. 
Our results are similar to those reported previously1z but 
show a lower sensitivity for low- amplitude carotid ES. In 
this previous study, carotid ES, a minority of the ES, were 
not separated from those from patients with heart valve 
replacements or left ventricular assist devices, and no anal- 
ysis of the intensity of the ES was made. Our results dem- 
onstrate that in patients with the more intense mechanical 
valve ES, high sensitivity and specificity are likely to be 
obtained; the only major difficulty appeared to be passage 
of emboli down a branching vessel between the two sam- 
ple volumes, and this may be improved by reduced gate 
separation. In patients with carotid ES, the less intense ES 
may be unclear in one or both channels. For these ES, 
combining the multigated method with a method analyzing 
the post- FFI' spectral data may improve sensitivity; use of 
the frequency spectra may provide greater resolution be- 
cause the intensity increase associated with an ES is usu- 
ally centered on a narrow frequency band. 
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